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A b s t r a c t
Over the last decade there have been dramatic improvements in paediatric cardiac surgery and 
the outcome for children with congenital heart disease. Whilst the majority recover promptly 
from surgery, a small unpredictable group of children have persistant requirements for 
ventilatory and intensive care support. For these children sepsis and systemic inflammatory 
response syndrome (SIRS) appears to be a major causes of morbidity and mortality. Antigens 
of the major histocompatibility complex type II (MHC Class II) are decreased on circulating 
monocytes of many critically ill patients. Persistently low expression of these antigens has been 
associated with poor prognosis and increased susceptibility to infection. The work presented 
here examines the hypothesis that ‘monocyte deactivation’, as indicated by reduced MHC Class 
13 expression and decreased whole blood secretion of pro-inflammatory cytokines in response to 
lipopolysaccharide (LPS), is a factor in the development of sepsis/SIRS following 
cardiopulmonary bypass.
Using flow cytometry, confocal microscopy, enzyme -linked immunosorbant assays, ex vivo 
whole blood stimulation, and real time-polymerase chain reaction it has been shown that 
(1) monocyte surface expression of MHC Class II falls following cardiac surgery involving 
CPB; (2) this reduction in surface expression is paralleled by a reduction in intracelleular MHC 
Class II stores, and increased transcription of MHC Class II related genes; (3) bypass results in 
the early and simultaneous rise in both pro-and anti-inflammatory cytokines; (4) whole blood 
drawn from patients following CPB is profoundly hyporesponsive to LPS stimulation; (5) whole 
blood hypo-responsiveness precedes the rise in circulating cytokine and that (6) the 
inflammatory response and morbidity following CPB may be influenced by the presence of 
cytokine polymorphisms.
The results shown here strongly suggest that monocyte MHC Class II surface expression is an 
excellent diagnostic tool for the identification of the subgroup of children most likely to develop 
post-operative complications. By identifying this subgroup of children immunomodulative 
therapy can be appropriately targeted to restore homeostasis and improve outcome.
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l . i  C o n g e n i t a l  h e a r t  d i s e a s e
Congenital heart disease (CHD) is the most common of all major birth defects, 
occurring in 0.8 to 1% of live bom children (Table 1.1). The incidence is higher in 
stillborn infants and spontaneous abortions. For paediatricians and parents, the last 30 
years has seen a dramatic change in the diagnosis, management and outcome for an 
infant with a congenital heart defect. The prognosis has changed from almost certain 
death, to the opportunity for complete surgical repair with a low risk of mortality.
Cardiac Lesions (Incidence per 10 000 live births)
Ventricular septal defect 30-50
Patent ductus arteriosus0 10
Atrial septal defect (secundum) 7
Endocardial cushion defect* 3-5
Coarctation of the aorta 6
Aortic stenosis 5
Pulmonary stenosis 7
Tetralogy of Fallot 5
Transposition of great arteries 5
Pulmonary atresia 1-2
Tricuspid atresia 1-2
Truncus arteriosus 1
Total anomalous pulmonary venous connection 1
Aortic atresia 1
Double outlet right ventricle <1
Atrial isomerism 2
Single ventricle 1
Ebstein’s malformation <1
Table 1.1 Incidence of common types of congenital heart defects at birth.
Ranges are a reflection of variation in different case reports.
“Incidence excludes pre-term infants. ^Incidence excludes Trisomy 21 
(Adapted from Rudolph’s Pediatrics 19th edition, 1991)
1.1.1 Development of Paediatric Cardiac Surgery
In order for complex surgery to take place on the heart or great vessels, a mechanical 
device is required that can temporarily take over the function of the heart and lungs. 
This provides the surgeon with a bloodless, motionless field. From the 1930’s to the 
1960’s progress in paediatric cardiac surgery paralleled progress in the development of 
cardiopulmonary bypass (CPB).
In 1937 John Gibbon built the first heart-lung machine using an animal subject. A 
roller pump was used as a substitute for the heart, and anticoagulated blood was directly 
exposed to oxygen as it dripped along wires on a vertically mounted screen. It was too 
small for humans and most animals died from haemolysis, air embolism or 
“inflammation”. The following year Robert Gross successfully ligated the patent 
arterial duct (PDA), ushering in the era of surgery for congenital heart disease (Gross 
and Hubbard, 1939). In 1946 Gibbon joined with engineers to invent a heart-lung 
machine, which minimised haemolysis and involved a closed circuit, preventing entry 
of air bubbles. About the same time Alfred Blalock and Helen Taussig developed a 
subclavian to pulmonary artery shunt, whilst doctors in Sweden carried out the first 
successful repair of an aortic coarctation (Blalock and Taussig, 1945;Crafoord and 
Nylin, 1945).
By the late 1940’s Bill Bigelow was performing open-heart surgery on dogs using 
cooling blankets and ice bags. By cooling the dog to 20°C he was able to decrease 
oxygen consumption significantly allowing isolation of the heart from circulation for 15 
minutes operating time. Within 6 years John Lewis utilised immersion hypothermia to 
close a paediatric atrial septal defect (ASD). In 1953 the first heart-lung machine was 
used in human cardiac surgery (Lillehei, Cohen, and Warden, 1955). By 1958 adult 
cardiac surgeons were utilising cardiopulmonary bypass, deep hypothermia and 
circulatory arrest to assist them in their repairs of cardiac defects. However it was not 
until the 1970’s, that these techniques were utilised in children (Barratt-Boyes, 1973).
Over the last two decades, cardiopulmonary bypass has been successfully used in the 
correction of congenital heart disease in children. Initially only older children
In t r o d u c t i o n
underwent a primary repair, with young children and infants having simpler palliative 
procedures. Gradually with increasing experience, a transition has been made from 
palliative to corrective surgery even in very small infants. Developments in 
cardiopulmonary bypass have been crucial to this transition in patient management.
1.2 C a r d io p u l m o n a r y  B y p a s s
The basic procedure involved in CPB is straightforward. Prior to placing the child or 
infant on bypass, a median incision through the sternum to expose the anterior 
mediastinum and pericardium is required. The bypass machine (Fig 1.1) is primed with 
a balanced electrolyte or blood solution. Venous blood is drained by gravity through a 
cannula placed in the right atrial appendage or by two cannulae placed in the inferior 
and superior vena cavas (Fig 1.2). Oxygenated blood is returned to the patient via 
another cannula placed in the ascending aorta.
Figure 1.1 Cardiopulmonary Bypass machine. Cardiopulmonary bypass in theatre 
is pictured. Blood from the patient can be seen entering and exiting the bypass machine 
through plastic tubing.
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Gas exchange takes place across a membrane oxygenator, and blood temperature can be 
adjusted by the use of a heat exchanger. The patient is anticoagulated for the duration 
of bypass. Depending on the surgery undertaken, the heart may be allowed to beat 
during bypass, or be temporarily arrested by the administration of cardioplegia solution.
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Figure 1.2 Basic anatomy of the heart. (Grants anatomy l ( fh edition)
1.2.1 CPB and Outcome
Over the past 30 years there has been a progressive reduction in the mortality associated 
with repair of congenital heart defects (Fig 1.3). The reasons for this are complex, but a 
combination of increased surgical expertise, technological advancements and improved 
post-operative care have all played an important role. As mortality has decreased 
however, there has been an unmasking of the degree of morbidity associated with CPB. 
Data from the Society of Thoracic Surgeons National Database report 20% of Tow-risk’ 
adult patients develop postoperative complications following cardiac surgery (Grover,
ON
1999). The incidence of multiple organ dysfunctional syndrome (MODS) following 
CPB was 11% with a mortality rate of 41% (Kollef, Wragge, and Pasque, 1995).
When death was the natural outcome associated with a congenital cardiac defect, 
parents and doctors were accepting of any morbidity associated with a successful 
surgical repair. However as survival has increased there has been a reduction in both 
the professional and lay communities acceptance of complications. There has therefore 
been an increasing interest in the reasons why CPB is associated with significant 
morbidity.
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Figure 1.3 Schematic diagram of outcome for patients undergoing surgery for 
Congenital Heart Disease. With improvement in cardiac surgical techniques and post­
operative care there has been a rapid reduction in mortality associated with surgery but 
an unmasking of morbidity. Advances in monitoring of end-organ functioning have 
suggested that morbidity is probably being underestimated.
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1.2.2 The inflammatory response to CPB
A consistent observation in patients undergoing CPB was that a high proportion of 
patients had features of a systemic inflammatory response. This was particularly 
noticeable in the early post-operative period and included clinical features such as 
capillary leak, oedema, and organ dysfunction. This was termed 4post-perfusion 
syndrome’. The aetiology of this syndrome was not known but felt to be due to a 
combination of the processes of CPB and cardiac surgery. The surgical insult, exposure 
of blood to foreign materials as well as fluctuations in temperature, fluids, coagulation 
and tissue perfusion were recognised as potential causes of this syndrome (Fig 1.4). It 
was felt likely that these events mediated the post-perfusion syndrome through 
activation of humoral and cellular pathways.
Figure 1.4 The surgical field during paediatric cardiac surgery.
During cardiac surgery involving CPB the patient is exposed to numerous pro- 
inflammatory triggers including local tissue trauma, foreign bodies, and exposure of 
blood to foreign surfaces.
More recent data has suggested that post-perfusion syndrome can be mimicked in 
animal models by the infusion of pro-inflammatory cytokines and components of the 
complement pathway (Pagani, Baker and others, 1992;Tracey, Beutler and others, 
1986;Yokoyama, Vaca and others, 1993). This led to attempts to improve the outcome 
of patients on CPB. by blocking individual mediators or even whole inflammatory 
cascades. To date these have failed to live up to expectations (Bouter, Schippers and 
others, 2002;Chaney, 2002;Harig, Feyrer and others, 1999;Wan, LeClerc, and Vincent, 
1997b). There are still many gaps in our understanding of the inflammatory response to 
CPB and in particular the detailed timing of individual cytokine production and release 
and how they interact with each other remains sketchy. Perhaps ignored in early 
studies, has been the recognition that mediators which act to oppose pro-inflammation 
may themselves be playing a role in the pathology associated with CPB.
1.2.2.1 Cardiopulmonary Bypass and Pro-inflammation
The division between pro and anti-inflammatory mediators is simplistic as many 
mediators have properties that correspond to both categories. However for the purposes 
of this introduction, cytokines will be discussed under these two headings.
Pro- inflammatory triggers during CPB include:
*  exposure of blood to foreign surfaces (bypass circuit)
*  ischemia-reperfusion injury to brain, heart, lungs, kidneys, and liver 
following aortic cross clamping
*  endotoxaemia during the procedure (Berendes, Mollhoff and others, 
1997;Mollhoff, Loick and others, 1999;te, Jansen and others, 1995)
*  hypothermia 
*■ tissue trauma
*  blood loss or transfusion.
(Roach, Kanchuger and others, 1996) (Martinez-Pellus, Merino and others, 1997)
These trigger release of mediators including tumour necrosis factor (TNF-a), 
interleukins (IL)-1, -6, and -8, products of the complement cascade, free oxygen 
radicals, acute phase reactants, and increased cellular expression of the adhesion 
molecules L-selectin, CD l ib  and CD 18 (Butler, Rocker, and Westaby, 1993) (Kirklin, 
Westaby and others, 1983)(Fig 1.5).
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Figure 1.5 A schematic representation of the inflammatory response to CPB
(adapted from Wan S et al 1998). CPB causes both direct and indirect activation of the 
immune system, many components of which feed back to further amplify the 
inflammatory response.
1.2.2.2 Cardiopulmonary Bypass and Anti-inflammatory Mediators
Along with the release of pro-inflammatory cytokines, CPB stimulates a phased anti­
inflammatory response, involving anti-inflammatory cytokines, soluble cytokine 
receptors, and cytokine receptor antagonists (McBride, Armstrong and others, 
1995;McBride, Armstrong and others, 1996). Key anti-inflammatory cytokines include 
interleukin-10 (IL-10), interleukin-1 receptor antagonist (IL-lra), TNF soluble receptors 
1 and 2 (sTNFR-1 and 2), and transforming growth factor p (TGF-p). These anti­
inflammatory cytokines are important in controlling the pro-inflammatory response 
initiated by the surgical insult, and it has been suggested that the clinical prognosis 
following CPB may depend on the balance between pro and anti-inflammatory 
cytokines (McBride, Armstrong and others, 1995).
Numerous studies of the inflammatory response to CPB have implicated the cytokine 
network in the pathogenesis of post-perfusion syndrome, however a direct cause-and- 
effect relationship has not been demonstrated (Casey, 1993;Wan and Yim, 1999). In 
particular, inflammatory cytokines have been shown to play a critical role in inducing 
myocardial injury. Before discussing the role of cytokines in morbidity following 
cardiac surgery and cardiopulmonary bypass, it is appropriate to outline the physical 
and chemical characteristics of the key cytokines.
1.2.3 Physical and chemical characteristics of cytokines implicated 
in post-operative morbidity
1.2.3.1 Tumour necrosis factor (TNF-a)
1.2.3.1.1 Structure
TNF-a is a 26-kDa transmembrane protein which is cleaved by a site specific 
metalloprotease (TNF-a converting enzyme) to generate the soluble 17-kDa form 
(Gearing, Beckett and others, 1994). Most biological activity of TNF-a is attributed to 
its soluble form, however membrane bound TNF does have some activity, and may be 
more able to bind and activate the TNF receptor 2 than its soluble form (Grell, Douni 
and others, 1995).
1.2.3.1.2 TNF-a production
Activated monocytes, macrophages, T and B-cells, NK cells, mast cells and fibroblasts 
secrete TNF-a. The biosynthesis of TNF-a is tightly controlled. Secretion is 
predominantly from activated cells, with low or undetectable levels of TNF-a from 
resting cells (Beutler, 2000;Beutler, Krochin and others, 1986). It is one of the major 
pro-inflammatory cytokines produced by monocytes after stimulation with 
lipopolysaccharide (LPS). Despite this, TNF-a has a short biological half life and 
circulating levels of TNF-a are short lived in the plasma even in the continued presence 
of endotoxin (Fong and Lowry, 1990). The presence of some cytokines such as 
interferon gamma (IFN-y), granulocyte-macrophage colony-stimulating factor (GM- 
CSF) can increase production of TNF-a by monocytes, whilst other cytokines, such as
IL-10, IL-4, IL-13, suppress its production (de Waal, Abrams and others, 
1991;Dickensheets, Freeman and others, 1997;Hart, Whitty and others, 1989). TNF-a 
secretion can be influenced further by genetic variability in the promoter region of the 
TNF-a gene in humans. This is discussed in section 1.3.1.2.
1.2.3.1.3 TNF receptors
There are two TNF-a receptors, TNFR-1 and TNFR-2. These are members of the TNF 
receptor superfamily which is defined by the presence of four cysteine-rich repeats in 
the extracellular region. The TNF receptor superfamily includes both cytokine 
receptors and other leukocyte surface glycoproteins such as CD40 and FAS antigen. 
Some of the receptors within this family bind more than one ligand. TNFR-1 and 
TNFR-2 bind both TNF-a and TNF-(3 with high affinity despite their large differences 
in amino acid sequence.
There is less than 25% homology between TNFR-1 and TNFR-2, with structurally 
different intracellular domains indicating different signalling mechanisms. The TNF 
receptors are present on all cells except for red blood cells. It is generally believed that 
TNFR-1 is responsible for the majority of biological actions of TNF-a. However cells 
of the immune system tend to express TNFR-2.
Under most circumstances TNFR-1 signals through protein kinases, such as I kappa B 
(I-kB) kinase, to increase pro-inflammatory gene expression. The central pro- 
inflammatory transcription factor appears to be nuclear factor kappa B (NF-kB). 
TNFR-1 can also signal through a series of protein-protein interactions to activate 
caspase-8 or caspase-2, resulting in apoptotic cell death. Far less is known about the 
signalling mechanism of TNFR-2 (Fig 1.6).
Soluble forms of both TNF receptors can be derived from the extracellular domains of 
the membrane bound receptor. Activation of monocytes by endotoxin or TNF-a 
induces rapid shedding of membrane bound TNFR-2 molecules, and internalisation of 
TNFR-1 (Ding, Sanchez and others, 1989;Higuchi and Aggarwal, 1994). Binding of 
only 1-5% of cell surface TNF-a receptors with TNF-a can induce shedding of soluble 
receptors from the entire cell surface (Curtis, McAtear and others, 1995). In contrast to 
TNF-a, sTNFR-2 molecules are stable with relatively long half-lives. Both agonist and
DUC'Tl
antagonist actions have been attributed to the soluble forms of the receptor. When 
sTNFR levels are high, they act to inhibit TNF-a by competing for ligand with the 
membrane bound TNFR (Van Zee, Kohno and others, 1992). However when soluble 
receptor concentrations are low, their presence may enhance activity by stabilizing the 
TNF-a molecule and prolonging its availability to bind to surface receptors (Aderka, 
Engelmann and others, 1992;Mohler, Torrance and others, 1993).
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Figure 1.6 The intracellular signalling pathways downstream of TNF receptors.
The TNFR-1, TNFR-2 and Fas, receptors are shown with their transmenbrane domains. 
Various adaptor proteins and signal transducing molecules that convey the signal 
initiated by TNF-a binding to its receptor are shown, as are the cross talk between 
molecules and pathways, (from Arthritis-Research)
1.2.3.1.4 Biological Effects o f TNF- a
1.2.3.1.4.1 Systemic
Circulating levels of TNF-a are associated with a rise in body temperature, anorexia, 
and release of acute phase proteins from the liver. TNF-a has a number of effects on 
the microvascular endothelium, which on the local level are important in host defence, 
but on a systemic level can be very harmful. TNF-a increases blood flow and vascular 
permeability. It increases endothelial adhesiveness to WBC and platelets via increased 
expression of tissue factor and adhesion molecules. Locally these act to limit the spread 
of bacteria, however if there is systemic overflow, then these same effects on blood 
vessels will result in disseminated intravascular coagulation (DIC) and shock.
1.2.3.1.4.2 Monocytes /  Macrophages
TNF-a acts synergistically with IFN-y in the activation of monocytes/macrophages, 
resulting in induction and secretion of many cytokines including IL-1, IL-6, IL-8, GM- 
CSF, IFN-y, TGF-p, IL-10, and prostaglandin E2. It also acts to induce further TNF-a 
secretion. It encourages migration of dendritic cells from the periphery to local lymph 
nodes where maturation takes place. This results in increased antigen presentation that 
is central to the link between innate and adaptive immunity.
1.2.3.1.4.3 T & B  cells
It promotes differentiation and activation of T & B-cells, and induction of apoptosis in 
mature T-cells.
1.2.3.2 Interleukin 6 (IL-6)
1.2.3.2.1 Structure
IL-6 is a 30-kDa glycoprotein with a four anti-parallel a-helical structure containing 
intramolecular disulphide bonds similar to IL-2, IL-4, GM-CSF (Somers, Stahl, and 
Seehra, 1997).
1.2.3.2.2 IL-6 production
IL-6 is produced at local sites and released into the circulation in almost all situations 
where normal homeostasis is disturbed. IL-6 is usually induced in combination with 
TNF-a and IL-1, and together these cytokines are responsible for the induction of fever, 
corticosterone release, and the hepatic proteins that constitute an acute phase reaction. 
IL-6 is secreted by T-cells, B-cells, monocyte/macrophages, bone marrow stromal cells, 
fibroblasts, keratinocytes, adipocytes, astrocytes, myocytes and endothelial cells. IL-6 
production is used in some studies as a correlate of cellular activation.
Compared to the major acute increases observed in inflammation, modest chronic 
elevations in circulating levels of IL-6 have also been observed in obesity, 
cardiovascular disease, and Type-2 diabetes (Hotamisligil, Amer and others, 
1995;Yudkin, Kumari and others, 2000). Low levels of circulating IL-6 can also be 
found in the blood of normal individuals.
1.2.3.2.3 IL-6 receptor
The IL-6 receptor belongs to the Class I  cytokine receptor superfamily and is formed by 
the noncovalent association of two subunits (gp80 and gpl30). The IL-6R a-chain 
(gp80) binds the IL-6 molecule with low affinity but does not signal. The P-chain 
(gpl30) does not bind IL-6 directly, but associates with the IL-6/a-chain complex and is 
responsible for signal transduction through the gpl30 subunit (Taga, Hibi and others, 
1989). The IL-6 receptor is expressed on activated B cells, plasma cells, T cells, 
monocytes, epithelial cells, fibroblasts, hepatocytes and neural cells (Fitzgerald, O'Neill 
and others, 2001).
Soluble forms of the IL-6 receptor are found in the blood of normal adult controls. 
Circumstances surrounding the generation of the soluble molecule are not clear. The 
soluble gpl30 subunit lacks the transmembrane segment, and has been shown to have 
an inhibitory action , on circulating IL-6. In contrast, the soluble form of the gp80 
subunit has been shown to bind circulating IL-6 and extends its half-life (1998).
1.2.3.2.4 Biological Effects o f IL-6
1.2.3.2.4.1 Systemic
Of all cytokines, IL-6 has been found most consistently in the circulation of septic 
patients (Hack, De Groot and others, 1989). It is unclear however whether IL-6 is 
merely an acute phase reaction-inducing cytokine or has any additional pro- 
inflammatory or anti-inflammatory actions. Serum IL-6 levels have been shown to 
correlate with C-reactive protein levels, fever, and mortality of patients with sepsis or 
trauma, but it is difficult to separate the biological effect of IL-6 from the degree of 
tissue injury that is stimulating the production of IL-6 (Hack, De Groot and others, 
1989;Holzheimer, Capel and others, 2000;Patel, Deen and others, 1994;Schluter, Konig 
and others, 1991).
1.2.3.2.4.2 Monocytes / Macrophages
IL-6 is secreted by monocytes following endotoxaemia, trauma, and acute infections. It 
has a negative feedback effect which inhibits further pro-inflammatory cytokine 
secretion (see below). IL-6 can be used to induce macrophage differentiation.
1.2.3.2.4.3 T & B  cells
IL-6 is important in T-cell proliferation and differentiation. The effects of IL-6 on T- 
cells are synergistic with IL-1 and TNF-a. In addition IL-6 produced by T-cells and 
macrophages following antigen presentation, stimulates B cells to proliferate and 
differentiate into antibody producing cells.
1.2.3.2.5 Anti-inflammatory properties o f IL-6
Recently the anti-inflammatory properties of IL-6 have been recognised. In IL-6 
knockout mice both local and systemic acute inflammatory responses are more marked, 
(Xing, Gauldie and others, 1998). IL-6 has been shown to inhibit the synthesis of TNF- 
a  and IL-1, promote the synthesis of ILl-ra and sTNFR, whilst having little effect on 
the synthesis of the anti-inflammatory cytokines IL-10 or TGF-P (Libert, Takahashi and 
others, 1994;Xing, Gauldie and others, 1998).
1.2.3.3 Interleukin-1 (IL-1)
1.2.3.3.1 Structure
There are 3 members of the IL-1 family; IL-1 a, IL-lp, and interleukin 1 receptor 
antagonist protein (IRAP or IL-lra). IL -la  and IL-lp are synthesised as large precursor 
molecules, but in contrast to other proteins, the synthesis occurs in association with
microtubules, not in the endoplasmic reticulum (Fig 1.7) (Stevenson, Torrano and
others, 1992). These precursor molecules have been shown to lack the series of amino 
acids (leader sequence) that enable the precursor protein to be inserted into the Golgi for 
cleavage, packaging and transport out of the cell. Instead the large precursor molecules 
remain intracellular or are expressed on the cell surface membrane where they are 
cleaved by proteases. Both the cytosolic and membrane bound IL -la  precursor are 
biologically active (Brody and Durum, 1989). Unlike IL -la, the IL-lp precursor 
requires cleavage for biological activity. The IL-ip precursor is cut intracellularly by a 
specific IL-lp converting enzyme (ICE) (Cerretti, Kozlosky and others, 1992). The 
mature biologically active molecule is then secreted through membrane channels.
1.2.3.3.2 IL-1 Production
IL -la  and p are made mainly by monocytes and macrophages, but also endothelial 
cells, fibroblasts and epidermal cells. Production is stimulated by LPS, other microbial 
products, cytokines (TNF-a, IFN-y, IL-2, GM-CSF), T-cell/antigen presenting cell 
interactions, and immune complexes (Stylianou and Saklatvala, 1998).
1.2.3.3.3 IL-1 Receptor
There are two IL-1 receptors. The type I receptor (IL-1RI), is ubiquitously expressed, 
binds both IL -la  and IL-lp with equal avidity, and transduces the IL-1 signal. The 
cytoplasmic tail of the type I receptor contains domains that are homologous with the 
Toll receptors. Binding of IL-1 signals the activation of a series of kinase cascades very 
similar to those activated by TNF-a (Stylianou and Saklatvala, 1998).
The type II receptor (IL-1RII) is more limited in its expression, being found on 
monocytes, B-cells, and neutrophils, and preferentially binds IL-lp. IL-1RH does not 
transduce a signal, but is shed from the surface on cellular activation, and in the soluble 
form binds IL-ipwith high affinity, inhibiting the cytokines action.
1.2.3.4.3 Biological effects
Increased IL-1 production has been reported in various disease states including 
infection, solid tumours, leukaemias, autoimmune disorders, graft versus host disease, 
following trauma and myocardial infarction, and in healthy subjects after strenuous 
exercise (Dinarello, 1996). However, most processes that cause production of IL-1 will 
also cause production of IL-6 or TNF-a, making it difficult to ascribe any particular 
finding specifically to IL-1. IL-1 stimulates hepatic acute-phase protein synthesis and is 
a major endogenous pyrogen. IL-1 acts on the hypothalamic-pituitary axis to induce 
corticosteroid release. On vascular endothelium, IL-1 increases expression of adhesion 
receptors causing leukocyte accumulation and chemokine secretion.
Whilst cells express a large number of IL-1RI, they require only a small number of 
receptors to bind IL-1 for cell stimulation (3-5 receptors per cell) (Gabay, 2002).
1.2.3.4 Interleukin-1 receptor antagonist (IL-Ira)
1.2.3.4.1 Structure
This is the 3rd member of the IL-1 family; and recognised predominantly as an anti­
inflammatory cytokine. In direct contrast to IL-1, IL-lra is a glycosolated protein (22 
kDa) that is synthesized in the endoplasmic reticulum, processed in the golgi, and 
actively secreted from the cell (Fig 1.7C)(Andersson, Bjork and others, 1992).
1.2.3.4.2 IL-lra Production
IL-lra is secreted predominantly by monocytes and macrophages, but also by 
neutrophils, hepatocytes, microglial cells, epithelial cells fibroblasts, and ketatinocytes 
(Arend and Guthridge, 2000;Stylianou and Saklatvala, 1998). Production of IL-lra 
follows the production of IL-1 by 1 to 2 hours, and may be stimulated by it. Compared 
to expression of IL-lp, IL-lra mRNA levels remain elevated for several hours 
following stimulation. Soluble IL-lra binds to both IL-1 receptors with an avidity equal 
to IL -la  and p, but does not induce receptor internalisation or intracellular signalling 
(Dinarello, 1996).
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Figure 1.7 Monocyte production of IL-la (A), IL-ip (B), and IL-lra (C). mRNA coding 
for both IL-la and IL-lp is translated in association with microtubules. (A) The majority of 
pro-IL-la remains in the cytosol but about 10-15% is transported to the cell membrane. Both 
the intracellular and membrane bound forms are biologically active. The pro-IL-la can be 
cleaved and released extracellularly by the cysteine protease, calpain. (B) After synthesis the 
pro-IL-ip remains primarily cytosolic until cleaved by ICE and transported out of the cell by 
membrane channels. A small amount of pro-IL-lp is secreted prior to cleavage. Pro-IL-ip has 
limited biological activity. (C) When stimulated, monocyte pro-IL-lra is translated in the 
endoplasmic reticulum and transported to the golgi. The leader sequence is cleaved and the 
soluble form of IL-lra is secreted from the cell. (Adapted from Dinarello CA et al 1996)
1.2.3.4.3 Biological effects
IL-lra competitively inhibits the binding of IL-1 to the cell surface receptors. However 
because of the extreme sensitivity of cells to the presence of even small concentrations 
of IL-1, IL-lra levels need to be in vast excess to effectively inhibit cellular activation.
Endogenously produced IL-lra is important in limiting inflammation and tissue damage 
in animal models of diseases such as arthritis, immune complex lung injury, graft versus 
host disease, septic shock, and ischemia/reperfusion (Arend and Guthridge, 2000). In 
studies of human disease, there has been some suggestion that the level of production of 
IL-lra in local tissues may not be sufficient to effectively block the inflammatory affect 
of IL-1 production (Arend and Guthridge, 2000). Despite its actions, recombinant IL- 
lra  has failed to show any benefit in human inflammatory trials to date (Arend, Malyak 
and others, 1998).
In addition to the soluble form of IL-lra, there are 3 intracellular isoforms, the 
biological functions of which are less clear.
1.2.3.5 Interleukin-10 (IL-10)
1.2.3.5.1 Structure
Interleukin-10 is an 18-kDa polypeptide, and the only cytokine considered to have a 
purely anti-inflammatory action. It is a member of the four a-helix family of cytokines. 
Human IL-10 is stable in basic conditions (up to pH 11) but rapidly inactivated by 
exposure to acid (pH <5.5).
1.2.3.5.2 IL-10 production
IL-10 is readily measurable in the circulation of patients with systemic illnesses and a 
variety of inflammatory states (Marchant, Deviere and others, 1994;van der, de Waal 
and others, 1997). It is secreted by monocytes/macrophages, T cells, activated B cells, 
and keratinocytes (Moore, de Waal and others, 2001;Moore, O’Garra and others, 1993), 
and considered one of the most important anti-inflammatory cytokine in humans (Opal 
and DePalo, 2000). It plays a major role in the regulation of immune response by 
inhibiting monocyte/macrophage, NK cells, and T cell effector function.
1.2.3.5.3 IL-10 receptor
The IL-10 receptor belongs to the interferon receptor superfamily, and is a single 
spanning transmembrane glycoprotein. Signal transduction by this receptor involves 
phosphorylation and activation of tyrosine kinases (Jakl) and transcription factors 
STATla & 3 (Fitzgerald, O'Neill and others, 2001). IL-10 receptors are constitutively 
expressed on most haemopoietic cells, and can be induced on non-haemopoietic cells 
such as fibroblasts and keratinocytes (Moore, de Waal and others, 2001). There is no 
literature describing a soluble form of the IL-10 receptor.
1.2.3.5.4 Biological effects o f  IL-10
1.2.3.5.4.1 Monocytes /  Macrophages
IL-10 acts on monocytes to inhibit cytokine, chemokine, and prostaglandin E2 
production (Niiro, Otsuka and others, 1994;Niiro, Otsuka and others, 1995). It reduces 
expression of the LPS recognition and signalling molecules CD 14 and Toll like receptor 
(TLR)-4, and inhibits antigen presentation, while enhancing phagocytosis, and 
expression of CD 16, and CD64 (Muzio, Bosisio and others, 2000;0pal, Wherry, and 
Grint, 1998). In addition, EL-10 strongly inhibits synthesis at both the mRNA and 
protein levels of EL-1, -6, -8, -10, TNF-a, G-CSF, and GM-CSF, following activation 
by LPS or LPS+EFN-y (de Waal, Abrams and others, 1991). The inhibitory effects of 
IL-10 on IL-1 and TNF-a production are central to its anti-inflammatory activity as 
these cytokines often act synergistically in inflammatory pathways and processes, and 
amplify responses by inducing secondary mediators such as chemokines, 
prostaglandins, and platelet activating factor (PAF).
IL-10 inhibits the differentiation of monocytes into dendritic cells, and promotes their 
maturation to macrophages with increased endocytic ability (Allavena, Piemonti and 
others, 1998). Despite the enhanced capacity of monocyte/macrophages to phagocytose 
opsonized particles, bacteria or fungi, IL-10 paradoxically reduces the ability of the cell 
to kill the ingested organisms by decreasing the generation of superoxide anion (O2 ') 
and nitric oxide (NO) (Bogdan, Vodovotz, and Nathan, 1991;Cenci, Romani and others, 
1993;Gazzinelli, Oswald and others, 1992;Moore, de Waal and others, 2001).
IL-10 reduces surface expression of MHC Class II antigens, CD54 (ICAM-1), CD80 
and CD86, significantly impairing the T-cell activating capacity of monocytes(de Waal,
Abrams and others, 1991;de Waal, Haanen and others, 1991). It decreases both the 
constitutive and inducible levels of MHC Class II expression (Wanidworanun and 
Strober, 1993), and has been shown to inhibit the transport of mature peptide loaded 
MHC Class II molecules to the plasma membrane (Koppelman, Neefjes and others, 
1997).
Whilst IL-10 inhibits the production of pro-inflammatory cytokines, it enhances the 
production of their natural antagonists. IL-10 enhances the production of IL-lra and 
sTNFR -1 and -2 (Cassatella, Meda and others, 1994;Joyce and Steer, 1996;Moore, de 
Waal and others, 2001). Of note, human IL-10 displays auto-regulatory activity by 
inhibiting its own production by LPS-activated monocytes.
1.23.5.4.2 T & B  cells 
The cytokine-producing CD4+ helper T lymphocytes are classified into 2 functionally 
dichotomous subsets on the basis of the cytokines produced; Thl and Th2. EL-10 
strongly inhibits cytokine production of both subsets directly and indirectly. Indirectly 
IL-10 inhibits proliferation and cytokine production of CD4+T-cells via its down- 
regulatory affects on antigen presenting function (de Waal, Haanen and others, 
1991;Fiorentino, Zlotnik and others, 1991b). In addition, IL-10 has been shown to 
directly inhibit cytokine production at both the protein and mRNA levels in Thl cells 
(IL-2, -3, IFN-y), Th2 cells (IL-4, -5), and NK cells (TNF-a, IFN-y), when 
monocytes/macrophages are the antigen presenting cells (Fiorentino, Zlotnik and others, 
1991b;Fiorentino, Zlotnik and others, 1991a;Moore, O'Garra and others, 1993;Vieira, 
Waal-Malefyt and others, 1991). This inhibition of cytokine production is not seen if 
dendritic cells are utilized as the APC (Fiorentino, Zlotnik and others, 1991a). In 
contrast, IL-10 has stimulatory effects on CD8+ T-cells, inducing their recruitment, 
cytotoxic activity, and proliferation (Groux, Bigler and others, 1998;Moore, de Waal 
and others, 2001).
Of particular interest is the more recent finding that activation of T-cells in the presence 
of IL-10 can induce a state of nonresponsiveness/anergy (Groux, Bigler and others, 
1996;Groux, Bigler and others, 1998). This IL-10 mediated anergy appears to be 
related to the induction of a population of regulatory T-cells, distinct from Thl and Th2 
cells, which produce high levels of IL-10 (Cobbold and Waldmann, 1998;Groux,
O'Garra and others, 1997). To date these regulatory T-cells have been isolated under 
different conditions and exhibit a varying cytokine expression profile. Preliminary 
evidence suggests that the regulatory T-cells are induced by a subset of dendritic cells 
producing high levels of IL-10.
Interleukin-10 has no effect on expression of MHC Class II on human B cells. IL-10 
enhances survival of normal B-cells by increasing expression of the anti-apoptotic 
protein bcl-2 (Itoh and Hirohata, 1995;Levy and Brouet, 1994). IL-10 is a potent co­
stimulator of B cells resulting in increased B cell proliferation and 
differentiation/isotype switching, which can be further enhanced by the presence of IL-2 
or IL-4 (Moore, de Waal and others, 2001;Rousset, Garcia and others, 1992). 
Combined, IL-10 and IL-4 have a synergistic effect on B cell proliferation.
1.2.4 Evidence for the role of these cytokines in morbidity following 
CPB
Each of the cytokines discussed above have been reported to play a role in the systemic 
inflammatory response seen following CPB, with circulating levels rising during or in 
the immediate post-operative period (Fig 1.8). What is currently known about 
relationship between surgery and systemic rise, and evidence from prior research that 
implicates each of these cytokines in the morbidity observed following CPB is outlined 
below.
1.2.4.1 Cardiopulmonary bypass and TNF-a
TNF-a is a potent pro-inflammatory cytokine that mediates much of the systemic 
inflammatory response seen in patients with sepsis (Blackwell and Christman, 
1996;Pinsky, Vincent and others, 1993;Thijs and Hack, 1995). Therefore TNF was a 
prime candidate for mediating post perfusion syndrome.
TNF-a has been shown in studies involving both human and animal myocardium, to 
produce a dose dependent negative inotropic response within minutes of production 
(Cain, Meldrum and others, 1999). There are 3 reported potential mechanisms through 
which TNF-a can cause myocardial depression: (1) an immediate pathway mediated by
activation of the neural sphingomyelinase pathway (Oral, Dorn, and Mann, 1997), (2) a 
delayed pathway involving alterations in nitric oxide (NO) homeostasis, with a shift 
from the cardioprotective constitutively produced NO to increased expression of the 
inducible nitric oxide synthase (iNOS) (Finkel, 2002;Finkel, Oddis and others, 
1992;Gulick, Chung and others, 1989;Kumar, Kumar, and Parrillo, 1999), and (3), 
activation and/or release of myocardial depressants such as IL-1 p and IL-18. The first 
and second of these mechanisms act by impeding Ca2+ release or desensitizing the 
myocytes to the effects of Ca2+ respectively, and predominantly affect systolic 
fimction(Cain, Meldrum and others, 1999;Goldhaber, Kim and others, 1996;Oral, Dorn, 
and Mann, 1997). TNF-a also induces structural damage to endothelial cells by 
rearrangement of actin filaments and loss of tight junctions resulting in capillary leak 
(Brett, Gerlach and others, 1989;Stephens, Ishizaka and others, 1988).
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Figure 1.8 Hypothetical serum cytokine response in patients undergoing cardiac 
surgery with CPB (Adaptedfrom Brix-Christensen V and Chew M., 2001)
While many studies have detected elevated levels of TNF-a following cardiac surgery, 
this is not always the case (McBride, Armstrong and others, 1996). Even when 
detected, concentrations are consistently lower than other circulating pro-inflammatory 
cytokines (Gilliland, Armstrong, and McMurray, 1998;Marano, Garulacan and others, 
2000;Roth-Isigkeit, Hasselbach and others, 2001). The obvious limitation with 
interpreting plasma cytokine levels is that they do not necessarily reflect cytokine 
concentrations at the local tissue level. Whilst the main source for circulating TNF-a 
following cardiac surgery is probably monocytes and macrophages (Tracey and Cerami, 
1993), the myocardium is also a recognised source (Wan, DeSmet and others, 1996). 
Levels of TNF-a have been shown to be significantly higher in coronary sinus blood 
compared to arterial blood. Thus low levels of TNF-a in plasma may not reflect the 
biological importance of TNF in outcome following CPB, however, the levels detected 
are markedly different from sepsis indicating potential differences in the aetiology of 
capillary leak, hypotension and end-organ dysfunction.
1.2.4.2 Cardiopulmonary Bypass and IL-6
Interleukin-6 has been consistently measured systemically following bypass in both 
paediatric and adult cardiac studies (Butler, Pathi and others, 1996;Defraigne, Pincemail 
and others, 2000;Roth-Isigkeit, Hasselbach and others, 2001;Rothenburger, Soeparwata 
and others, 2001;Wei, Kuukasjarvi and others, 2001). It is thought to be related to the 
extent of tissue injury, and has been used as a predictor of outcome (Hauser, Ben Ari 
and others, 1998;Oka, Murata and others, 1992). Plasma levels of IL-6 have been 
shown to correlate with, duration of aortic cross-clamping, circulatory arrest time and 
hypothermia (Hovels-Gurich, Vazquez-Jimenez and others, 2002;Steinberg, Kapelanski 
and others, 1993). Like TNF-a, IL-6 has been implicated in post bypass myocardial 
dysfunction via nitric-oxide dependant pathways (Finkel, Oddis and others, 
1992;Hennein, Ebba and others, 1994). IL-6 is also thought to play a role in leukocyte- 
mediated injury to the myocardium by the induction of intercellular adhesion molecule- 
1 (ICAM-1) expression on cardiac myocytes (Sawa, Ichikawa and others, 1998;Youker, 
Smith and others, 1992). Measurable levels of IL-6 have been reported pre-operatively 
in children with congenital heart disease (Chew, Brandslund and others, 2001;Duval, 
Kavelaars and others, 1999).
1.2.4.3 Cardiopulmonary Bypass and IL-10
The stimulus for IL-10 production during cardiac surgery is uncertain. Adult studies 
report a rise in both IL-10 and pro-inflammatory mediators intra-operatively or within 
the first two hours of aortic cross clamp release (Dehoux, Philip and others, 
1995;Tabardel, Duchateau and others, 1996). However similar studies in children have 
shown that the IL-10 response may precede any pro-inflammatory response (McBride, 
Armstrong and others, 1996;Seghaye, Duchateau and others, 1996).
It is unlikely that the IL-10 response arises as a direct result of contact of the blood with 
the bypass circuit, as neither IL-10, TNF-a, or IL-6 is detected in isolated CPB models 
(Gormley, Armstrong and others, 2003;McBride, Armstrong and others, 1996). There 
has been no consistent correlation between IL-10 levels and measures of surgical stress, 
although individuals have reported correlations between postoperative levels and 
duration of bypass or operative temperature (Sablotzki, Welters and others, 
1997;Seghaye, Duchateau and others, 1996;Wan, LeClerc, and Vincent, 1997a). EL-10 
has been reported to have cardioprotective effects. It inhibits neutrophil-endothelial 
interactions, and inhibits vascular smooth muscle proliferation (Hayward, Nossuli and 
others, 1997;Selzman, McIntyre, Jr. and others, 1998). Peri-operatively treatment with 
steroids significantly increases both IL-10 and IL-lra production (Giomarelli, Scolletta 
and others, 2003;Kawamura, Inada and others, 1999;Rasmussen, Kelly, and Clausen, 
2001;Seghaye, Duchateau and others, 1996;Tabardel, Duchateau and others, 
1996;Tassani, Richter and others, 1999), suggesting a modulating effect of 
corticosteroids on IL-10 synthesis. Whether high levels of circulating IL-10 following 
CPB is protective or harmful is still not clear.
Yang et al (2000) attempted to address this issue in a model of myocardial 
ischemia/reperfusion using an IL-10 knockout mouse (Yang, Zingarelli, and Szabo, 
2000). It was shown that IL-10 knock out mice had significantly greater reperfusion 
injury both histologically and biochemically. Serum TNF-a levels were much greater 
in the IL-10 knockout mice compared to the wild type mouse (>300 vs <100pg/ml), 
suggesting that endogenously produced IL-10 serves to suppress the production of TNF- 
a  following an ischemic/reperfusion event. Variation in EL-10 production may in part, 
explain why some studies fail to detect systemic overflow of TNF-a.
There is also significant interindividual variation in IL-10 secretion following 
cardiopulmonary bypass. Whilst genetics may play a role in this (discussed below), the 
presence of hypoxaemia pre-operatively has been associated with lower peri-operative 
IL-10 release (Hovels-Gurich, Schumacher and others, 2002).
1.2.4.4 Cardiopulmonary Bypass and other cytokines
A pronounced rise in plasma IL-1 receptor antagonist (IL-lra) has been seen in both 
adults and children following CPB (Duval, Kavelaars and others, 1999). Consistent 
with in vitro findings where IL-10 leads to the production of IL-lra, most studies show 
an IL-lra response occurring late in CPB (Duval, Kavelaars and others, 1999;McBride, 
Armstrong and others, 1995;McBride, Armstrong and others, 1996). There is no data to 
suggest a direct role of IL-lra on the heart or circulation, however it is recognised to 
play a significant role in limiting the inflammation and tissue damage caused by IL-1.
Raised plasma levels of IL-8 are consistently reported following cardiac surgery 
involving CPB (Defraigne, Pincemail and others, 2000;Finn, Naik and others, 
1993;Rothenburger, Soeparwata and others, 2001). The plasma rise in IL-8 appears to 
coincide with the systemic rise in IL-6, beginning towards the end of theatre, peaking 1- 
3 hours post-op and remaining elevated at 24 hours (Defraigne, Pincemail and others, 
2000;Finn, Naik and others, 1993;Rothenburger, Soeparwata and others, 2001). Plasma 
levels have been shown to correlate with duration of CPB and ischemic time, (Finn, 
Naik and others, 1993;Steinberg, Kapelanski and others, 1993). Both IL-6 and IL-8 
have been shown to be produced by cardiac myocytes under conditions of ischemia- 
reperfusion, and levels have been found to reflect the extent of early myocardial damage 
(Dreyer, Phillips and others, 2000;Metinko, Kunkel and others, 1992;Pannitteri, Marino 
and others, 1997;Sawa, Ichikawa and others, 1998). IL-8 is a potent chemokine with 
neutrophil-stimulating properties. These properties have been postulated to have a 
causative role in the lung injury seen following CPB (Casey, 1993;Finn, Moat and 
others, 1993;Wan, LeClerc, and Vincent, 1997b). Interestingly the stimulus of CPB 
alone is sufficient to induce IL-8 secretion (Bums, Newburger and others, 
1995;McBride, Armstrong and others, 1995).
1.2.5 Mechanisms to reduce the Inflammatory response to CPB
With the identification of the mediators of inflammation activated by CPB, and 
recognition of the mechanisms most likely to stimulate their release, strategies 
attempting to control the inflammatory response following surgery were developed. 
Techniques such as maintenance of haemodynamic stability, minimisation of exposure 
to CPB circuitry, pharmacological and immunological agents have all undergone 
clinical trials (recent review (Laffey, Boylan, and Cheng, 2002)). Hypothermia, 
haemofiltration and heparin bonded circuits are all currently utilised in an effort to 
decrease the inflammatory response to CPB and to minimise the occurrence of post­
perfusion syndrome (Fig 1.9).
1.2.5.1 Minimisation of trauma
Advances in minimally invasive surgery such as laparoscopic and thoracoscopic 
procedures have prompted questions about whether the avoidance of a full median 
sternotomy would lessen the inflammatory response. There has been one non­
randomised study which suggested shorter recovery to normal lifestyle, however at 
present operating times are considerably longer with minimal invasive techniques 
(Glower, Landolfo and others, 1998).
A crucial factor triggering the inflammatory response to CPB is the cellular trauma 
caused by exposure of blood to nonphysiological surfaces. Heparin bonding of the 
artificial surface was proposed as a means of reducing cellular activation. Heparin- 
bonded circuits have been shown to significantly reduce complement activity, 
granulocyte activation, platelet adhesion and circulating levels of TNF-a, IL-6 and IL-8 
in children (Ozawa, Yoshihara and others, 2000). Their use however, has not been 
associated with improvement in outcome measures.
1.2.5.2 Leukocyte depletion
Circulating white blood cells play a central role in the inflammatory response to cardiac 
surgery. There is increasing evidence that leukocyte depletion, by means of leukocyte 
specific filters, may attenuate pulmonary and myocardial injury especially in patients 
with long bypass time (Johnson, Thomson and others, 1995;Morioka, Muraoka and 
others, 1996). A large scale clinical trial in adult CPB patients showed that
leukodepleting transfused blood significantly reduced the overall 60-day mortality 
primarily by reducing multiorgan failure (van de Watering, Hermans and others, 1998).
1.2.5.3 Removal of inflammatory mediators
Since the late 1990’s, haemofiltration has been routinely used in children undergoing 
surgery requiring long bypass time, and most neonatal repairs. Haemofiltration has 
been associated with decreased systemic levels of IL-1, 6, 8, 10, TNF-a, and reduced 
complement activation(Bando, Vijay and others, 1998;Joumois, 1998;Joumois, Israel- 
Biet and others, 1996). Clinically there appears to be reduced postoperative bleeding, 
increased cardiac contractility, improved haemodynamic stability, and decreased length 
of stay (LOS) (Bando, Turrentine and others, 1998;Bando, Vijay and others, 
1998;Davies, Nguyen and others, 1998;Joumois, 1998;Joumois, Israel-Biet and others,
1996). Initially it was believed that this reduction in post perfusion syndrome following 
haemofiltration was secondary to the filtering off of pro-inflammatory mediators, 
however it is probably due to the removal of excess free water.
1.2.5.4 Suppression of pro- and enhancement of anti-inflammatory 
mediators
Steroidal pre-treatment has been used on and off in cardiac surgery for 30 years, but its 
role in improving clinical outcome is still unproven. The main mechanism of action 
proposed is direct inhibition of NF-kB, and hence reduced levels of pro-inflammatory 
cytokines, however this may be an over simplification of more complex cellular 
interactions (Lee and Burckart, 1998). In adult patients the use of peri-operative 
steroids has been shown to be associated with reduced systemic levels of pro- 
inflammatory cytokines and increased anti-inflammatory cytokines (particularly IL-10), 
however clinical benefits have not been consistently evident (Chaney, 2002;Giomarelli, 
Scolletta and others, 2003;Kawamura, Inada and others, 1999;Tabardel, Duchateau and 
others, 1996;Tassani, Richter and others, 1999;Wan, LeClerc, and Vincent, 1997b). 
Control trials using steroids in children undergoing CPB have not been associated with 
decreased levels of inflammatory mediators, and are not routinely used at the centre in 
which this work was undertaken.
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Figure 1.9 Therapeutic strategies to reduce inflammatory response to CPB
(adaptedfrom Wan S et al 7997)(Wan, LeClerc, and Vincent, 1997b).
Many effector proteins of the cytokine, complement, and haemostatic cascades are 
serine proteases -> amplification of the inflammatory cascade. Inhibiting these 
proteases may limit inflammation to local tissues and reduce systemic overflow. The 
most commonly used serine protease inhibitor is aprotinin. Use of aprotinin at the end 
of cardiac surgery not only prevents excessive blood loss, but has pronounced anti­
inflammatory affects (Levi, Cromheecke and others, 1999). Anti-inflammatory 
properties of aprotinin include:
4- increased IL-10 secretion (Hill, Diego and others, 1998)
4- attenuating platelet activation and maintenance of platelet function 
(Wachtfogel, Kucich and others, 1993)
4-  decreased complement activation (Wachtfogel, Kucich and others, 1993) 
4 - decreased systemic release of IL-6 , IL-8 , and TNF-a (Harig, Feyrer and 
others, 1999;Soeparwata, Hartman and others, 1996)
4-  inhibition of cytokine-induced iNOS induction (Hill and Robbins, 1997)
4  inhibition of the upregulation of monocyte and granulocyte adhesion 
molecules (Gilliland, Armstrong, and McMurray, 1999;Hill, Alonso and 
others, 1995)
-4 reduced post-bypass myocyte damage (Wendel, Heller and others, 1995)
Directed anti-mediator therapies have not been tested in the field of cardiopulmonary 
bypass. The poor results seen in human sepsis trials have resulted in caution in their 
application in CPB patients. However bypass may provide the opportunity to trial these 
therapies prior to the inflammatory insult with a more successful outcome.
1.3 G e n et ic s  a n d  in f l a m m a t io n
As a clinician in Intensive Care it is impossible not to ask the question ‘Why do some 
children experience an inflammatory insult (e.g. cardiac surgery or an infectious 
disease) and respond with minimal systemic inflammation, while others require 
prolonged intensive care support, develop nosocomial infection, and progressive 
multiorgan dysfunction, despite all the advances of the 21st century?’ The presence of 
significant inter-individual variation in cytokine response to LPS stimulation raises the 
possibility of a role for genetic factors in the inflammatory response to an insult 
(Eskdale, Keijsers and others, 1999;Heesen, Kunz and others, 2003;Jacob, Fronek and 
others, 1990;Molvig, Baek and others, 1988;Westendorp, Langermans and others, 
1997a). However, this difference between individual’s cytokine response is unlikely to 
be a single-gene effect but rather polygenic in nature, with many confounding 
environmental variables. This makes identification of a genetic component to the 
inflammatory response exceedingly difficult. One method is to select candidate genes 
that are known or hypothesised to have a biological effect important in the pathogenesis 
of the disease and test for the association of the polymorphism with the disease 
phenotype of interest.
1.3.1 Candidate Genes Influencing the Intensity of the 
Inflammatory Response.
Allelic variations that exist stably in a population and have a frequency of at least one- 
percent or more are known as polymorphisms. The most frequent type of 
polymorphism in DNA is caused by single base-pair substitution (SNP). When the SNP 
is within a protein-coding region of a gene, the variant allele may lead to an amino acid 
substitution that functionally alters the resultant protein. Much more commonly SNP’s 
occur in the nontranslated regions. These SNP’s may still have biological effects. 
SNP’s in the promoter region may alter binding affinity of transcription factors, such as 
NF-kB, and therefore alter the rate of gene transcription and translation. SNP’s within 
the 5’upstream region and 3’downstream region may alter stability of the transcribed 
messenger RNA (mRNA) or enhancer activity, therefore altering the efficiency of gene 
transcription and mRNA translation. SNP’s within introns are less likely to have 
biological effects, although they may be linked with biologically active SNP’s within 
other parts of the gene.
Three of the cytokines recognised to play an important role in the systemic 
inflammatory response and outcome following cardiopulmonary bypass have functional 
promoter polymorphisms. These are IL-6 -174, TNF-a -308, and IL-10 -1082, -819, 
and -592.
1.3.1.1 IL-6 -174 promoter polymorphism
IL-6 is rapidly cleared from the plasma, therefore the systemic concentrations of IL-6 
are largely reflective of the level of gene expression (Castell, Geiger and others, 1988). 
Expression of EL-6 is tightly regulated by a number of transcription factors which bind 
to the IL-6 promoter region. In 1998 a single nucleotide polymorphism deriving from a 
G to C substitution was identified at position -174 of the human IL-6 promoter within a 
negative regulatory domain (Fishman, Faulds and others, 1998). The C allele is 
common in Caucasians (UK frequency 0.41, 95% Cl 0.38-0.43) (Fishman, Faulds and 
others, 1998). In luciferase reporter vector assay, the -174 C construct exhibited both a 
decreased spontaneous and inducible expression of transcripts as compared to the -174 
G construct (Morse, Olomolaiye and others, 1999). To further support this, the C allele
was associated with significantly lower plasma levels of IL-6 in healthy adults 
(Burzotta, Iacoviello and others, 2001;Fishman, Faulds and others, 1998).
These results lead to the concept that a certain IL-6 promoter genotype may be 
associated with a low or high IL-6 producer phenotype, which in turn may positively or 
negatively influence the outcome of IL-6 mediated pathology. A number of clinical 
situations have been studied describing their relationship with the -174 allele (Georges, 
Loukaci and others, 2001;Humphries, Luong and others, 2001;Jones, Brull and others, 
2001;Marshall, Webb and others, 2002;Vickers, Green and others, 2002). Whilst in 
most cases the -174 G allele has been associated with high IL-6 production more 
recently data suggests that when the genotype is stressed (e.g. surgery), the -174 CC 
genotype results in significantly higher IL-6 production (Brull, Leeson and others, 
2002;Brull, Montgomery and others, 2001).
1.3.1.2 TNF-a -308 promoter polymorphism
The gene coding for TNF-a is located within the MHC Class HI region of chromosome 
6, resulting in linkage disequilibrium between TNF-a alleles and certain MHC alleles. 
It is probably because of this that those diseases with an HLA association (e.g. 
rheumatoid arthritis, inflammatory bowel disease) frequently have an association with a 
TNF-a polymorphism. To date 11 polymorphisms have been reported in the TNF-a 
promoter region, some of which have been reported to affect either TNF-a production 
and/or TNF-a secretion.
Tumour necrosis factor-a is regulated both transcriptionally and post-transcriptionally. 
A G to A substitution at position -308 in the promoter region occurs with a frequency of 
about 30% in Caucasians (Mira, Cariou and others, 1999). The A allele has been 
reported to affect the ability of nuclear factors to bind to the -308 region (Kroeger, 
Carville, and Abraham, 1997), strongly enhancing transcriptional activation (Braun, 
Michel and others, 1996;Wilson, Symons and others, 1997) and has been associated 
with substantially increased (6-9 fold) in vitro gene transcription and protein synthesis 
(Bouma, Crusius and others, 1996;Heesen, Kunz and others, 2003;Louis, Franchimont 
and others, 1998;Morse, Olomolaiye and others, 1999;Wilson, Symons and others,
1997). The presence of the A allele has been associated with increased severity of
clinical disease in some, but not all studies (Allen, 1999;Mira, Cariou and others, 
1999;Nadel, Newport and others, 1996;Stuber, Petersen and others, 1996). It is worth 
noting, the -308 polymorphism is actually only 307 base pairs upstream of the 
transcription site and was originally misnumbered (Uglialoro, Turbay and others, 1998))
1.3.1.2.1 Clinical disease and the TNF-a polymorphism
Just as TNF-a levels have been examined in a wide range of clinical pathologies, the 
finding of functional polymorphisms in the TNF-a promoter has quickly resulted in a 
number of studies examining their prevalence in diseases. The results of these studies 
have also been conflicting. Some authors believe that TNF-a genotype does influence 
clinical disease (Allen, 1999;Bouma, Crusius and others, 1996), whilst others conclude 
that TNF-a promoter polymorphisms exist solely because they are in linkage 
disequilibrium with HLA alleles, and are of no functional significance (Uglialoro, 
Turbay and others, 1998).
The -308 polymorphism has a strong association with the autoimmune haplotypes 
HLA-Ai, Bg, and DR3 through linkage disequilibrium (Wilson, de Vries and others, 
1993) However Bouma et al (1996) showed that secretion of TNF-a was elevated in 
individuals with the -308A allele whether they were DR.3+ or D R/, suggesting that 
linkage to HLA-DR3 was not responsible for the difference in TNF-a production 
observed.
There have been four studies examining the association between the -308 polymorphism 
and outcome from sepsis, one of which was in children (Mira, Cariou and others, 
1999;Nadel, Newport and others, 1996;Stuber, Petersen and others, 1996). Nadel et al 
reported a higher frequency of the TNF-a -308A allele in children who did not survive 
their admission to hospital with meningococcal disease (relative risk for -308 A/A 
homozygote 2.5; Cl, l.l-5.7)(Nadel, Newport and others, 1996). Ethnicity was not 
reported, nor was TNF-a levels measured in this study. Whilst these findings have not 
been reproduced, a multicentre adult study done a few years later showed increased 
prevalence of the TNF-a -308A allele in patients admitted to ICU with septic shock 
compared to healthy controls, and an association between -308A and death after 
controlling for age and severity of illness (Mira, Cariou and others, 1999). This study
however found no difference in serum TNF-a levels between groups stratified by 
genotype. In 2000, a study confirmed the association between the presence of the - 
308A allele and increased mortality among septic ICU patients , and for the first time 
reported higher circulating levels of TNF-a in non-survivors compared to survivors 
(Tang, Huang and others, 2000). The TNF-a- 308 polymorphism has not been shown 
to play a role in the development of sepsis and outcome in a general surgical cohort 
(Stuber, Petersen and others, 1996).
There have been two studies examining the association between TNF-a -308 
polymorphism and outcome following adult cardiac surgery and one examining the role 
of the polymorphism in heart transplant patients. Yende and colleges studied 400 adult 
patients following coronary artery bypass grafting (CABG) and found that the presence 
of the more common -308G allele, in combination with the TGF-P +250G allele, was 
associated with prolonged mechanical ventilation independent of preoperative risk 
factors (Yende, Quasney and others, 2003). Ryan et al found no association between 
the -308 polymorphism and the development of lactic acidosis post-operatively (Ryan, 
Balding and others, 2002). In a study of 175 heart transplant recipients and 212 healthy 
controls, Densem and co-workers found an overrepresentation of the TNF-a -308A 
allele in patients with end-stage non-ischemic myocardial dysfunction (Densem, 
Hutchinson and others, 2002).
The -308A genotype has been associated with a number of clinical outcomes including 
bronchial hyper responsiveness in asthma (Li Kam Wa, Mansur and others, 1999), 
idiopathic dilated cardiomyopathy, celiac disease and severe outcomes in infectious 
diseases including meningococcal disease (mentioned above), cerebral malaria, 
leishmaniasis, and leprosy (McGuire, Hill and others, 1994;Nadel, Newport and others, 
1996;Roy, McGuire and others, 1997). Levels of TNF-a production are also felt to be 
important in liver, cardiac and renal allograft rejection, where anti-TNF-a antibodies 
have been utilised in an attempt to reduce the rate of rejection. Some groups advocate 
screening all allograft recipients for the -308 polymorphism and tailoring the amount of 
immunosuppression according to the presence or absence of the polymorphism.
1.3.1.3 IL-10 promoter polymorphisms
Stimulation of human blood cultures with endotoxin reveals large inter-individual 
variation in IL-10 secretion (van der Linden, Huizinga and others, 1998), which has 
been shown in monozygotic twins to have a genetic component of over 70% 
(Westendorp, Langermans and others, 1997a;Westendorp, Langermans and others, 
1997b). Levels of secreted IL-10 are directly proportional to levels of IL-10 mRNA. A 
series of bi-allelic polymorphisms in the promoter of the IL-10 gene, which regulate IL- 
10 transcription, have been described at positions -1082, -819, and -592 (Turner, 
Williams and others, 1997). Three major haplotypes have been reported -  GCC, ACC, 
and ATA. The GCC haplotype is associated with the highest IL-10 levels (1.3 fold) 
using Con-A stimulated cells homozygous for the GCC haplotype (Eskdale and 
Gallagher, 1995;Tumer, Williams and others, 1997;Westendorp, Langermans and 
others, 1997b). In western populations, GCC, ACC and ATA haplotype frequencies are 
54.1%, 28.3% and 16.8% respectively. A rare GTA haplotype has a frequency of 0.6% 
(Eskdale and Gallagher, 1995). Recently it has become apparent that the GCC 
haplotype group should be subdivided into two groups ; GGCC and GACC due to a 
G/A polymorphism at -851 described by Alfonso et al and verified by Wood et al 
(Turner, Williams and others, 1997;Wood, Keen and others, 2001).
The promoter region for IL-10 contains putative binding sites for a number of 
transcription factors known to be involved in the regulation of other cytokines (Kube, 
Platzer and others, 1995;Kube, Rieth and others, 2001). However the precise 
transcription factors involved in IL-10 regulation in humans are still uncertain.
1.3.1.3.1 Clinical disease and IL-10polymorphisms
Levels of IL-10 production are critical in immune regulation, controlling the balance 
between inflammatory and humoral responses, limiting and ultimately terminating 
inflammation. IL-10 has been suggested to play a role in peripheral tolerance and in 
protection against autoimmunity (Moore, de Waal and others, 2001). The concept that 
the presence or absence of a functional IL-10 promoter polymorphism could alter 
susceptibility to a chronic inflammatory or autoimmune disease has become much 
investigated. To date there has been no clear association between the prevalence or
severity of chronic hepatitis, multiple sclerosis, rheumatoid arthritis or systemic lupus 
disease and IL-10 genotype (Bathgate, Pravica and others, 2000;Eskdale, Gallagher and 
others, 1998;Eskdale, Wordsworth and others, 1997;Hajeer, Lazarus and others, 
1998;Koch, Kastrati and others, 2001;Lazarus, Hajeer and others, 1997;Middleton, 
Taylor and others, 1998;Mok, Lanchbury and others, 1998). There has been only one 
study examining the association of an IL-10 polymorphism in sepsis (Lowe, Galley and 
others, 2003). This study of 67 critically ill patients admitted to ICU showed that the 
presence of the IL-10 -592C allele was associated with a higher IL-10 response 
following whole blood stimulation with endotoxin, but with decreased mortality. 
Recently an association of the IL-10 -1082G allele with lower circulating levels of IL- 
10 three hours following CPB has been shown, but there was no association between 
genotype and outcome measures (Galley, Lowe and others, 2003).
Because the nature of functional polymorphisms is to amplify an initial inflammatory 
response, promoter polymorphisms may have their greatest effect when the cytokine 
response to an inflammatory insult is unbalanced.
1.4 THE ROLE OF CYTOKINE BALANCE
Initially the model used to explain the clinical findings following cardiopulmonary 
bypass was one of persistent, uncontrolled inflammation, and the key mediators were 
thought to be pro-inflammatory. In 1996, Roger Bone’s landmark editorial revised the 
model for inflammation and raised the possibility that an excessive anti-inflammatory 
response may also be harmful, and the concept of immune balance emerged (Bone, 
1996). From this point, research into inflammation following an insult has trended 
away from identifying and blocking a single mediator of inflammation towards methods 
of quantitating the state of cytokine balance that exists, and targeting treatment towards 
restoring homeostasis (Fig 1.11).
1.4.1 The intricate balance that exists between TNF-a and IL-10
In contrast to TNF-a, IL-10 is constitutively produced at low levels by circulating 
monocytes and macrophages, and inhibits its own production via a negative feedback
loop. As mentioned before, high concentrations of IL-10 are a potent inhibitor of 
monocyte/macrophage production of TNF-a. IL-10 has been shown to inhibit both the 
proteolytic cleavage of the membrane bound TNF-a molecule and NF-kB activation 
during TNF-a transcription (Bogdan, Paik and others, 1992). In addition IL-10 
increases the synthesis and release of sTNFR-2 at a transcriptional level (Dickensheets, 
Freeman and others, 1997). Figure 1.10 illustrates the effect of IL-10 on the immune 
balance between TNF-a and sTNFR-2. As the dose of IL-10 increases, TNF-a levels 
decrease, whilst levels of the inhibitory sTNF-R increase.
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Figure 1.10 The dose related effect of IL-10 on production of TNF-a and sTNFR- 
2 by LPS stimulated monocytes (adapted from Wan S et al 1998).
In healthy individuals, although circulating levels of TNF-a are negligible, TNF-a 
mRNA levels in monocytes increase strikingly within 15-30 minutes of stimuli such as 
LPS. In contrast, LPS-induced IL-10 expression by monocytes in vitro occurs several 
hours after activation (de Waal, Abrams and others, 1991). TNF-a increases 
monocyte/macrophage production of IL-10 by increasing mRNA, however a second 
stimulus appears to be required before this increased mRNA is translated into increased 
protein levels.
TNF-a acts through a positive feedback mechanism to increase its own production 
(Philip and Epstein, 1986). Thus, in the presence of a functional promoter 
polymorphism, a small initial increase in TNF-a production secondary to an 
inflammatory insult may be magnified considerably during an in vivo immune response 
with the potential to have a significant effect on outcome.
1.4.2 Cytokine balance and sepsis
The concept of cytokine balance has been most intensively studied in the field of sepsis. 
In humans, both TNF-a and IL-10 are produced during septicaemia and septic shock, 
and serum levels have been shown to correlate with the clinical grading of the 
inflammatory response (Sherry, Cue and others, 1996;Tracey and Cerami, 1993;van der, 
de Waal and others, 1997). Research has shown both high and low circulating levels of 
either IL-10 or TNF-a to be associated with poor clinical outcome (van der, de Waal 
and others, 1997).
Repeatedly, high levels of IL-10 have been shown in experimental models to be 
protective against lipopolysaccharide (LPS) induced septic shock (Gerard, Bruyns and 
others, 1993;Howard, Muchamuel and others, 1993). The administration of IL-10 
improves survival in animal models of endotoxaemia, and reduces systemic symptoms 
(e.g. fever, tachycardia), neutrophil responses, and cytokine production in human 
volunteers given endotoxin (Marchant, Bruyns and others, 1994;Pajkrt, Camoglio and 
others, 1997). Mice that have genetic deletions of the IL-10 gene are more susceptible 
to endotoxic shock than normal mice (Dai, Kohler, and Brombacher, 1997). Equally so, 
a physiologically inadequate IL-10 response after systemic injury has been shown to 
have detrimental consequences: - low lung concentration of IL-10 in patients with acute 
lung injury is associated with a greater risk of acute respiratory distress syndrome 
(ARDS) (Donnelly, Strieter and others, 1996). An inadequate IL-10 response to 
systemic injury or endotoxin challenge is associated with excess pro-inflammation, poor 
outcome, and increased mortality.
Yet in contrast, it has been reported that IL-10 levels are highest in critically ill patients 
with sepsis, multi-organ failure and in non-survivors (Doughty, Carcillo and others,
1998). Whilst this may just be indicative of the severity of the underlying disease in 
these patients, it may also represent the opposite end of a continuous spectrum. Patients 
who preferentially express high levels of IL-10 and reduced levels of TNF-a when 
challenged, are more likely to die from meningococcemia and a variety of other 
community acquired infections (Pajkrt, Camoglio and others, 1997;van Dissel, van 
Langevelde and others, 1998;Westendorp, Langermans and others, 1997a). It appears 
that there is evidence to support that too little or too much of either pro-inflammation or 
anti-inflammation in the systemic inflammatory response can be associated with poor 
outcome (Howard, Muchamuel and others, 1993).
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Figure 1.11 Hypothetical responses of a patient following an inflammatory insult.
A balanced immune response involves an initial pro-inflammatory response with a rapid 
counter-balancing anti-inflammatory response, resulting in the systemic levels of 
cytokines returning rapidly to normal. An excessive early pro-inflammatory response to 
the insult results in SIRS, multi-organ failure, and high risk of early death. Prolonged 
or extreme anti-inflammatory response to the primary insult places the patient at risk of 
increased susceptibility to secondary infection, multi-organ failure, and late death.
The same model of inflammation (Sepsis-SIRS-CARS) probably holds true for surgery 
and trauma, including cardiopulmonary bypass. The most likely and important outcome
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factor after good surgical repair may be the inter-relationship between the pro- 
inflammatory and anti-inflammatory mediators produced and immune balance.
1.4.3 Quantitating cytokine balance
The concept of balance and imbalance in a complex, apparently chaotic system of inter­
related mediators is very attractive. However the problem arises of how to best assess 
balance. Attempting to assess balance based simply on circulating cytokine levels 
raises the dilemma discussed in section 1.2.3.1:- are systemic levels necessarily 
reflective of local tissue levels? Systemic levels may greatly underestimate the
biological impact a cytokine is having locally (Wan, DeSmet and others, 1996). In
addition, the complex interplay between cytokines at any single moment, their 
ubiquitous distribution, and short half-life, means that it is highly unlikely that a simple 
ratio between 2 circulating cytokines (e.g. IL-6:IL-10) at a single time point would 
adequately assess the inflammatory system (Hovels-Gurich, Schumacher and others, 
2002).
The biological features of cytokines and their highly complex, and still poorly 
understood, interactions with each other, make them unlikely candidates for quantitating 
the resultant effect of an inflammatory response. Two alternative methods have 
emerged:
■ monocyte hypo-responsiveness to lipopolysaccharide / endotoxin 
stimulation
■ reduced surface expression of Major Histocompatibility Complex 
(MHC) Class II on monocytes
1.5 M o n o c y t e s  a n d  s u r f a c e  e x p r e s s i o n  o f  MHC C l a s s  II
1.5.1 Background
Monocytes are immune cells derived from the bone marrow through the myeloid 
lineage. They constitute 5-8% of total circulating leukocytes in paediatric whole blood 
(2 - 8 xlO5 monocytes/ml of blood). The monocyte measures 16-20pm in diameter with
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a deeply indented or U-shaped nucleus (Figure 1.12). Monocytes circulate in blood for 
approximately a day (ti/2 = 17 hours), before leaving and entering the tissues where they 
mature and differentiate into macrophages, with a life-span of months to years.
Monocyte production and release from the bone marrow is increased during an 
inflammatory response. Circulating monocytes have pinocytic and phagocytic activity 
and express receptors for immunoglobulin and complement. They are the major antigen 
presenting cells in the circulation, playing a central role in innate immunity by 
processing and presenting antigen in association with major histocompatibility 
complexes Class I and II. In addition, monocytes are able to traffic to sites of infection 
by utilising their migratory and chemotactic functions.
Figure 1.12 Normal peripheral blood monocyte (courtesy Haematology 
Department, Great Ormond Street Hospital).
1.5.2 Major Histocompatibility Complex (MHC) Class II structure 
and function
The major histocompatibility complex (MHC) describes a collection of genes sited on 
the short arm of Chromosome 6  that code for molecules involved in immune function.
The MHC Class II molecules are responsible for presenting peptides derived from 
external pathogens to CD4+ T cells. In man there are 3 classical MHC Class II 
molecules known as Human Leukocyte Antigens or HLA - DR, DQ and DP. In 
addition to these structures, the MHC region encodes for so-called nonclassical 
molecules; HLA-DM and HLA-DO. These molecules do not reside on the cell surface 
and are not involved in antigen presentation, but are important in modulating the 
binding of peptides to classical MHC molecules and cellular trafficking.
MHC (or HLA) molecules are cell-surface glycoproteins with a peptide-binding groove. 
MHC class II molecules (MHC Class II) in humans consist of 2 chains - a  and (3, which 
span the cell membrane. Each chain has 2 extracellular domains, oti and CC2 , and Pi and 
P2 respectively. In MHC Class II, the distal oci and Pi domains fold together to form a 
single peptide-binding site composed of two anti-parallel a-helical loops supported by a 
platform of eight antiparallel p strands (Fig 1.13).
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Figure 1.13 Structure of MHC Class II molecules.
The MHC Class II molecule is composed of 2 transmembrane glycoproteins chains (a 
and p). Figure 1A is a ribbon diagram of the structure, illustrating the ai and Pi 
domains, which form the peptide binding groove. Figure IB is a schematic diagram 
showing the peptide binding groove and the 012 and p2 domains, which span the cell 
membrane. (Adapted from Janeway CA et al. 4th edition 1999).
In t r o d u c t i
There are several characteristics of the MHC Class II binding groove that enable 
binding of a wide range of peptides:
> the ai and Pi domains feature a high level of polymorphism
> the ends of the binding groove are open allowing peptides to bind in an extended 
conformation
> the peptide is held by a series of hydrogen bonds between the peptide backbone 
and conserved amino acid side chains lining the groove. Since the bonds do not 
involve peptide side chains, they confer sequence-independent binding.
Combined, these features help to explain how MHC Class II molecules can bind 
multiple peptides with high affinity and low specificity. In contrast the peptide binding 
site of the nonclassical Class II molecule HLA-DM is an almost fully closed groove, 
with the oti and pi domain in contact over the first and last thirds of their length.
MHC Class II molecules are generated in the endoplasmic reticulum (ER). In order to 
prevent them binding prematurely to ER-resident peptides, each newly synthesised 
molecule is associated with a protein known as the MHC Class-II associated invariant 
chain (li). Each invariant chain can occupy the binding groove of three MHC Class II 
molecules (Fig 1.14). The grooves of the MHC Class II molecules are occupied by a 
section of the li chain called CLIP. In the absence of invariant chains it appears that 
MHC Class II molecules are retained in the ER as complexes with misfolded proteins.
Figure 1.14 Invariant chain occupies 3 
newly synthesised HLA-DR molecules. The
invariant chain (in green) occupies the protein 
binding groove of 3 newly synthesised HLA- 
DR molecules (in yellow) in the ER to prevent 
binding of other proteins synthesised by the 
ER. (Adapted from Janeway CA et al. 4th 
edition 1999).
The main function of the invariant chain seems to be as a chaperone to ensure correct 
folding and delivery of MHC Class II molecules from the ER to the endosomal 
compartment where peptide loading can occur. The chain contains a di-leucine 
targeting signal in its cytoplasmic tail which helps to divert the folded complex from the 
default secretory pathway to lysosomal-like vesicles called MIIC (MHC Class II 
compartment), where peptide is loaded. The MHC Class II:invariant chain complexes 
are then exposed to an acidic, proteolytic environment in which the invariant chain is 
cleaved by proteases such as cathepsin L and S leaving just the CLIP fragment 
occupying the binding groove (Fig 1.15). Cathepsin S inhibition in vitro and cathepsin 
S deficient mice results in a profound reduction in MHC Class II surface expression 
(Nakagawa, Brissette and others, 1999).
Preferential exchange of CLIP for antigenic peptides is mediated by HLA-DM. With a 
binding groove effectively sealed, the structure of HLA-DM makes it highly unlikely to 
bind peptides. Most of the DM molecules reside in the MHC vesicles where it binds 
transiently to MHC Class ILCLIP and stabilizes an intermediate state where CLIP can 
be released and peptide loaded. Once antigenic peptide has been stably bound, it has 
been proposed that DM looses its affinity for MHC Class II (Ting and Trowsdale, 
2002).
The role of the other nonclassical molecule, HLA-DO, is less certain. Like DM it 
resides in the MIIC vesicles and appears to counterbalance the effect of DM. A narrow 
acidic pH range of the MHC Class II compartment has been described as essential for 
antigenic peptide loading and thus for surface expression of MHC Class II molecules 
(Ullrich, Doring and others, 1997). At a pH of 6  HLA-DO appears to block peptide 
exchange, however at lower pH’s (pH=5) the acidic environment favours DM-mediated 
peptide exchange.
MHC Class II molecules in uninfected cells bind peptides derived from self-proteins. In 
addition, immature unloaded MHC Class II molecules, together with the invariant 
chain, have been shown to be directly transported to the cell surface with subsequent re- 
endocytosis and peptide loading (Roche, Teletski and others, 1993). Empty MHC Class 
II molecules that do not bind peptide after cleavage of the invariant chain are unstable,
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and rapidly degraded in the acidic pH of the MIIC vesicles. At any time it appears that 
there is excessive production of MHC Class II molecules; therefore should infection 
occur, peptides generated from the pathogen are rapidly associated with empty MHC 
Class II molecules. MHC molecules must be able to bind, not only a wide variety of 
peptides, but also bind the peptide with high affinity so that peptide exchange at the cell 
surface does not occur.
Additional genes have also been identified in the class II region, some of which encode 
for proteins involved in antigen presentation.
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Figure 1.15 The transition of MHC Class II from the endoplasmic reticulum, 
through protein loading, to antigen presentation on the surface of the monocyte.
The far left box shows newly synthesised MHC Class II in a vesicle. The protein 
binding groove is not available to bind peptides or misfolded proteins present in the 
vesicle because of the invariant chain. The second box shows cleavage of the invariant 
chain in the acidic environment. The binding groove still being occupied by the short 
peptide fragment known as CLIP. The vesicle then fuses with an endosome containing 
peptides from a foreign antigen. The final box shows removal of the CLIP protein and 
binding of the antigen. This is assisted by the presence of the HLA-DM molecule. 
(Adapted from Janeway CA et al. 4th edition 1999).
1.5.3 MHC Class II regulation
Expression of MHC Class II genes is tightly regulated. In contrast to the ubiquitous 
expression of Class I molecules, MHC Class II molecules are expressed on only a small 
number of specialised cells. Constitutive expression of MHC Class II is largely 
restricted to cells that serve as antigen presenting cells for CD4+ T-cells, such as B- 
lymphocytes, dendritic cells, monocytes and macrophages. Expression on other cell 
types can be induced by IFN-y.
Many agents are recognised to modulate MHC Class II expression depending on cell 
type. Basal expression can vary according to the developmental stage of the cell -  early 
B-lymphocytes are MHC negative, but expression can be induced by IL-4. Immune and 
neuroendocrine mediators can further modulate constitutive expression. For example 
IL-4, IL-10, and IL-13 all increase MHC Class II expression in B-lymphocytes, whilst 
prostaglandins and glucocorticoids decrease expression (Defiance, Carayon and others, 
1994;Erb, Holtschke and others, 1994;Glimcher and Kara, 1992;Go, Castle and others, 
1990). GM-CSF is a powerful inducer in dendritic cells (Sallusto and Lanzavecchia, 
1994). IFN-y increases levels of expression on existing cells (monocyte -  macrophage 
lineage, endothelial cells) and can induce expression on certain cell types that do not 
normally express MHC Class II (epithelial cells, fibroblasts, and muscle cells). The 
same modulator can have opposite effects in different target cells. For example, IL-10 
inhibits basal and IFN-y induced MHC Class II expression on monocytes (de Waal, 
Abrams and others, 1991) but increases expression on B lymphocytes (Go, Castle and 
others, 1990). MHC Class II expression may also be mediated by direct cell-to-cell 
contact. CD40-CD40L and CD5-CD72 interactions increase MHC Class II expression 
in B-lymphocytes and dendritic cells (Sallusto and Lanzavecchia, 1994), whilst MHC 
Class II expression on endothelial cells can be induced by contact with Natural Killer 
(NK) cells (Watson, Petzelbauer and others, 1995). Whilst many of these effects occur 
at a transcription/translation level, TNF-a, LPS, GM-CSF and IL-10 have also been 
shown to modulate cell surface MHC Class II expression at a post-translational level by 
altering rates of exocytosis and recycling (Celia, Engering and others, 1997;Koppelman, 
Neefjes and others, 1997;Pierre, Turley and others, 1997).
Expression of MHC Class II genes is regulated primarily at the level of transcription. 
The main control element regulating transcription is the highly conserved promoter 
proximal region situated upstream of the transcription initiation site. Additional 
promoter distal regulatory elements have been described, but these appear to play a 
lesser role (Glimcher and Kara, 1992).
MHC Class II molecules are critical for the generation and maintenance of an immune 
response. Congenital absence of MHC Class II surface expression results in a severe 
immunodeficiency, whilst over expression is often seen in the setting of autoimmune 
diseases.
1.5.4 MHC Class II deficiency (Bare Lymphocyte Syndrome)
Bare lymphocyte syndrome (BLS) is a heterogeneous group of genetic disorders 
characterised by a lack of MHC Class II expression on both the thymus and antigen 
presenting cells. The disease is autosomal recessive and associated with extreme 
susceptibility to viral, bacterial, fungal, and protozoal infections. Cells from a BLS 
patient typically lack constitutive and inducible Class II, have reduced CD4+ cell 
numbers, and severely impaired T-cell activation. Understanding the precise regulation 
of MHC Class II expression and the involvement of promoters and transcription factors 
has largely been achieved through the study of the heterogeneous group of defects 
present in BLS patients.
This syndrome is not caused by mutations in the MHC genes themselves, but by a 
specific defect in a transcription factor that is necessary for MHC Class II expression. 
Bare lymphocyte syndrome is a disease of gene regulation. One gene defect involves 
the MHC Class II transactivator (OITA).
1.5.5 CIITA: the master control factor for MHC class II expression
CIITA does not bind DNA directly, but mediates its function as a transcription factor 
through interaction with other proteins. Levels of CIITA expression precisely parallel 
that of MHC Class II synthesis both in vitro and in vivo (Sims and Halloran, 1999;Ting 
and Trowsdale, 2002). CIITA is constitutively expressed in the same cell types that 
constitutively express MHC Class n, and is not expressed in those cells that do not have
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MHC Class II. CIITA transcription is increased by IFN-y, endotoxin, and IL-4, and is 
decreased by IL-10, TGF-P, nitric oxide and IFN-P in-vitro (Harton and Ting, 
2000;Reith and Mach, 2001). When induced, CIITA expression precedes MHC Class II 
mRNA induction by several hours. Over expression of recombinant CIITA by a factor 
of 5-10 above wild type levels in transfected cells is accompanied by a corresponding 
increase in MHC Class II expression (Mach, Steimle and others, 1996), whilst 
fibroblasts from CIITA-deficient Bare Lymphocyte Syndrome patients cannot be 
induced by IFN-y to express MHC Class II molecules. Constitutive expression of 
recombinant CIITA renders MHC Class II negative cell lines MHC Class II positive in 
the absence of IFN-y. Therefore, it appears that the level of CIITA protein determines 
MHC Class II promoter activity.
CIITA itself is regulated primarily at the transcription level, with most regulators acting 
through promoters (Fig 1.16). There are 4 recognised promoters (PI-4). Each promoter 
appears to lead to the expression of a different isoform of CIITA. Some iso forms have 
been shown to be more efficient at activating the Class II promoters than others, and 
their activation may explain the differing surface expression of Class II amongst 
different cell types. In some cases such as IFN-y the promoter is known, but in other 
cases such as IL-10 the promoter affected is less clear.
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Figure 1.16 Positive and negative regulation of CIITA.
Regulatory processes of MHC Class II typically target CIITA transcription or protein. 
Positive regulators include IFN-y, LPS, IL-4 and IL-1. IFN-y acts on CIITA promoters 
P3 and P4. Negative regulators include IL-10, TGF-P, NO, and IFN-p. TGF-p acts to 
suppress P4, however the mechanism of action for IL-10 is not known. (Adapted from 
Ting JP and Trows dale J  2002).
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Once CIITA has been produced it interacts with a large number of DNA-binding 
transcription factors across the MHC Class II promoter region to form an active and 
more stable transcriptosome (Fig 1.17). Whist the presence of CIITA is important, it is 
not essential. One transcription factor, regulatory factor X (RFX), appears to be crucial 
for the transcriptosome to access the Class II promoters (Kara and Glimcher, 
1991a;Kara and Glimcher, 1991b). In RFX-defective cell lines, the Class II promoter 
remains bare even in the presence of IFN-y (Brickey, Wright and others, 1999). In the 
absence of CIITA, the other transcription factors appear to bind weakly to the Class II 
promoters in cells that constitutively express MHC Class II. However, the presence of 
CIITA ensures proper histone acetylation of the transcriptosome making it both more 
stable and more active (Beresford and Boss, 2001;Harton, Zika, and Ting, 2001;Ting 
and Trowsdale, 2002). CIITA -/- mice are largely devoid of MHC Class II, although 
there is some residual expression (Landmann, Muhlethaler-Mottet and others, 
2001;Williams, Malin and others, 1998). Despite this however, both RFX -/- and 
CIITA -/- mice show severe immunodeficiency and CD4+ T-cell defects that replicate 
the findings in humans with BLS (Ting and Trowsdale, 2002).
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Figure 1.17 Schematic diagram of MHC Class II promoter and transcriptosome.
A number of DNA binding factors (RFX, NF-Y, and CREB) along with the co activator 
CIITA bind to the MHC promoter activating transcription of the Class II gene. 
(Adapted from Ting JP and Trowsdale J  2002).
Polymorphisms within the CIITA promoters have recently been identified, but their 
significance is unclear. In theory they could result in a difference in the responsiveness 
of the cell to the local environment, with altered CIITA and MHC Class II induction, 
and variable T-cell response to infection (Rasmussen, Kelly, and Clausen, 2001).
1.5.6 IL-10 and MHC Class II expression
IL-10 has been shown to decrease both the constitutive and IFN-y induced expression of 
MHC Class II on monocytes ex vivo in a dose dependant manner (de Waal, Haanen and 
others, 1991). In the presence of IL-10, monocytes had reduced capacity to present 
antigen and induce CD4 + T cell proliferation (de Waal, Haanen and others, 1991). In 
1997 Koppelman et al demonstrated that IL-10 affects antigen presentation by inhibiting 
the post-translational processes of MHC Class II exocytosis and recycling (Koppelman, 
Neefjes and others, 1997). Subsequently IL-10 has been shown to have several post- 
translational biological effects. It has been shown to modify the pH of the MHC 
vesicles, block the activity of cathepsin enzymes required for efficient MHC Class H 
peptide loading, and increase the activity of cystatin C an inhibitor of cathepsin 
(Fiebiger, Meraner and others, 2001;Longoni, Piemonti and others, 1998;Morel, 
Quaratino and others, 1997;Pierre and Mellman, 1998). However the signalling 
molecules activated by ligation of IL-10 to its receptor, that are responsible for these 
post-translational effects remain to be identified.
The idea that the reduction in MHC Class II expression on monocytes is occurring at a 
post-translational stage was support by a recent study in septic adult patient (Fumeaux 
and Pugin, 2002). Whilst having significantly decreased surface expression of MHC 
Class n, monocytes from septic patients had no significant difference in mRNA levels 
of HLA-DR and related molecules critical for DR expression compared to normal 
controls. This clinical study could not however address the question of whether the 
reduced surface expression was due to the sepsis or whether the MHC Class H decrease 
preceded the infection, and therefore represents a ‘risk factor’ for the development of 
sepsis.
1.6 M o n o c y t e  ‘d e a c tiv a  tio n ’ a n d  Im m une P a r e s is
1.6.1 Endotoxin (LPS) tolerance
In order to discuss monocyte deactivation and immune paresis, it is necessary to first 
describe a state termed endotoxin tolerance. Endotoxin tolerance was first described in 
the late 1960’s, when it was observed that animals given a low dose of LPS had a 
markedly reduced mortality when re-challenged with a higher, normally lethal dose of 
LPS (Brooke, 1965;Greisman, Young, and Carozza, Jr., 1969). Re-exposure of animal 
or cell lines to LPS after a previous challenge was associated with diminished TNF-a 
secretion. This impaired TNF-a secretion was thought to be an adaptive response, 
designed to limit pro-inflammation, and at least in part, explain the decreased mortality 
observed in tolerant animals.
An altered immune response similar to that seen with endotoxin tolerance has been 
shown to occur in critically ill patients, particularly those with sepsis. Ex vivo LPS 
challenges of both whole blood and monocytes isolated from septic patients has been 
associated with a reduction in TNF-a secretion (Cross, 2002;de, I, Zanetti and others, 
2001;Kawasaki, Ogata and others, 2001;Ogata, Okamoto and others, 2000;Randow, 
Syrbe and others, 1995;West and Heagy, 2002;Yadavalli, Auletta and others, 2001). In 
addition, plasma from septic patients has been shown to induce hypo-responsiveness in 
control monocytes (Brandtzaeg, Osnes and others, 1996). Parenteral treatment with the 
pro-inflammatory cytokines TNF-a or IL-1 can induce an identical state.
The mechanism behind endotoxin tolerance are not yet understood but is thought to be 
an anti-inflammatory mediated effect. A common feature appears to be the presence of 
systemic inflammation. The state of endotoxin tolerance has been shown to occur in 
adult trauma and surgical patients, and this altered host defence is considered a risk 
factor for the subsequent development of septic complications (Kawasaki, Ogata and 
others, 2001;Keel, Schregenberger and others, 1996;Lemaire, van der and others, 1998). 
One cell which appears to be central in the development of endotoxin tolerance is the 
monocyte.
1.6.2 Monocyte deactivation
The term of monocyte ‘deactivation’ has been coined to describe a decrease in surface 
HLA-DR expression and a reduced capacity of monocytes to secrete pro-inflammatory 
cytokines on subsequent LPS stimulation (Brandtzaeg, Osnes and others, 1996). The 
major candidate for the induction of monocyte deactivation is IL-10. Plasma 
concentration of the anti-inflammatory cytokine IL-10 has been shown to be greatest in 
the serum of patients who demonstrate monocyte deactivation, and removal of IL-10 in 
in-vitro cultures using a monoclonal antibody partially restores the capacity of 
monocytes to respond to LPS (Brandtzaeg, Osnes and others, 1996).
1.6.3 Monocyte deactivation and Immune Paresis
MHC Class II expression, monocyte responsiveness and circulating IL-10 levels appear 
to be intricately related. Low levels of monocyte MHC Class II expression, monocyte 
hypo-responsiveness and elevated levels of plasma IL-10 have all individually been 
shown to correlate with poor clinical outcome (Brandtzaeg, Osnes and others, 
1996;Cheadle, Hershman and others, 1991;Ditschkowski, Kreuzfelder and others, 
1999;Haveman, Kobold and others, 1999;Sachse, Prigge and others, 1999;Westendorp, 
Langermans and others, 1997a). Monocyte MHC Class II expression is, in part, under 
the regulation of cytokines in the micro-cellular environment. Reduced surface 
expression on circulating monocytes may reflect immune dysregulation, with an 
excessive anti-inflammatory response. In vitro experiments have provided the final link 
by showing that monocytes expressing low levels of HLA-DR not only have impaired 
antigen presentation, but secrete markedly reduced amounts of pro-inflammatory 
cytokines (de Waal, Haanen and others, 1991;Piani, Hossle and others, 2000), 
suggesting that MHC Class II may have a direct role in mediating the cellular response 
to endotoxin. Thus, prolonged or extreme release of anti-inflammatory mediators 
following an inflammatory insult may contribute to impaired monocyte function by 
down regulating MHC Class II expression, impairing antigen presentation, and 
decreasing pro-inflammatory cytokine release. This is termed a state of ‘immune 
paresis \
1.7 H y p o th e s is  a n d  A im s o f  t h i s  T h e s is
Placing all these facts together it is possible formulate a hypothesis. An unbalanced 
inflammatory response where IL-10 and other anti-inflammatory mediators predominate 
over TNF-a and other pro-inflammatory mediators, results in reduced monocyte MHC 
Class II expression and a state of monocyte ‘deactivation'. Under these conditions a 
second inflammatory insult would be poorly tolerated (immune paresis) with reduced 
capacity to mount an inflammatory response, placing the patient at risk of severe sepsis.
The aims of this thesis are:
1. To determine if monocyte surface MHC Class II expression is affected by 
cardiopulmonary bypass in children
2. To determine if alteration in MHC Class II expression is associated with an 
increased risk to the subsequent development of sepsis / systemic inflammatory 
response syndrome.
3. To examine the systemic pro- and anti-inflammatory cytokine response to 
cardiopulmonary bypass and examine its relationship to circulating monocyte 
MHC Class II expression, cardiac function and outcome measures.
4. To determine if  CPB induces a state of immune paresis in the post-operative 
period.
5. To examine the frequency of polymorphisms amongst candidate genes of 
inflammation in the bypass population and their effect on circulating cytokine 
levels and recovery.
6 . To identify the mechanism by which MHC Class II expression on monocytes is 
reduced following cardiopulmonary bypass.
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2.1 I n t r o d u c t i o n
The following chapter describes established scientific methods that have been used during 
this PhD. Some of these methods have been optimized for use in children, in particular 
modifying techniques to obtain reproducible results when only 1-2 ml of blood was 
available. The list of reagents including antibodies, solutions and buffers are listed in this 
section.
2.2 M a t e r i a l s  a n d  R e a g e n t s :
2.2.1 Chemicals
Agarose Invitrogen/Life Technologies, Paisley, 
UK
Bovine serum albumin (fraction V) Sigma, Poole, UK
Cell lysis BD Bioscience, Oxford, UK
Cell fix (1% formaldehyde, 0.1% sodium 
azide)
BD Bioscience, Oxford, UK
Citi-fluor (Glycerol/PBS Solution) Citifluor Ltd, UK
Citric acid (C6H8 0 7 .H2 0 ) Sigma, Poole, UK
di-Sodium hydrogen phosphate (Na2HP0 4 ) BDH Merck, Poole, UK
DNA ladder Gibco, Invitrogen/Life Technologies, 
Paisley, UK
DNTPs (Deoxynucleotide Triphosphates) Promega, Southampton, UK
DTT Invitrogen/Life Technologies, Paisley, 
UK
EDTA (Ethenediaminetetraacetic acid, 
disodium salt
Sigma, Poole, UK
Ethanol Sigma, Poole, UK
Ficoll hypaque gradient (Lymphoprep) Nycomed (Amersham), Little Chalfont, 
UK
Fluorescein isothiocyanate (FITC) Sigma, Poole, UK
Foetal Calf Serum (FCS) Sigma, Poole, UK
Gel loading solution Sigma, Poole, UK
Glycerol Sigma, Poole, UK
M a t e r 1ETH0DS
GM-CSF (Granulocyte-Monocyte Colony 
stimulating factor)
Schering-Plough, Henilworth, NJ, USA
Heparin 5000U/ml (preservative free) CP Pharmaceuticals, Wrexam, UK
Hydrogen Peroxide Sigma, Poole, UK
Interleukin-10 (IL-10) NIBSC, Hertfordshire, UK
Interferon gamma (IFN-y) NIBSC, Hertfordshire, UK
Magnesium Chloride (MgCl2 ) BDH Merck, Poole , UK
Monocyte mRNA isolation kit Dynal Biotech, Bromborough, UK
Oligonucleotide sequences (customised) Applied Biosystems, Cheshire, UK
Paraformaldehyde (CH2 0 )n Sigma, Poole, UK
Permeabilisation Liquid Caltag, Towcester, UK
Percoll Amersham, Little Chalfont, UK
Phosphate buffered saline (PBS) tablets Oxoid, Basingstoke, UK
Potassium di-hydogen phosphate (KH2 PO4 ) BDH Merck, Poole , UK
Potassium Chloride (KC1) BDH Merck, Poole , UK
Primers for TaqMan Applied Biosystems, Cheshire, UK
Probes (fluorescent) for TaqMan Applied Biosystems, Cheshire, UK
RPMI 1640 medium Invitrogen/Life Technologies, Paisley, UK
Saponin Sigma, Poole, UK
Sodium Azide (NaNs) BDH Merck, Poole , UK
Sodium Chloride (NaCl) BDH Merck, Poole , UK
Streptavidin-HRP BD Biosource, Oxford, UK
Sulphuric Acid BDH Merck, Poole , UK
Superscript Reverse transcriptase Invitrogen/Life Technologies, Paisley, UK
Taq Polymerase Promega, Southampton, UK
TEMED Sigma, Poole, UK
TMB tablets Sigma, Poole, UK
To-pro-3 iodine (642/661) Molecular probes, Ludwig Institute , 
London
Tris-HCl BDH Merck, Poole , UK
Trypan Blue Invitrogen/Life Technologies, Paisley, UK
Tumour necrosis factor alpha(TNF-a) NIBSC, Hertfordshire, UK
Tween 20 (Polyoxethylene sorbitan 
monolaurate)
Sigma, Poole, UK
)  M e t h o i
2.2.2 Buffers
All solutions were made up to 1000ml in Milli-Q water unless otherwise indicated.
Blocking Solution for 
ELISA
Coating Buffer (as below) 
Bovine Serum Albumin 0.5% (5g/litre)
7.4
Citrate Buffer for 
ELISA
Citric Acid 0.1 M (21 g/litre) 5.0
Coating Buffer for 
ELISA
(Phosphate buffered 
saline)
Sodium Chloride
Potassium Chloride
di-Sodium hydrogen 
phosphate
Potassium di-hydrogen 
phosphate
140 mM (8 g/litre) 
2.7 mM (0.2g/litre) 
8.0 mM (1.42g/litre)
1.5mM (0.2g/litre)
1
7.4
Diluent for ELISA Blocking Solution (as 
above)
Tween 20 0 .0 1 % (v/v)
7.4
FACS washing buffer PBS (lx)
Sodium azide 
Bovine Serum Albumin
0 .0 2 %
0.5% (5g/litre)
Lysis/Binding buffer 
for RNA isolation
Tris-HCL
LiCL
EDTA
LiDS
Dithiothreitol (DTT)
100 mM 
500 mM 
10 mM 
1 %
5 mM
7.5
8 . 0
MACS buffer PBS (IX)
EDTA
Bovine Serum Albumin
2 mM 
0.5%
Formamide (MADGE) 
Dye
Deionised formamide 
xylene cyanol 
bromophenol blue 
EDTA 0.5M
49mls
12.5mg
12.5mg
1 ml 7.9
Phosphate Buffer for 
ELISA
di-Sodium hydrogen 
phosphate
0.2 M (28.5g/litre) 5.2
M a t e r i a l s  a n d  M e t h o d s
Phosphate Buffered saline 
(PBS)
PBS tablet 1 per 100 MilliQ
Phosphate Citrate buffer Citrate 
Phosphate r
0.05M
0.025M
5
PBS/BSA buffer for RNA 
isolation
Sodium Chloride
di-Sodium hydrogen 
phosphate
Potassium di-hydrogen 
phosphate
Bovine serum albumin 
Sodium Citrate
140 mM (8.1 g/litre) 
8.0 mM (0.98g/litre)
1.5mM (0.16g/litre)
0 .1 % (w/v)
0 .6 % (w/v)
7.4
Polmix Potassium Chloridel 50mM
Tris HC1 lOmM 8.3
Gelatin 0 .0 0 1 %
dATP,dGTP,dTTP,dCTP 0.2mM of each
Polyacrylamide Gel lOx TBE
30% acrylamide- 
bisacrylamide (ratio 19:1)
N’-
tetramethylethylenediamine
25% ammonium per 
sulphate
5ml
12.5ml
150pl
150pl
Sticky Silane ETOH
Glacial Acetic Acid 
y-methacryloxypropyl- 
trimethoxy silane
99%
0.05%
0.05%
EDTA 0.5M 0 .0 1 % 7.9
Stop Solution di-Hydrogen Sulphate 4 N
TMB ELISA substrate 
buffer
Phosphate/Citrate buffer 
TMB
30% hydrogen peroxide
1 0 ml
lmg
2 pl
i a i s  a n d  M e t h o d s
Tris-Boric acid- Trizma Base 0.9M
Ethylenediaminetetraacetic
op iH Boric Acid 0.9MCltlu
EDTA 0.2M(10x TBE)
Wash Buffer for ELISA Sodium Chloride 0.15M 7.4
Tween 20 0 .0 1 % (v/v)
Wash Buffer A for RNA Tris-HCl 10 mM (pH 7.5)
isolation LiCl 0.15 M
EDTA 1 mM
LiDS 0 .1 %
Wash Buffer B for RNA Tris-HCl 10 mM (pH 7.5)
isolation LiCl 0.15 M
EDTA 1 mM
M a t e r i a l d  M e t h o d s
2.2.3. Antibodies
All antibodies used for flow cytometry or confocal microscopy are listed here. These 
include mouse monoclonal anti-human antibodies, isotype control antibodies, and one 
secondary antibody raised in goat. Where available, the table includes the species in 
which the antibodies were derived, and the clone.
CD14 _ mouse IgG2a TUK4 Dako M0825
CD14 RPE mouse IgGl TUK4 Dako R0864
CD14 RPE-Cy5 mouse IgG2a TUK4 Serotec MCA1568C
CD64 RPE -Cy5 mouse IgGl 1 0 . 1 Dako C7220
HLA-DP mouse IgGl HI43 Pharmingen 32431 A
HLA-DQ _ mouse IgG2a TUK169 Pharmingen 32421A
HLA-DR - mouse IgG2a G46-6 Pharmingen 34231A
HLA-DR FITC mouse IgGl G46-6 Pharmingen 555811
HLA-DP, -DQ, -DR - mouse IgGl CR3/43 Dako F0816
HLA-DP, -DQ, -DR FITC mouse IgGl CR3/43 Dako F0817
IgGl isotype control FITC mouse _ Dako X0927
IgGl isotype control RPE mouse _ Dako X0928
IgG2a isotype 
control
FITC mouse - Dako X0933
IgG2a isotype 
control
RPE mouse - Dako X0950
Goat-Anti-mouse 
IgG
Texas
Red-X
- - Molecular
Probes
T-6390
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2.2.4 Antibodies and Standards for ELISAs
Antibody pairs and standards utilised for ELISA’s are listed below.
Human TNF-a Cytosets™ Biosource CHC1754
Capture TNF-a mouse IgGl & 
IgG2
68B6A3 & 
68B2B3
Biosource 58.175.08
Detection TNF-a mouse IgGl 68B3C5 Biosource 58.175.02
Recombinant human TNF-a Biosource 58.175.10
Human IL-10 Cytosets™ Biosource CHC1324
Capture IL-10 mouse IgGl 945A5D11 Biosource 58.132.08
Detection IL-10 mouse IgGl 945A5A10 Biosource 58.132.02
Recombinant human IL-10 Biosource 58.132.10
Human IL - 8  Cytosets™ Biosource CHC1304
Capture IL-8 mouse IgGl 893A6G8 Biosource 58.130.08
Detection IL-8 mouse IgGl 790A28G2 Biosource 58.130.02
Recombinant human IL-8 Biosource 58.130.10
Human IL - 6  Cytosets™ Biosource CHC1264
Capture IL-6 mouse IgGl 677B6A2 Biosource 58.126.08
Detection IL-6 mouse IgGl 505E23C7 Biosource 58.126.02
Recombinant human IL-6 Biosource 58.126.10
Human IL -lra  Cytosets™ Biosource CHC1184
Capture IL-lra mouse IgGl 998A2A2 Biosource 58.118.08
Detection IL-lra mouse IgGl A71B6D11 Biosource 58.118.02
Recombinant human IL-lra Biosource 58.118.10
a  i s  a n d  M  e t h o d s
2.2.5 General Equipment and Consumables
Beckman’s 96 well array plates
Bijou (5ml) SLS, Wilford, Nottingham, UK
Biohit repeating dispenser Alpha Laboratories, UK
Confocal Microscope Leica Microsystems, Milton Keynes, 
UK
Coverslips for microscopy BDH Merck, Poole, UK
Dako Pen for Immunohistochemistry Dako, Cambridge, UK
Dynal Magnet Dynal Biotech, Bromborough, UK
Dynal magnetic particle concentrator Dynal Biotech, Bromborough, UK
Dynatech MRX ELISA plate reader Dynex technologies, UK
FACScalibur Flow Cytometer Becton Dickinson (BD Bioscience) 
Oxford, UK
FACScan Research and Lysis II Software Becton Dickinson (BD Bioscience) 
Oxford, UK
FACs tubes Becton Dickinson (BD Bioscience) 
Oxford, UK
Falcon tubes (5ml) BD Falcon, BD Bioscience, Oxford, UK
Falcon tubes (15ml) TPP, Trasadingden, Switzerland
Falcon tubes (50ml) TPP, Trasadingden, Switzerland
Finnipipette multichannel dispenser Life Sciences International
Macs CD14+ magnetic MicroBeads Milteny Biotech, Bisley, UK
Macs Column Milteny Biotech, Bisley, UK
Macs Mini Magnet Milteny Biotech, Bisley, UK
Macs Magnet Stand Milteny Biotech, Bisley, UK
MADGE Perspex forma MadgeBio Ltd, Huntingdon, 
Cambridgeshire, UK
Maxisorb ELISA plates (96 well) Nalgene NUNC, Rochester, NY, USA
Mikrotek ELISA Software Dynatech Laboratories, Chantilly, VA, 
USA
MJ Tetrad DNA Engine Thermocycler MJ Research, UK
MRX ELISA microplate reader Dynatech Laboratories, Chantilly, VA, 
USA
96-well microtiter plate (Omniplate) Hybaid, Thermolife Sciences, UK
Oligo (dT)25 magnetic Dynabeads Dynal Biotech, Bromborough, UK
96-well polycarbonate PCR plates 
(Model M)
Coming Costar, High Wycombe,UK
Slides- poly-L-lysine coated for 
Microscopy
BDH Merck, Poole, UK
Syringe filters 0.22pm Millipore, Watford, UK
TaqMan sequence detection system 
(ABI Prism 7000 SDS Software)
Applied Biosystems, Cheshire, UK
Tecan GENios 96 well 
absorbance/fluorescence reader
Tecan, Reading, UK
Universal tubes (20ml) Helena Bioscience, UK
UVP Gel Documentation System Synoptics Ltd, Cambridge, UK
2.3 P a t ie n t  D a t a  C o l l e c t i o n :
In each of the following chapters, results are presented from infants and children 
undergoing cardiopulmonary bypass. In order to interpret results, detailed and accurate 
phenotypic data on each patient, the operation undertaken, and their post-operative 
recovery was required (Appendix I). Up until the time of this project, there was no one 
source within the hospital that recorded this data collectively. The patient data 
presented in the following chapters was the result of clinical review of the patient, 
review of the anaesthetic and operative records, the surgical database maintained by 
cardiothoracic surgery, and daily review of the Intensive Care bedside electronic 
charting system (Careview, Hewlett Packard, USA).
Combining the patient details with the scientific data resulted in an extremely large 
database that was beyond the capacity of a standard spread sheet. Statistical analysis 
also required cross referencing data from various areas of data collection. In order to 
achieve these requirements, a purpose designed Access Data Base (Microsoft 
Office’98/XP) was developed over the first 6  months of this PhD. Results from each 
study were then entered into the databases and queries run to address each of the 
original study hypotheses. Results from the queries were imported into Statistical 
Package for the Social Sciences (SPSS 8.0) for statistical analysis. Graphs were drawn 
using SPSS, Excel (Microsoft 0ffice’98/XP), or PRISM 3.0 (GraphPad Software Inc).
Each study undertaken was approved by the local Research Ethics Committee and 
informed written consent was obtained from the parents of all participating children. 
Patient data was password protected and managed according to the data protection 
policy of University College London.
2.4 BLOOD COLLECTION AND HANDLING
Whole blood was collected from subjects via an arterial line after discarding the initial 
3mls as heparin rich dead space. Samples were placed immediately into sterile 5ml 
bijous containing preservative free heparin (final concentration 10 U/ml). To avoid ex
vivo activation, all blood samples were processed immediately. When blood was 
required for genetic analysis, a second sample anticoagulated with 4.2 mM 
ethylenediaminetetraacetic acid (EDTA) was collected and samples stored at -70°C 
until required.
2.4.1 Separating monocytes from whole blood
For several experiments a more concentrated form of monocytes was required than that 
provided by whole blood. In order to achieve this, density gradients and positive 
selection methods were utilised.
2.4.1.1 Isolation of peripheral blood mononuclear cells (PBMC’s)
Lymphocytes and monocytes (PBMC’s) were isolated from whole blood by 
centrifugation over a density gradient (Fig 2.1). Anticoagulated whole blood was 
diluted with an equal volume of RPMI 1640 medium, layered over a Ficoll hypaque 
gradient (density 1.077g/ml) and centrifuged at 400g for 25 minutes at room 
temperature. The cells present at the interface were recovered and washed twice with 
RPMI 1640 medium supplemented with 5% foetal calf serum (FCS). Cell numbers 
were counted using a haemocytometer (Weber, UK) and concentration (cells/ml) 
recorded.
2.4.1.2 Isolation of monocytes
Where a pure population of monocytes was required, PBMC’s were further purified by 
either a secondary density gradient or positive selection on a MACS column (Figure 
2.1). The two methods were assessed for purity when small volumes of whole blood 
were utilised.
2.4.1.2.1 Standard Isotonic Percoll Gradient (SIP)
Standard Isotone Percoll was prepared by adding 1 part phosphate buffered saline (PBS) 
(lOx) to 9 parts Percoll (density 1.793 g/ml). The SIP was then diluted to 3
concentrations using RPMI 1640 with 5% FCS: 60% SIP
47.5% SIP 
34% SIP
Serum /R PM I
TVt.TVfl ^ .TWTKTWm.
34% SIP 
&*««««»
47.5%
SIP
SUUH«8«
60% SIP
K+ 0 S
Platelets
Monocytes
Lymphocytes
SIP gradient
PBMC’s & some platelets 
\
Lymphoprep
\
RBC’s & granulocytes
CD14+ beads 
& monocytes
Lymphocytes 
& platelets
Magnet
Positive selection
Figure 2.1: Isolation of Monocytes from whole blood.
Monocytes and lymphocytes (PBMC’s) were recovered from whole blood at the serum- 
lymphoprep interface after centrifugation over a Ficoll hypaque density gradient. 
PBMC’s were further purified by either a second density gradient or positive selection 
using CD14+ labelled magnetic beads (~ 50nm in size).
PBMC’s were resuspended in 2ml of 60% SIP. Then 4.5ml of 47.5% SIP was layered 
carefully over the 60%, followed by 2ml of the 34% SIP. The tube was centrifuged at 
1750g for 45 minutes at room temperature, before the interface between the 34% and 
47.5% SIP was recovered. Monocytes recovered from this interface were washed a 
further 3 times using cold RPMI with 5% FCS, counted and concentration recorded.
The purity & activation status of the monocyte preparation was checked using flow 
cytometry. When > 20ml of whole blood was used, purity was typically >95%.
2.4.1.2.2 Positive selection using CD 14 beads
PBMC’s isolated from 2-3ml of whole blood were re-suspended in 25pi MACS buffer 
and incubated on ice for 15 minutes with 6pi of magnetic MicroBeads labelled with a 
CD14+ monoclonal antibody. The solution was then passed through a matrix filled 
column lying within a magnetic field. Cells binding to the magnetic labelled CD14+ 
antibody were retained and the remaining cells washed away with MACS buffer (x2). 
The column was removed from the magnetic field and washed a 3rd time with MACS 
buffer to release the CD14+ cells. A cell count was performed and cells were assessed 
by flow cytometry to note any change in surface expression of MHC Class II, and 
confirm a purity of > 95%.
2.5 F l o w  C y t o m e t r y
Flow cytometry allowed identification of monocytes from whole blood samples based 
on the cell size and granularity, in addition to the presence of fluorescence labelled 
monoclonal antibody to CD 14. Flow cytometry was used throughout this work to 
quantitate monocyte expression of MHC Class II. Whilst specific details are given in 
the relevant chapters, the general principals of antibody staining and data collection 
using flow cytometry are outlined here.
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Figure 2.2 Flow cytometric profile of whole blood after lysis of red blood cells.
Anticoagulated whole blood was incubated with the appropriate monoclonal antibodies 
before the red blood cells are lysed and the remaining cells fixed. The sample was then 
passed through the flow cytometer where each particle was assessed and plotted 
according to its size (forward scatter) and granularity (side scatter). Monocytes were 
readily recognisable as the smaller cloud of cells located between granulocytes and 
lymphocytes.
2.5.1 Surface Staining
Whole blood was incubated with the appropriate fluorescent monoclonal 
antibody/antibodies at room temperature, in the dark for 10-15 minutes. A final 
antibody concentration of 5pg/ml or 0.5pg/10 cells was used unless otherwise 
specified. For each antibody an isotype matched control was used to control for non­
specific binding. One ml of cell lysis buffer was added to lyse red blood cells, before 
the remaining cells were pelleted by centrifuging at 350g for 5 minutes. The 
supernatant was discarded and the pellet resuspended in 200-3OOpl of cell fix solution. 
To conserve fluorescence, samples were protected from the light and stored at 4°C until 
analysed.
The same method was utilised for staining of PBMC’s or monocytes. However in these 
experiments lysis of red blood cells was not required, so excess antibody was washed 
off using FACS wash, before cells were fixed.
2.5.2 Measurement of MHC Class II expression
A dual staining technique was used to determine monocyte MHC Class II expression. 
Monocytes were identified using a R-phycoerythrin (R-PE) conjugated antibody to 
CD 14 and MHC Class II expression determined with fluoroscein isothiocyanate (FITC) 
conjugated antibody to MHC Class II. Non-specific staining was determined with a 
mouse IgGl monoclonal antibody raised against keyhole limpet haemocyanin. 
Monocytes were identified on both physical characteristics (size & granularity) and 
positive CD 14 staining. MHC Class II expression was determined on 2500 events, and 
expressed as the percentage of cells positive for fluorescence (%), or as the median 
fluorescence intensity (mfi).
2.5.3 FACS analysis
Flow cytometric analysis was performed on a FACScalibur and analysed using 
CellQuest software (Becton Dickinson Immunocytometry Systems, USA). Laser 
excitation was at 488nm and data were collected on FITC fluorescence at 525nm and 
PE fluorescence at 575nm. Forward and side scatter measurements were made with 
gain settings in linear mode. The monocyte population could be easily identified by 
their size and granularity (Fig 2.2). Accuracy of the gate was confirmed by staining 
with an antibody against the surface antigen CD 14. Only cells that were both of the 
correct size and granularity, and stained with CD14+ monoclonal antibody were 
collected for analysis.
The performance of the flow cytometer was monitored through out the period of this 
thesis with weekly calibration checks. These were undertaken with CaliBrite3 Beads, 
(Becton Dickinson, UK) and analysed with the automated calibration programme, 
FACSComp (BD, UK).
2.6 E n z y m e -L in k e d  I m m u n o s o r b e n t  A s s a y  (ELISA)
Enzyme-linked immunosorbent assays (ELISA) were used to measure cytokines in 
plasma and culture supernatant. The protocol was based on manufactures instructions 
but optimised further to maximise detection of cytokines at low concentrations.
High-binding 96-well plates were coated with lOOpl/well of the capture antibody of 
choice diluted to lpg/ml (except TNF-a which was diluted to 5pg/ml) with Coating 
Buffer A, covered and left at 4°C for 12-18 hours. Coating antibody was aspirated from 
the wells and each well washed once with wash buffer before 300pl/well of blocking 
solution was added. Plates were incubated for a minimum of 2 hours at room 
temperature (18-25°C). The block was aspirated and wells washed 4x before plasma 
samples and serially diluted standards were added at lOOpl/well (Table 2.1).
TNF-a standard curve 10,000pg/ml to 5pg/ml
IL-10 standard curve (stimulated) 5,000pg/ml to lpg/ml
IL-8 standard curve (stimulated) 10,000pg/ml to lpg/ml
IL-6 standard curve (stimulated) 10,000pg/ml to 2.5pg/ml
IL-lra standard curve (stimulated) 10,000pg/ml to 2.5pg/ml
Table 2.1 Ranges of Cytokine Standard Curves. Standard curves for the cytokines 
of interest were created using 12 serial dilutions over a range of concentrations.
Attempts to optimise a standard curve starting with a top standard of < 5,000pg/ml 
resulted in loss of the sigmoid curve with no improvement in discrimination at lower 
concentrations. Samples were added neat except IL-lra, which was diluted 1 in 10. 
Where stimulated samples were off the upper limits of the standard curve all samples 
for that patient and cytokine were re-run at a dilution of 1 in 10. A substrate blank was 
used on all plates, and all standards, samples and blanks were assayed in duplicate.
Plates were covered and left overnight at 4°C. Wells were aspirated and washed 4 
times, following which the respective biotinylated antibody diluted (0.1-0.4pg/ml) in 
diluent was added (50pl/well). Plates were incubated at room temperature on a 
rotational shaker for 2 hours. After 4 washes, lOOpl/well of Streptavidin-horse radish 
peroxidase (HRP) 1/2500 was added and plates incubated for a further 30-45 minutes at 
room temperature with continual shaking. Following 4 washes, tetramethylbenzidine 
(TMB) substrate was added to each well (lOOpl/well). Plates were protected from light 
and incubated at room temperature with continued shaking. The colour reaction was 
stopped after 45-60 minutes (time individualised to each plate) with 4N Sulphuric Acid 
(lOOpl/well) and optical densities of each well were measured using a Dynatech MRX 
ELISA plate reader at 450nm (reference filter 650nm). Cytokine concentrations in the 
unknown sera were read from the curve generated from a known standard included on 
each plate (Fig 2.3). This technique allowed confidence to a lower detection range of 
between 5-10pg/ml for TNF-a and 3-5pg/ml for IL-10, -8 , -6 , and -Ira respectively.
To determine assay precision, the coefficient of variation (standard deviation of the 
replicate responses x 1 0 0  / mean of the response) was determined using replicas on one 
plate (intra-plate precision) as well as multiple plates (inter-plate precision). The 
highest coefficient of variation for any of the assays used was 4.2 for intra-plate 
precision (n=4), and 8 . 8  for inter-plate precision (n=4).
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Figure 2.3a &b: Standard Curves for Cytokine ELISA’s
Standard curves for each cytokine were generated by 1:2 serial dilutions of a known 
concentration of human recombinant protein. The optical densities were measured on a 
Dynatech MRX plate reader and analysed by sigmoid (2.6a) and quadratic regression 
(2.6b) to generate 2 standard curves. All serum cytokine concentrations for a single 
patient were calculated from one of the two curves depending on the range of 
concentrations. Results were read from the standard curve generated by quadratic 
regression if all values in a patient’s time course were < 300pg/ml.
2.6.1 General scheme for human cytokine ELISA
CAPTURE ANTIBODY
Wash
Mouse monoclonal anti-Human IgGl antibody 
on Maxisorp plates
(12-18hrs 4°C)
4
Saline with Tween 20 (xl)
BLOCK
Wash
SERA
Wash
DETECTION ANTIBODY
Wash
STREPTAVIDIN
Wash
SUBSTRATE
STOP
COLOUR
0.5% BSA in PBS (2hrs RT)
4
Saline with Tween 20 (x4)
4
Sera (neat or diluted 1/10 
in 0.5% BSA-PBS-T) 
(overnight 4°C)*
4
Saline with Tween 20 (x4)
4
Biotinylated mouse monoclonal anti-Human 
IgGl antibody (2hrs RT)*
4
Saline with Tween 20 (x4)
4
Streptavidin-HRP in PBS 
(30-45min RT)
4
Saline with Tween 20 (x4)
4
TMB in P0 4 /citrate/H2 0 2  
(45-60 min RT covered)*
4
2N H2S04 
4
Absorbance 450nm
*  denotes steps differing from manufacturers recommendations discussed in detail in 
section 4.4.1
2 .7  G e n o t y p i n g  f o r  C y t o k i n e  P r o m o t e r  P o l y m o r p h i s m s
2.7.1 DNA extraction and standardisation
A single sample of l-2mls of whole blood was collected in 4.2mM EDTA for each 
patient, and DNA extracted in batches by the genetics laboratory at Great Ormond 
Street Hospital using established techniques. Prior to standardisation, 3 random 
samples of DNA were selected from each batch and UV quantification performed using 
a 1:1, 1:9, 1:19 and 1:99 dilution to determine the dilution which fell within the linear 
part of the standard curve. DNA samples were then appropriately diluted (1:19) with 
double deionised water (dd-H2 0 ) on 96-well plates, and optical densities read using a 
spectrophotometer (Tecan Genios 96 well absorbance/fluorescence reader, TECAN, 
Austria,). The concentration of DNA in each sample was calculated using the formula 
below, and 96 x 150pl stock arrays of DNA standardised to a concentration of 15ng/pl 
were created.
[DNA] present = Optical density (260 wavelength) x dilution (1:19) x 50
Each array was clearly labelled and had a corresponding grid sheet listing samples by 
study number within an 8x12 grid (Fig 2.4). All arrays had a minimum of 3 blank 
wells. From the stock arrays, 2 x 96-well working arrays were made each with 
25pl/well. The creation of working arrays, minimised risk of contamination of stock 
DNA, and reduced the number of freeze/thaw episodes for the total DNA. All arrays 
were stored at -80°C. Creation of 96 well arrays facilitated higher throughput and 
minimised risk of contamination of stock DNA.
E fHODS
1 2 3 4 5 6 7 8 9 1 0 1 1 1 2
A 1 9 17 25 33 41 49 57 65 73 81 89
B 2 10 18 26 34 42 50 58 66 74 82 90
C 3 11 19 27 35 43 51 59 67 75 83
.
91
D 4 12 20 28 36 44 52 60 68 76 84 92
E 5 13 21 29 37 45 53 61 69 77 85 PC
F 6 14 22 30 38 46 54 62 70 78 86 Blank
G 7 15 23 31 39 47 55 63 71 79 87 Blank
H 8 16 24 32 40 48 56 64 72 80 88 Blank
Figure 2.4: An example of a standard array grid sheet. Each plate contained at
least 3 blanks, and space for a positive control (PC).
2.7.2 Polymerase Chain Reaction (PCR)
The technique of PCR relies on the fact that a DNA strand can be denatured into single 
strands by heat, and will anneal with primers and nucleotide bases to reform a double 
strand on cooling. Primers complimentary to sections of DNA on either side of the 
sequence to be studied bind to the genomic DNA, and a DNA polymerase adds 
nucleotides base by base between the 2 primers. The polymerase used in PCR is 
derived from the bacterium Thermus aquaticus (Taq) and is heat stable, thus 
replenishment of polymerase after each cycle of heating and cooling was not required. 
PCR enabled very small initial amounts of DNA to be increased in quantity until there 
was sufficient DNA for genotyping to be performed.
The primer sequences and PCR cycle conditions specific to each PCR are detailed in 
Tables 2.1 and 2.3.
Polymorphism Oligonucleotide Sequence 5’-3’ 
(Forward / Reverse)
Fragment 
Size (bp)
IL - 6  -174 G/C 5’-TGA CTT CAG CTT TAC TCT TGT-3’ 
5’-CTG ATT GGA AAC CTT ATT AAG-3’
190
IL-10 -1082 G/A 5’-CCA AGA CAA CAC TAC TAA GGC TCC TTT -3’ 
5’-GCT TCT TAT ATG CTA GTC AGG TA-3’
377
IL-10 -819 C/T 5’-CAA CTT CTT CCA CCC CAT CTT T-3’ 
5’-GTG GGC TAA ATA TCC TCA AAG TT-3’
A ll
IL-10 -592 C/A 5’-CAA CTT CTT CCA CCC CAT CTT T-3’ 
5’-GTG GGC TAA ATA TCC TCA AAG TT-3’
A ll
TNF-a -308 G/A 5’-GGA GGC AAT AGG TTT TGA GGG cCA T-3’ 
5’-CCT TGG TGG AGA AAC CCA TGg GCT-3’
253
Table 2.2: Primer pairs for allele-specific restriction enzyme analysis
The sequences of primers used for each of the cytokine promoter polymorphisms 
studied and size of fragment generated is shown. Sequences are in 5’-3’ direction. 
Sequences of the upstream primer are shown above the sequence of the downstream 
primer. Primer nucleotides that differ from the genomic sequences are in lower case 
letters.
2.7.2.1 Sample preparation for PCR
Working arrays were defrosted and centrifuged at 1450g for 1 minute. This minimised 
DNA loss or cross-well contamination on removal of array lid. Two microlitres of each 
DNA sample was removed and transferred into a 96-well polycarbonated PCR plate 
using a multichannel Finnipipette. Positive and negative controls were used in each 
array to ensure accuracy. Extreme care was taken to ensure that samples were placed in 
the identical orientation as in the original array. Loaded PCR plates were then 
centrifuged at 160g for 1 minute to ensure the DNA was at the bottom of each well, 
before drying on a Thermal Cycler block at 80°C for 10 minutes.
Polymerase chain reactions were performed in a total volume of 20pl. Each reaction 
was prepared on ice and contained lx concentration of polmix (50mM KC1, lOmM 
Tris-HCl (pH 8.3), 0.2mm dATP, dGTP, dTTP and dCTP), 1.5-2.5mM MgCl2, 600- 
lOOOpmol of forward and reverse primers, and 25-30 units of Taq polymerase. The 
magnesium concentration was optimised for each PCR (see Chapter 6, section 6.4.2).
The PCR mix was added to each well of the PCR plate using an automatic Biohit 
repeating dispenser. Each sample was overlaid with 20pl of paraffin oil to prevent 
evaporation. PCR amplification was performed on an MJ Tetrad DNA engine 
Thermocycler, using cycle conditions specific to each PCR. Presence of product was 
confirmed on a 2% agarose gel stained with ethidium bromide.
Polymorphism Step 1
(denature)
Step 2 Step 3 Step 4 No. of cycles 
(steps 2-4)
Termination
step
IL - 6  -174 G/C 95°C 
4 min
95°C 
40 sec
50°C 
30 sec
72°C 
1.5 min
35 cycles 72°C 
5 min
IL-10 -1082 G /A 95°C 
5 min
95°C 
45 sec
59.8°C 
45 sec
72°C 
45 sec
30 cycles 72°C 
10 min
IL-10 -819 C/T 95°C 
5 min
95°C 
45 sec
65°C 
45 sec
72°C 
45 sec
30 cycles 72°C 
10 min
IL-10 -592 C/A 95°C 
5 min
95°C 
45 sec
65°C 
45 sec
72°C 
45 sec
30 cycles 72°C 
10 min
TNF-a -308 G/A 95°C 
5 min
95°C 
45 sec
57°C 
45 sec
72°C 
45 sec
30 cycles 72°C 
10 min
Table 2.3: PCR cycle conditions for each promoter polymorphism
2.7.3 Restriction Enzyme Digest
Restriction enzymes are enzymes derived from bacteria that will cleave double stranded 
DNA at a particular sequence. The restriction enzyme is sensitive even to a single base 
change in the recognition sequence, and thus can be used to detect point mutations and 
single base polymorphisms. A single base change, such as those seen in the promoter 
polymorphisms studied, eliminate or create a cutting site for the restriction enzyme.
Following generation of the PCR product, a restriction enzyme digest mix was made 
containing sufficient enzyme to digest the PCR product. 8-10pl of PCR mix was added 
to 5 pi of digest mix in a 96-well microtiter plate, and the plate centrifuged at 210g for 1 
minute. The PCR/digest mix was incubated for a minimum of 4 hours at a temperature 
appropriate for the specific enzyme used (Table2.4).
2.7.4 Microtitre Array Diagonal Gel Electrophoresis (MADGE)
The DNA fragments produced by restriction enzyme digest were separated using 
electrophoresis on a non-denaturing polyacrylamide gel, using a technique known as 
microtitre array diagonal gel electrophoresis (MADGE). This technique made it 
possible to electrophorese the 96 wells of a standard PCR plate on a single gel by 
running the samples diagonally. This allowed the 96 well DNA array format to be 
retained throughout the genotype processing.
MADGE gels consist of an open arrangement of 8  x 12 wells each 2mm deep. The 
wells are arranged at an angle of 71.2°C to the short access of the array, but 
perpendicular to the long-axis of the Perspex formers used. Thus the maximum track 
length for genotype resolution was 26.5mm (Fig 2.5).
Polymorphism Restriction
Enzyme
(units/sample)
M anufacturer Units / 
sample
Temperature 
of digest
Sequence
recognised
Fragments generated 
(bp)
IL - 6  -174 G/C Nla III New England 
Biolabs
0.5 37°C c a tg I -174 G - 190 bp 
-174 C -  143/47 bp
IL-10 -1082 G/A EcoNl New England 
Biolabs
3 37°C c c t n n I nnn agg -1082 G - 253/97/27 bp 
-1082 A -280/97  bp
IL-10 -819 C/T Mae III Roche Applied 
Science
0.3 55°C J^GTNAC -819 C - 217/ 175/85 bp 
-819 T - 392/85 bp
IL-10 -592 C/A CSP61 Fermentas 2 37°C g 4<tac -592 C - 311 / 116/42/8  bp 
-592 A -240/  116/71 / 42/ 8 bp
TNF-ct -308 G/A Ncol 1 New England 
Biolabs
4 37°C dCATGG -308 G - 210/23/20 bp 
-308 A -  233 / 20 bp
Table 2.4: Details of Restriction Digests
The details of the specific restriction enzyme and optimal temperature for digest are outlined for each cytokine polymorphism. The sequence 
recognized by the restriction enzyme, cutting site and size of fragments generated are tabulated in the last 2 columns.
Figure 2.5 Creating a 96 well polyacrylamide gel using the MADGE perspex 
forma. The polyacrylamide mix is poured onto the forma, and a sticky silane coated 
glass plate is placed on top. After setting the gel and plate are lifted off the forma and 
placed in ethidium bromide for staining prior to use.
Six or 7.5% polyacrylamide gels stained with 0.5pg/ml ethidium bromide were used for 
gel electrophoresis. Adherence of polyacrylamide gels to glass plates was enhanced by 
coating the glass with y-methacryloxypropyltrimethoxy silane (sticky silane). Five 
microlitres of digested PCR product was added to 2pl of formamide dye prior to loading 
the polyacrylamide gel. Gels were electrophoresed at 100-120V to separate digest 
products and visualised using UVP Gel Documentation System (Fig 2.6). Each gel 
contained a positive and negative control and genotype was checked by 2 individuals. 
Any conflict in genotype between the 2 observers was resolved by repeated genotyping.
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Figure 2.6 Image of a 7.5% polyacrylamide gel with digested PCR product
The microtitre array diagonal gel electrophoresis (MADGE) allowed 96 patient samples 
to be analyses simultaneously on a horizontal polyacrylamide gel. As each step 
involves a 96 well template, there is conservation of the patient’s position from the 
stock DNA array through to genotyping. At least 3 blanks were included on every plate 
(in this gel 12C to 12H), and a positive control (12B). The digested PCR product is 
loaded into the well marked with a green arrow, and is electrophoresed at an angle along 
the red line. Very small products (<50 bp) may travel to the next well (marked with a 
black arrow) and therefore not be seen.
2.8 Confocal Microscopy
2.8.1 The Microscope
For the final part of this thesis, a microscopic technique was required to complement 
flow cytometry in establishing the amount and location of MHC Class II. Confocal 
microscopy was chosen because of its superior ability to differentiate between surface 
and intracellular fluorescence.
In attempting to localise a molecule to either an intracellular or surface position, it was 
important not to have surface molecules on either side of the section being 
superimposed. The combination of a laser and a pinhole avoids the common problem in 
conventional microscopy of in-focus information being presented simultaneously with 
defocused information from the same cell, creating a blur. Use of confocal microscopy 
enabled detailed imaging and semi-quantitation of cellular components that were 
labelled with fluorochromes.
Confocal images were obtained using a Leica SP2 confocal laser scanning microscope 
system, and Adobe Photoshop 5.0 software (Adobe, USA) was used to maximise the 
quality of the digital images where appropriate.
2.8.2 Surface Staining
PBMC’s or monocytes were incubated with purified mouse anti-human monoclonal 
antibody to CD 14 (0.5pg/106 cells) at room temperature for 30-45 minutes. Cells were 
washed once with FACS wash, and fixed with 2% paraformaldehyde. An appropriate 
second layer anti-mouse flurochrome was then added (Cy-5) and the sample was 
incubated in the dark at room temperature for a further 30-45 minutes. Cells were 
washed and incubated with a primary conjugated antibody to MHC Class II (FITC) or 
isotype matched control (5pg/106  cells), for 30-45 minutes.
The sample was washed in FACS wash (x2) and a cell count was performed. The 
sample was adjusted to 2xl0 6 cells per ml, and 50pl placed on a polylysine coated 
microscope slide, air dried and mounted with Citi-fluor. Cells were examined using 
lOOx oil immersion magnification on the confocal microscope.
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Figure 2.7 Surface staining o f monocytes for CD14 and MHC Class II expression.
PBMC’s isolated by density gradient from 2 patients were incubated with monoclonal 
antibody to CD14 (2nd layer Cy-5-red) and MHC Class II (FITC-green). Imaging was 
performed using a confocal immunofluorescence microscope (x 1 0 0 ).
2.8.3 Nuclear staining
Where nuclear staining was required, cells were permeabilised after surface staining 
using either 1 % saponin or permeabilisation liquid, and incubated with the nuclear stain 
To-pro-3 iodine (1:800 dilution). If intracellular staining of the sample was required, 
To-pro-3 iodine was combined with the flurochrome labelled monoclonal antibody to 
the intracellular structure of choice. Following 30-45 minute incubation, cells were 
washed twice and mounted.
2.8.4 Intracellular staining
PBMC’s or monocytes were surface stained for CD 14 using the two-layer method 
described above. After fixing, cells were then permeabilised and the fluorochrome 
labelled antibody to the structure of interest was added. An isotype-matched control 
was used in a duplicate sample, for each intracellular structure being examined. 
Following 30-45 minute incubation, cells were washed (x2) and mounted as described 
above.
2.8.5 Analysis
Slides were stored at -20°C until examined using the confocal microscope. All slides 
from a single patient were examined at the same time, with the examiner blinded to the 
flow cytometry and mRNA results. Monocytes were selected based on cell 
morphology. For each patient, microscope settings were optimised for monocytes from 
the pre-operative sample and then settings were left unchanged for images acquired 
from post-operative samples. For each sample 5 monocytes were randomly chosen, 
examined, and photographed for both surface and intracellular MHC Class II staining. 
Images were taken at 200x, 400x and 800x magnification.
2.9 St a t ist ic s
A number of parametric and non-parametric tests were used to analyse the results 
presented here. A description of individual tests and their application is given in the 
relevant chapters. Parametric tests were used wherever the data were normally 
distributed or could be transformed to normality. As much of the data was not normally 
distributed and group numbers small, non-parametric tests were utilized to detect 
differences between groups. Results between groups were compared using Mann- 
Whitney U test, Kruskal-Wallis test, or Spearman’s correlation coefficient. The change 
of the data over the study period was analysed with a one-way analysis of variance for 
repeated measures (ANOVA) if  normally distributed, or the Friedman test if  a non 
parametric equivalent was required.
In an effort to avoid repeated analysis and the associated risk of a chance finding being 
significant, intergroup comparisons and correlation analyses were only performed on 
cytokine samples collected at end of surgery, 8 , 24, and 48 hours post operatively. 
These samples where chosen for based on previous reports in the literature (Wemovsky, 
Wypij and others, 1995). Analysis was performed using the Statistical Package for the 
Social Sciences (SPSS 10.0). A p  value less than 0.05 was considered significant
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3.1 In t r o d u c t io n
The recognition that surgery and trauma caused a prolonged alteration in monocyte 
function, with reduced antigen presenting capacity and reduced mitogen-induced 
synthesis of IL-1 and IFN-y, occurred as early as 1988 (Faist, Mewes and others, 1988). 
In the same year, a report appeared showing a close correlation between the failure of
tliperipheral blood monocytes to express HLA-DR by the 7 day after injury, and the 
development of infection and death in severely injured patients (Hershman, Cheadle and 
others, 1988). Since this report there have been numerous similar studies showing that 
persistently reduced HLA-DR expression following surgery or trauma identifies a 
subgroup of patients at increased risk of infection and poor prognosis (Cheadle, 
Hershman and others, 1991;Giannoudis, Smith and others, 1999;Hershman, Cheadle 
and others, 1990;Klava, Windsor and others, 1997;Tschaikowsky, Hedwig-Geissing and 
others, 2002;van den Berk, Oldenburger and others, 1997;Wakefield, Carey and others, 
1993). However the surgical patients reported were general, orthopaedic or adult 
trauma patients, and there is little research into the effect of cardiac surgery and bypass 
on MHC Class II expression.
There are three reports showing that cardiac surgery reduces monocyte surface HLA- 
DR expression, and that the reduction is greater in patients where CPB was utilized 
(Hiesmayr, Spittler and others, 1999;McBride, Armstrong and others, 1995;Rinder, 
Mathew and others, 1997). However none of these studies correlate expression with 
measures of surgical insult, development of sepsis or other outcome measures. One 
very recent adult study reported a significant reduction in MHC Class II expression in 
patients undergoing cardiac surgery, but found no predictive value in the level of 
reduction at 24 hours and the development of sepsis/SIRS (Oczenski, Krenn and others, 
2003). However their measurements did not continue beyond 24 hours.
At the initiation of this thesis there was only one study describing the presence of 
reduced monocyte HLA-DR expression in critically ill children, and no studies on the 
effect of CPB on monocyte function in the paediatric population (Peters, Petros and 
others, 1999). This chapter sets out to describe in detail the effect of cardiac surgery 
involving cardiopulmonary bypass on monocyte MHC Class II surface expression, and
to determine if  monocyte deactivation, as indicated by reduced MHC Class II 
expression, was a factor in the development of sepsis/SIRS following cardiopulmonary 
bypass.
3.2 M e th o d s
3.2.1 Patient group
This was a prospective observational study carried out over an 11 month period 
involving children up to 16 years of age. Patients were excluded if they had a known 
immunodeficiency, were on immunomodulatory medication, or were pre-term at the 
time of the operation (< 36 weeks gestation). Children undergoing surgery for 
hypoplastic left heart syndrome, were also excluded as this condition had a high early 
complication/death rate not representative of other paediatric cardiac surgery, which 
may have biased outcome.
All children were elective admissions for cardiac surgery involving CPB. Children 
were clinically well and believed to be free from infection at the time of surgery. At 
surgery all children routinely had arterial and central venous catheters placed, and blood 
sampling for this study was obtained through one of these lines. Depending on the 
operation undertaken, and the perceived risk of arrythmias or pulmonary hypotension, 
some children had additional direct atrial lines and pacing wires placed at the end of 
surgery.
3.2.2 Anesthesia and CPB Management
Within the institution where this study took place, there is a team of dedicated cardiac 
anaesthetists and perfusionists. Whilst the anaesthetic agents used in cardiac surgery 
vary slightly depending on the child’s age and cardiac defect, the pharmacological 
agents used in theatre can be summarised as follows. Anaesthesia was induced with 
either intravenous ketamine (2 mg/kg), or the inhalational agent sevoflurane in oxygen. 
During bypass, anaesthesia was maintained with isoflurane and fentanyl, with 
pancuronium for neuromuscular blockade. Prior to aortic cannulation, 300 IU/kg of
heparin were administered to achieve systemic anticoagulation. The bypass circuit was 
primed with crystalloid, colloid, mannitol (0.5g/kg), packed red blood cells (150- 
300ml), heparin (2500 IU/unit packed cells), 8.4% sodium bicarbonate (20 ml/unit 
packed cells), and calcium chloride (3 mmol/unit packed cells). Hollow fibre 
membrane oxygenators were used to achieve gas exchange. Mean perfusion pressure 
during bypass was maintained using non-pulsatile flow with isoflurane to vasodilate and 
metaraminol to vasoconstrict as required. Full flow on bypass was calculated using a 
cardiac index of 2.4 1/min/m2. Systemic perfusion pressure was maintained at a mean of 
35-45mmHg throughout the time the child was on bypass.
After the surgeon determined the desired temperature for operating, core temperature 
was controlled using a heat exchanger in the bypass circuit and monitored with a 
nasopharyngeal probe. All operative repairs requiring circulatory arrest were performed 
at 18°C, and the myocardium was protected with ‘St. Thomas #1* crystalloid 
cardioplegia solution (30 ml/kg). Modified ultrafiltration was utilised at the end of 
bypass, to raise the haematocrit to 40 in all neonates, and any child who had undergone 
haemodilution, long bypass time or been cooled. The effects of heparin were reversed 
at the end of the procedure with protamine ( 6  mg/kg).
3.2.3 Clinical Care
All patients were admitted to a specialised cardiac intensive care unit (CICU) from 
theatre, where they were looked after by paediatric cardiac intensivists and senior 
specialist registrars in conjunction with the cardiothoracic surgeon and consultant 
cardiologists. Clinical care was unaffected by participation in the study and results of 
investigation were not available to the clinical team. Operations were grouped 
according to technical difficulty utilising the classification published by Stark et al. 
(Stark, Gallivan and others, 2000). The Paediatric Index of Mortality (PIM) (Shann, 
Pearson and others, 1997) was assessed on admission to the Cardiac Intensive Care 
(CICU) as an indication of the physiological state of the patient at the end of theatre 
(Appendix II).
Clinical progress was monitored daily, with duration of ventilation and postoperative 
complications recorded. Postoperative complications which were marked as present or 
absent each day included: sepsis, low cardiac output, arrhythmias, ischemic changes on 
ECG, bleeding, requirement for chest re-exploration, lobar collapse or consolidation, 
tracheobronchomalacia, and hepatic or renal dysfunction. As per protocol, all children 
received 24hrs of perioperative antibiotic cover (amikacin and flucloxacillin). Blood 
cultures were taken at the treating clinicians discretion if there was a clinical concern 
about sepsis and an empirical antibiotic regimen according to hospital protocol was 
started (amikacin and teicoplanin).
For the purpose of this study, the following outcome measures were recorded: sepsis, 
SIRS, length of stay (LOS) in CICU, and death. An ongoing audit (April 1998 -)  
demonstrated that CICU length of stay is bimodally distributed, with the majority of 
children staying < 5 days. Short stay was defined as < 5 days on ICU, and long stay as > 
5 days. A modification of the consensus conference (1992) definition of sepsis/SIRS 
was used (Appendix III). In view of the frequency with which these children received 
ventilation and inotropic support, respiratory and heart rates were felt to be unreliable 
indicators. Therefore SIRS was more tightly defined as:
temperature >38°C or <36°C (not artificially controlled), and
WCC >12,000 or <4,000 cells/mm3.
Sepsis was defined as positive blood cultures in the setting of SIRS.
3.2.4 Study design
An overview of the study design is given in figure 3.1. Patients were recruited 
preoperatively and the first blood sample collected after induction of anaesthesia on line 
insertion. The second sample was taken at the end of surgery following modified 
ultrafiltration. A third sample was collected in the cardiac intensive care unit 6  hours 
post surgery. Subsequent samples were collected at 0900 each morning, to avoid any 
effect of diumal variations in MHC Class II expression, for the duration of the patient’s 
intensive care stay.
TCOME?
Patients Study D
,s? Short Stay
CICU
Blood samples
Theatre
V Long Stay
Sepsis SIRS Other
complications
Figure 3.1 An overview of study design.
Patients were consented pre-operatively and the first sample was taken on induction of 
anaesthesia. Additional samples were drawn following bypass before skin closure, 6 
hrs post-operatively, and daily at 0900 throughout the ICU stay. Outcome measures 
included duration of CICU stay, development of sepsis or SIRS and death.
3 . 3  S t a t i s t i c s
As MHC Class II was expressed as a percentage, and therefore not normally distributed, 
comparison between groups was performed with the Mann-Whitney test. A 2-tailed t- 
test for equality of means was utilised when comparing MFI pre-operatively. Exact 
confidence limits were calculated for proportions with correction for small sample sizes. 
Multivariable logistic-regression analysis was used to evaluate individual variables and 
the best combination of variables predicting: prolonged stay; development of sepsis; and 
sepsis/SIRS.
3 .4  R e s u l t s
Prior to collecting patient samples a series of experiments were undertaken to assess the 
stability of the staining technique. In view of the range of times and conditions over 
which blood samples were going to be collected, the effect of delaying the time to 
staining and time to analysing were examined. In addition the first 20 patients were 
examined in duplicate to ensure reproducibility of staining.
3.4.1 Reproducibility of Staining
As described in section 2.4 and 2.5 whole blood was collected into anti-coagulant and 
stained for MHC Class II expression. Analysis of duplicates from the first patients 
revealed a variability of less than 2% (Fig 3.2). This was independent of the level of 
MHC Class II as shown in Fig 3.2
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Figure 3.2 Surface staining of monocytes for MHC Class II. Two histograms 
demonstrate MHC Class II staining pre-operatively and on Day 1 post-operatively for 
study patient 3. Duplicate staining of initial patient samples showed high 
reproducibility for the technique used. The marker on each histogram indicates the 
percentage of monocytes that are staining positive for MHC Class II above the 
background control staining.
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3.4.2 Effect of delay in staining on whole blood MHC Class II 
expression
Experiments were performed in order to ascertain whether the result obtained for MHC 
Class II varied if the sample of whole blood was left on the bench or in the fridge in the 
anaesthetic room prior to staining. Figure 3.3 shows that there was a downward drift in 
the percentage of monocytes expressing MHC Class II. This reached as much as 10% 
when anticoagulated whole blood was left at room temperature for 2 hours prior to 
staining. The reduction in cells expressing MHC Class II was less if the patient sample 
was placed at 4°C. In contrast, the expression of MHC Class II per cell, as assessed by 
the median fluorescence intensity, appeared to drift up when there was a delay between 
collection of the blood sample and staining regardless of whether the sample was left at 
room temperature or 4°C.
o
Room temperature
100
o>c
'£
CO+-*(/>
4°C
</)in«
O
0 10 20 30 45 60 90 120 150
60
*—.40
E
U)c
20
O 60 CO
3
t/> 40
(/)
m 20  <0
o
Room Temperature
“ i r ~ " i "
4°C
. 't"  
✓ \
 I------------1----------- 1----------- I------------?----------- 1----------- 1----------1—
0 10 20 30 45 60 90 120 150
Time to  stain ing (m inutes)
Figure 3.3 The effect of delay in antibody staining of whole blood. Blood drawn 
from 3 healthy controls was allowed to stand at either room temperature or 4°C for 10- 
150 minutes before staining for monocyte MHC Class II expression. Results of 
antibody staining were compared to samples stained immediately. Whole blood 
samples that were left at room temperature had a reduction of up to 8% in surface 
staining for MHC Class II expression (%) and a trend upwards in median fluorescence 
intensity. This was less marked when the samples were placed at 4°C between 
collection and staining.
3.4.3 Effect of delaying analysis on MHC Class II expression
Preliminary experiments were undertaken to examine the effect of time on the 
fluorescence of bound antibody. Whole blood from 3 of the initial patients was stained 
for surface expression of MHC Class II, stored at 4°C and repeatedly analysed over a 7 
day period. Analysis of samples showed a marked reduction in surface MHC Class II 
expression (both % and mfi) from 24 hours after staining (Fig 3.4). Samples analysed 
within 24 hours of staining showed minimal variation.
Taken together the results form the above experiments indicated that MHC Class II 
expression should be analysed on samples that are stained within thirty minutes of 
venesection and analysed within 24 hours.
100
80
§
« 60
£o.xQ)
2 : 4 0
</>iro
o  20
0 H------------7------------I----------- 1------------7------------1------------7------------I------------1
0 1 2 3 4 5 6 7
Time betw een  staining and an alysis  
(days)
Figure 3.4 Effect of delaying analysis on MHC Class II expression. Samples from 
three initial patients were repeatedly analysed each day for 7 days to assess the effect on 
the measurement of MHC Class II expression. Initial staining occurred within 30 
minutes of venesection, and samples were fixed and stored at 4°C protected from light 
between times of analysis. There was little difference in results obtained from samples 
analysed on the day or 24 hours after staining, but there was a marked reduction in 
Class II expression if samples were left 48 hours or more before analysis. Inset shows 
MHC Class II histogram for subject 1.
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3.4.4 Patient Characteristics and Operative Details
Once the optimal conditions for MHC Class II staining and analysis had been 
determined, patient enrolment proceeded. Eighty-two infants and children were studied 
over the 11 months. An additional five parents. - were approached but refused 
participation. The median age of the population studied was 10 months (range 2 days -  
16 years). The male:female ratio was 3:2 and the median weight was 8  kg (2 -  50 kg).
A range of operative procedures were performed on these patients, 
subdivided into the following groups:
relief of right ventricular outflow tract obstruction 
ventricular or atrial septal defect closure 
pulmonary artery reconstruction
complex shunts including total cavopulmonary connection, 
arterial or atrial switch, and Glenn procedure 
complete atrioventricular septal defect repair 
valve repair / replacement 
and others
Details of cardiac surgery are described in section 3.2.2. In this population, the median 
duration of CPB and aortic cross-clamp time was 82 min (range 16-305), and 40 min 
(range 5-178) respectively. Eleven percent (9/82) of the operations were performed 
under deep hypothermic circulatory arrest. Sixty-one (75%) patients had modified 
ultrafiltration prior to coming off bypass in an effort to remove excess total body water. 
Four of the 82 patients had delayed sternal closure, indicating significant local tissue 
oedema impairing cardiac function. All enrolled patients completed the study protocol.
3.4.5 Outcome
As expected, the intensive care stay (LOS) following surgery was distributed bimodally, 
with an overall median stay of 3 days (Fig 3.5). In the majority of patients (63%, 52/82) 
the LOS was < 5 days, with the remainder (37%, 30/82) requiring a median of 10 days 
(6-50 days). There was no statistically significant difference between LOS in this study
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group and the audited population (p=0.82). Eleven patients developed proven sepsis 
and three further patients fulfilled the criteria for SIRS in the postoperative period.
Other complications seen included arrhythmias (43%), poor cardiac function requiring 
inotropic support (23%), pulmonary hypertension (16%), and multiorgan failure (10%). 
All complications were identified and classified by a single senior clinician as part of 
the on-going audit programme. Only 2 patients died during this study, both within the 
long stay group. These data were included.
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Figure 3.5: Duration of stay in CICU following cardiac bypass surgery.
Short stay was defined for the purpose of this study as < 5 days (median 48 hrs), and 
long stay as > 5days (median 10 days). The median length of stay for the whole study 
population was 3 days.
3.4.6 Monocyte MHC Class II expression in patients undergoing 
CPB
The expression of MHC Class II on the surface of circulating monocytes was high in all 
patients pre-operatively. The majority (80%) of patients had MHC Class II expression 
greater than 95% (Fig 3.6). Following cardiac bypass, MHC Class II expression was
significantly reduced compared to pre-operative levels. Surface expression of MHC 
Class II remained reduced for several days, with the lowest levels seen at 48-72hours
(p< 0 .01).
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Figure 3.6 Monocyte MHC Class II expression in all patients following 
cardiopulmonary bypass. Blood was taken from each study patient at anaesthetic 
induction (pre op), and at 9 am each day following the operation. Data are shown in 
box and whiskers plots, indicating the median, IQR and range. There was a significant 
reduction Mann-Whitney p< 0.01 ) in monocyte MHC Class II expression (HLA-
DR) for the first 4 post operative days, compared with pre operative expression.
3.4.7 Monocyte MHC Class II expression related to Morbidity: 
Length of Stay
In order to address the question of whether this early reduction in surface expression of 
MHC Class II was related to patient recovery, the MHC Class II levels were compared 
with length of stay. The nadir of MHC Class II expression in the first 72 hours post
bypass was significantly lower in long stay (>5 days) as compared to the short stay 
patient group (< 5days); median 53% vs. 87% (Mann-Whitney p<0.001) (Fig 3.7a). 
That is, those patients that subsequently required prolonged intensive care support had a 
far greater reduction in their MHC Class II expression in response to cardiac surgery.
3.4.8 Monocyte MHC Class II expression related to Morbidity: 
Development of Sepsis / SIRS
If the reduction in MHC Class II expression in the early post-operative period directly 
affected the patients recovery, one possible means may have been through increased 
susceptibility to infection. The eleven patients who developed proven sepsis all 
required a prolonged stay in Intensive care. Three further patients, who were classified 
as SIRS, also required a prolonged stay. While no patients fulfilled the criteria for 
sepsis/SIRS in the first 72 hours post-operatively, the nadir of MHC Class II in this 
period was significantly lower in patients that went on to develop sepsis/SIRS. Those 
patients who subsequently developed sepsis/SIRS had a marked reduction in the 
expression of MHC Class II on circulating monocytes (<30%) in the early post­
operative period. This compared to 84.7% of monocytes expressing MHC Class II in 
the patient group that remained non-septic (p< 0.0001). This reduction in MHC Class 
II expression was only slightly less and still highly significant, when patients classified 
as SIRS were considered together with sepsis: median 32% vs 85% (p< 0.0001) (Fig 
3.7b&c).
It is important to note that the reduction in surface MHC Class II expression preceeded 
the clinical development of both sepsis and SIRS, with the median interval between the 
lowest value of MHC Class II and development of sepsis being 5 days (IQR 4-12).
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Figure 3.7 a,b,&c. Class II expression in the 1st 72 hours following cardiopulmonary bypass is lower in the long stay and sepsis groups.
The nadir of MHC Class II expression in the first 72hrs was significantly lower (p < 0.001) in patients who required intensive care support for >5 days 
(long) compared to <5 days (short) A, and those that subsequently developed sepsis (p<0.0001) B, or sepsis / SIRS {p<0.0001).
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3.4.9 Surgical insult and the reduction in postoperative monocyte 
MHC Class II expression
The most obvious question is whether the reduction in post-operative MHC Class II 
expression is merely reflective of the degree of surgical insult, and therefore at a greater 
risk of post-operative complications. MHC Class II expression in the first 72 hours 
post-operatively did not correlate with any of the markers of of the severity of insult 
(Table 3.2). Nor did it correlate with age or the physiological state of the patient on 
arrival to ICU. In addition, post-operative MHC Class II expression was unrelated to 
the identity of the surgeon (Kruskal Wallis /?=0.57).
Lowest MHC Class II expression in 
first 72 hours post-op
Correlation
coefficient Significance {p)
Age -0.04 0.71
Bypass time -0.09 0.43
Cross-clamp time -0.14 0 . 2 2
Lowest
temperature
0 . 2 0 0.09
Operation 
severity group
-0.06 0.62
PIM -0.16 0.26
Table 3.1 Correlation between MHC Class II expression post-operatively and age, 
measures of surgical insult, and physiological state of the patient on return to ICU 
from theatre (PIM). There was no correlation between the lowest recorded level of 
MHC Class II expression on monocytes post-operatively and measures of surgical 
insult.
3.4.10 Post-operative outcome was related to surgical insult
Whilst the observed reduction in MHC Class II expression did not appear to be directly 
related to the severity of the surgical insult, the surgery performed did influence patient 
post-operative recovery. In table 3.3 indicators of the complexity of the surgery 
(operation group, bypass time, and cross-clamp time) and the physiological state on 
arrival on ICU (PIM risk of mortality) for the patient group studied, are shown. Patients 
who developed sepsis, (or sepsis/SIRS) or required >5 days ICU care had longer, more 
complex procedures and greater physiological derangement on return to the ICU.
Stay Sepsis Sepsis / SIRS
Short
n=52
Long
n=30
p  value no
n=71
yes
n=l 1
p  value no
n=68
yes
n=14
p  value
Age 0.96
(0.32-5)
0.63
(0.15-3.3)
0.29 0.75
(0.27-4.5)
1.79
(0.23-13.8)
0.47 0.78
(0.26-4.6)
1.04
(0.3-12)
0.5
Operation group 2
(1-2)
2
(2-3)
0.08 2
(1-2)
2.5
(2-3)
0.005 2
(1-2)
2
(2-3)
0.02
Bypass time 62
(33-92)
87
(69-133)
0.007 69
(34-97)
112
(85-145)
0.004 69
(34-98)
108
(81-141)
0.01
X-clamp time 22.5
(0-41)
43
(13-64)
0.021 27
(0-46)
48
(20-67)
0.08 26
(0-46)
65
(23-66)
0.09
Risk of Mortality 
(PIM)
0.06
(0.05-0.1)
0.09
(0.06-0.11)
0.042 0.07
(0.05-0.1)
0.11
(0.09-0.13)
0.02 0.07
(0.05-0.1)
0.11
(0.08-0.13)
0.02
Table 3.2 Age, measures of the perioperative course and severity of physiological derangement at ICU admission between outcome groups.
Median values and interquartile ranges (IQR) are shown. Comparison are made with the Mann-Whitney tests. Higher PIM score and bypass times 
were seen in the long stay patients and in those that developed sepsis or SIRS.
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3.4.11 Reduced monocyte MHC Class II expression remains 
strongly associated with the development of sepsis, sepsis/SIRS, and 
prolonged requirement for intensive care after correcting for other 
factors.
So the question arises, what role does reduced monocyte MHC Class II expression play 
in the morbidity observed following cardiac surgery involving CPB? To assess the 
contribution of MHC Class II to outcome, 3 logistic regression models were constructed 
to identify the factors that were independently associated with a requirement for (i) 
prolonged ICU stay, (ii) development of sepsis, and (iii) development of sepsis/SIRS 
(Table 3.4 & 3.5). MHC Class II remained highly significantly associated with a 
requirement for increased stay, development of sepsis, or sepsis/SIRS (p<0.001), after 
correction for all covariates (age, sex, operation group, bypass time, surgeon, PIM) 
regardless of the method of variable entry. Whilst univariate analysis showed that 
bypass time was associated with these outcomes, this effect was no longer apparent after 
correction for the MHC Class II expression. This indicates that monocyte MHC Class 
II expression was independently associated with the subsequent development of sepsis 
or sepsis/SIRS.
Because length of stay is a continuous measure, and the division of length of stay into 
short (< 5 days) and long stay (> 5 days) is a somewhat arbitrary one, further regression 
models were constructed utilising length of stay as the continuous dependant variable. 
The monocyte Class II expression remained independently associated with length of 
stay after correction for all of the above covariates (p<0.001). (Results not shown)
3.4.12 Reduced monocyte MHC Class II expression predicts the 
development of post-operative sepsis/SIRS.
Finally, the performance of reduced MHC Class II expression as a predictor of the 
development of sepsis, sepsis/SIRS or prolonged ICU stay was examined. The receiver 
operating characteristic (ROC) curve (Hanley and McNeil, 1982;Hanley and McNeil, 
1983) examines the probability that MHC Class II expression on monocytes will 
correctly predict those patients most likely to develop complications. This analysis 
addresses the performance of MHC Class II across all values. The ROC curve for
Stay Sepsis Sepsis / SIRS
Signif. O.R 95% C.I Signif. O.R 95% C.I Signif. O.R 95% C.I
Age 0.81 1 . 0 1 (0.92-1.12) 0.30 1.07 (0.94-1.21) 0.16 1.09 (0.97-1.22)
Operation group 0.14 1.60 (0.85-3.01) 0.01 4.13 (1.40-12.2) 0.09 2.07 (0.90-4.77)
Bypass time 0.13 1 . 0 1 (1.00-1.02) 0.02 1 . 0 1 (1.00-1.02) 0.04 1 . 0 1 (1.0-1.02)
X-clamp time 0.04 1 . 0 2 (1.00-1.03) 0 . 2 2 1 . 0 1 (0.99-1.02) 0.42 1 . 0 1 (0.99-1.02)
Risk of Mortality 
(PIM)
0.94 0.89 (0.05-
15.12)
0.81 0.96 (0.64-1.40) 0.46 0.47 (0-153.7)
Lowest MHC Class II 
expression in 1st 72hrs 0.0003 0.96
(0.94-0.98) 0.0003 0.94 (0.92-0.97) 0.0002 0.95 (0.93-0.98)
Table 3.3 Univariate logistic regession analyses were performed to assess the contribution of each variable to the 3 outcome measures of stay, 
sepsis, and sepsis/SIRS. Whilst bypass time significantly contributed to the likelihood of developing sepsis or sepsis/SIRS, it was not significantly 
associated with a prolonged stay in Intensive Care. The lower the MHC Class II expression recorded in the first 72 hours post operatively, the more 
likely the child was to require prolonged stay, and the greater the risk of developing sepsis or SIRS. A significance level of < 0.15 was chosen to 
determine which variable would be analysed in the multivariate analysis below.
Stay Sepsis Sepsis / SIRS
Signif. O.R
(95% C.I)
Signif. O.R
(95% C.I)
Signif. O.R
(95% C.I)
Operation Group 0.57 1.26
(0.56-2.78)
0.07 3.73
(0.89-15.7)
0.53 1.4
(0.49-3.97)
Bypass time 0.069 1.01
(1.00-1.02)
0.21 1.01
(1.0-1.02)
0.17 1.01
(1.0-1.02)
Lowest MHC Class II 
expression in 1st 72hrs
0.008 0.96
(0.94-0.98)
0.0007 0.94
(0.90-0.97)
0.0003 0.95
(0.93-0.98)
Table 3.4 Multivariate logistic regression analysis reveals that low Class II expression remains highly significantly associated with 
requirement for prolonged stay, development of sepsis or SIRS, after correction for other covariants.
Variables with a significance o f  < 0.15 on univariate analysis were combined in a logistic regression model in order to control for multiple influences.
This analysis addresses the performance of MHC Class II across all values. The ROC 
curve for prediction of requirement for Tong stay’, subsequent development of sepsis or 
sepsis/SIRS by the lowest value of MHC Class II expression in the first 72 hours is 
shown in figure 3.8. The area under the ROC curve is greatest for prediction of the 
development of sepsis/SIRS at 0.85.
For MHC class II expression to be useful for the prediction of patients at risk from 
sepsis/SIRS in the clinical setting, a value/threshold with an associated risk is required. 
Utilising the data presented in figure 3.9 it was possible to calculate a threshold of MHC 
Class II expression that enabled good prediction of increased risk of sepsis/SIRS. When 
MHC Class II fell below 60% in the first 72 hours there was a 7.6 fold risk for 
prolonged ICU stay (95% ci 2.5-23.1). The risk associated with the development of 
sepsis or sepsis/SIRS was even greater at 11.9 (2.8-51.4) and 12.9 (3.4-47.5) 
respectively.
Figure 3.8 Monocyte MHC Class II expression as a predictor of long stay, sepsis, 
or sepsis / SIRS. The area under the receiver operating characteristic curve for MHC 
Class II as a predictor of long stay is 0.75. This increases to 0.84 and 0.85 for sepsis 
and sepsis/SIRS respectively.
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Figure 3.9 Relationship between the lowest postoperative level of Class II 
expression and the three primary outcome measures of sepsis, sepsis/SIRS and 
long stay. Flow charts of the proportion of cases classified with sepsis (A), sepsis/SIRS 
(B) or long stay on intensive care (>5days) (C) are shown according to monocyte MHC 
Class II expression in the first 72 hours. O.R., odds ratio. At a threshold value of a 
minimum MHC Class II expression of <60%, highly significant increased odds of these 
complications were observed.
3.4.13 Monocyte MHC Class II expression in the pre-operative 
period
The data above indicated that in all patients there was a reduction in MHC Class II in 
response to surgical stress. However there was marked variability in the MHC Class II 
expression in response to surgery which could not be explained by the severity or type 
of surgical insult alone. This raises the possibility that other factors such as the host’s 
capacity to respond to the surgical insult or the inflammatory/immune status of the 
patient prior to undergoing surgery could be important. To explore this idea, the MHC 
Class II expression prior to surgery was examined in detailed
There was no significant difference in the percent of monocytes expressing MHC Class 
II above background pre-operatively between patients who subsequently required short 
or long stay (median 99 vs. 99.5,p=0.66). However, when the intensity of MHC Class 
II expression (median fluorescence intensity, mfi) on each monocyte was examined, this 
was significantly lower in cases who subsequently required long stay (long stay vs short 
stay,/?<0.01) or developed sepsis (/K0.001) or sepsis / SIRS (/?<0.001) (Fig 3.10).
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Figure 3.10 Monocyte MHC Class II expression (mfi) pre-operatively. The
median fluorescent intensity of MHC Class II on the surface of monocytes was 
significantly lower pre-operatively in those patients who subsequently required 
prolonged intensive care support (/?<0.01), developed sepsis, or sepsis/SIRS (p<0.001).
This variability in M HC Class II expression w as not a function o f  age (Fig 3.11).
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Figure 3.11 Scatter plot of pre-operative MHC Class II expression on monocytes 
(mfi) against age. The intensity of Class II staining on each monocyte (mfi) pre- 
operatively is plotted against age at time of surgery. The solid red line show a clear lack 
of correlation between these two variables.
3.4.14 Reduction in MHC Class II surface expression represents a 
reduction in HLA-DR surface expression
There are 3 human MHC Class II molecules expressed on the surface of human cells, 
HLA-DP, -DQ, and -DR. The most abundant of these is HLA-DR. Whilst many 
clinical studies refer to alterations in monocyte HLA-DR expression, some of these 
studies use a pan-MHC Class II monoclonal antibody, staining for HLA-DR, -DP, and - 
DQ (Fumeaux and Pugin, 2002;Giannoudis, Smith and others, 1999;Klava, Windsor 
and others, 1997;Peters, Petros and others, 1999). In order to confirm that the reduction 
in MHC Class II expression obtained in this work predominantly represented a 
reduction in surface expression of HLA-DR, a dual staining technique was utilised. A
subgroup of 10 patients had whole blood stained with a pan -MHC Class II antibody 
and a specific monoclonal antibody to HLA-DR. The reduction seen in HLA-DR 
expression over the first 72 hours post operatively paralleled the reduction in surface 
expression of Class II (both % and mfi) seen in all patients examined (Fig 3.12 and 
3.13). Therefore for the duration of this work, the changes seen in the levels of 
expression surface MHC Class II can be assumed to also represent changes in surface 
expression of HLA-DR.
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Figure 3.12 Co-staining of samples for both MHC Class II and HLA-DR. A
subgroup of 10 patients samples were stained with both MHC Class II -  and 
monoclonal antibody to HLA-DR - .  When superimposed, changes seen in Class II 
expression (% and mfi) were paralleled by the same changes in HLA-DR expression
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Figure 3.13: HLA-DR expression as compared to Class II expression on whole 
blood flow cytometry (single patient result shown).
In order to ascertain whether the reduction seen in Class II surface expression was due 
to a reduction in HLA-DR expression, a subgroup of patients were analysed using 
monoclonal antibodies to both MHC Class II and HLA-DR. The changes seen on flow 
cytometry were similar whether whole blood was stained using the pan-MHC Class II 
antibody or the antibody specific to HLA-DR
3.5 D isc u ssio n
This study is the first to describe the expression of monocyte MHC Class II in children 
undergoing cardiopulmonary bypass. All children showed a fall in monocyte MHC 
Class II expression following surgery, but levels were lowest in cases that subsequently 
required prolonged intensive care support, predominantly due to an increased incidence 
of sepsis (or SIRS). A low level of MHC Class II within the first 72 hours was an 
independent predictor of the development of sepsis a minimum of 4 days later.
To date the majority of studies in this field have been performed in adults. McBride et 
al (1995) reported a reduction in MHC Class II expression in adults undergoing CPB 
ten minutes after induction of anesthesia, with the lowest levels (a reduction of 40%) 2 
hours post bypass (McBride, Armstrong and others, 1995). In the results presented 
above, minimum values for MHC Class II were observed over the first 24 to 72 hrs, 
which contrasts with the earlier nadir seen in adult patients. Whilst there are now many 
studies confirming that an inflammatory insult results in a reduction of surface MHC 
Class II on monocytes, there is conflicting evidence as to whether the Class II 
expression is predictive of clinical outcome. In two recent adult studies, Perry et al 
(2003), and Oczenski et al (2003) found that low monocyte Class II expression did not 
serve as a predictive parameter for the incidence of sepsis and/or as a prognostic 
parameter for clinical outcome (Oczenski, Krenn and others, 2003;Perry, Mostafa and 
others, 2003).
There are a number of reasons for possible conflicting results. Oczenski et al (2003) 
found monocyte HLA-DR fell significantly in all adult patients following cardiac 
surgery, but that the decrease in levels over the first 24 postoperative hours was not 
associated with a higher incidence of postoperative sepsis/SIRS, or increased length of 
stay. This is a short period of monitoring. Results presented in this chapter showed a 
strong association between MHC Class II expression over the first 72 hours and 
subsequent complications. In the papers by Hershman, Haveman, Docke, Volk and 
Monnerat it was the persistence of low MHC Class II expression following an 
inflammatory insult (5 days to 3 weeks) that correlated with sepsis and a poor prognosis 
(Docke, Randow and others, 1997;Haveman, van den Berg and others, 1999;Hershman,
Cheadle and others, 1990;Monneret, Elmenkouri and others, 2002;Volk, Reinke and 
others, 1996;Volk, Thieme and others, 1991). Oczenski’s apparent conflicting results 
may just have been due to the study design, where a sustained decrease in MHC Class II 
expression would have been missed.
Perry’s study, which also failed to show MHC class II as a useful predictor of outcome, 
examined HLA-DR expression on whole blood from septic patients. She looked daily 
for the first 3 days following admission to ICU. However there was no attempt to 
correct for duration of illness and therefore phase of inflammatory response. Nor was 
the persistence of reduced MHC Class II expression examined as a predictor of 
outcome.
While there are many other reasons why the data presented in this chapter may differ 
from other studies, including different methodologies, variation in sample handling and 
timing between staining and analysis, there is increasing evidence to support the 
findings presented here. There are now more than 10 papers published that support the 
findings that decreased MHC Class II expression on peripheral blood monocytes is 
associated with increased risk of infective complications, and an equal number showing 
that the degree of expression of MHC Class II in patients with established sepsis can be 
of prognostic significance.
The reasons why MHC Class II expression is associated with the subsequent 
development of sepsis is unclear. MHC Class II could be reflecting the complexity of 
the surgery, a prolonged bypass time or deranged post-operative physiology (e.g. low 
cardiac output). However whilst all of these were associated with the development of 
sepsis they did not correlate with MHC Class II expression using logistic regression 
models. Indeed the independence of the relationship between MHC Class II and sepsis, 
after correction for bypass time and severity of illness (PIM score) on admission, argues 
against MHC Class II being a non-specific marker of poor perfusion or a difficult intra­
operative course. However only more detailed studies looking at cardiac dysfucntion in 
relation to MHC Class II expression can address this issue with some] certainty (see 
Chapter 4).
It is also possible that low MHC Class II expression was indicative of pre-clinical 
sepsis. However the longish interval between the lowest MHC Class II and the 
diagnosis of sepsis (median time =5 days; IQR 4- 12 days) argues against this 
proposition.
As described in Chapter 1, Class II is a component of the major histocompatibility 
complex (MHC) which is central to the process of antigen presentation. The level of 
monocyte MHC Class II expression may reflect local concentrations of cytokines. 
MHC Class II may represent one of the mechanisms by which an initial inflammatory 
insult (in this case CPB) attenuates the subsequent pro-inflammatory response to a 
second insult, so called immune paresis or inflammatory stimuli-induced anergy 
(Docke, Randow and others, 1997;Volk, Reinke and others, 1996). The mechanisms 
involved in the development of immune paresis are not fully understood. However, 
recent data suggesting that MHC Class II may have a direct role in mediating the 
cellular response to endotoxin (Piani, Hossle and others, 2000) may be particularly 
pertinent. Other mechanisms that may contribute to immune paresis include the balance 
of Interleukin-1 and Interleukin-1 receptor antagonist, NF-kB and heat shock factor 
(HSF) at the intracellular level (Adrie and Pinsky, 2000).
In this study, the high rate of sepsis/SIRS may be due to exposure of severely 
immunoparalysed children to nosocomial pathogens (this is addressed in more detail in 
Chapter 5). Immune paresis has been proposed to be an adaptive self-protective 
mechanism to prevent the host from excessive pro-inflammatory immune stimulation. 
However, while this may be of benefit in many scenarios, in a postoperative intensive 
care patient this may render the host susceptible to nosocomial sepsis. As such, it could 
be argued that pro-inflammatory stimulation could be of benefit to such individuals. 
Support for this is provided by a small unblinded study in adult septic patients which 
suggested that restoration of MHC Class II expression by the administration of 
Interferon-y was associated with clinical improvement (Docke, Randow and others, 
1997).
This study provides evidence that sub group of patients have reduced low MHC Class II 
expression and have a 13 fold higher risk of sepsis or systemic inflammation following 
cardiac surgery with bypass. These individuals can be identified within 72 hours of
surgery and a minimum of four days prior to the onset of sepsis/SIRS. The observation 
that there was a small but significant difference in Class II expression in the pre­
operative samples of patients who subsequently developed sepsis or SIRS suggests the 
potential of a genetic/other predisposition to devloping sepsis/SIRS. This will be 
examined further in Chapter 6 .
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4.1 In t r o d u c t io n
Chapter 3 demonstrated that cardiac surgery utilising cardiopulmonary bypass was 
associated with a significant reduction in the surface expression of MHC Class II on 
peripheral blood monocytes. The study did not address why cardiac surgery was 
responsible for the reduction in MHC Class II. It did however explore the possibility of 
whether particular features of the surgery, such as bypass time, aortic cross-clamp time, 
temperature, and nature of the cardiac repair, were responsible for the change in MHC 
Class II expression. They all proved to be unrelated to the degree of fall in surface 
expression. This raises the question as to why cardiac surgery led to a reduction in 
MHC Class n.
Cardiac surgery is invariably associated with a release of both pro- and anti­
inflammatory mediators (Chapter 1 section 1.2.4), and it is possible that the reduction in 
MHC Class II expression was due to this cytokine response. In vitro studies have 
shown that MHC class II expression is sensitive to some of the mediators seen during or 
following cardiac surgery. As the cytokine response is believed to reflect the extent of 
tissue damage, with the degree of release of pro-inflammatory cytokines directly related 
to the duration of bypass and ischemia (Grunenfelder, Zund and others, 2000;Neuhof, 
Wendling and others, 2001 ;Wan, LeClerc, and Vincent, 1997;Wan, Marchant and 
others, 1996), it is perhaps surprising that MHC Class II expression did not correlate 
with markers of surgical insult (bypass time, cross-clamp time, operating temperature, 
operating group). One explanation is that the indices used were poor surrogates for the 
surgical insult. Some authorities believe that a better correlate of the host response to 
the surgery is early post-operative cardiac function.
In 1995, Wemovsky published a landmark paper in which he described for the first time 
the detailed haemodynamic profile and post-operative course of 171 neonates and 
infants following an arterial switch procedure (Wemovsky, Wypij and others, 1995). In 
this paper, he was able to show that the nadir in cardiac index occurred 9-12 hours post 
release of the aortic cross clamp. The reasons for this nadir are unknown but were 
suggested to be due to pro-inflammatory mediators (Cain, Meldrum and others, 
1999;Hovels-Gurich, Vazquez-Jimenez and others, 2002;Wan, DeSmet and others, 
1996;Wan and Yim, 1999;Wemovsky, Wypij and others, 1995). Whilst there have
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been several studies describing various aspects of the inflammatory response to CPB in 
children, there is no detailed description of cytokine release over the first 24 hours and 
how this relates to cardiac function.
This chapter sets out to describe in detail the pro and anti-inflammatory cytokine 
response to cardiac surgery involving CPB over the first 24 post-operative hours, and to 
test the following hypotheses:
(i) the nadir in cardiac function seen during the first post-operative night 
is due to the pro-inflammatory response to bypass.
(ii) the reduction in surface expression of Class II on monocytes in the 
early post-operative period is a reflection of the cytokine balance 
arising from the inflammatory insult.
4.2 M e t h o d s
4.2.1 Patient Selection
This prospective observational study was conducted over a 15-month period, involving 
thirty-nine infants and children up to 24 months of age undergoing cardiac surgery 
involving cardiopulmonary bypass. Children were excluded if they were neonates <36 
weeks gestation, were less than 2500gm, or had known immunodeficiencies. This was 
part of a collaborative study undertaken with the Cardiothoracic Surgeons at Great 
Ormond Street Hospital for Sick Children, NHS Trust.
4.2.2 Anaesthesia and CPB management
Anaesthesia and cardiopulmonary bypass was carried out as described in section 3.2.2, 
except that either blood or cold crystalloid cardioplegia (St. Thomas* #1 solution) was 
used dependant on the operator’s preference. In addition all children entered in this 
study were intubated with cuffed endotracheal tubes (Mallinckrodt Medical, 
Northampton, UK), and a pulmonary arterial line was inserted before the termination of 
CPB. No child received dexamethasone peri-operatively
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Details collected for later analysis as measures of the surgical insult included: minimal 
operative temperature, duration of cardiopulmonary bypass, duration of aortic cross 
clamp and circulatory arrest if applicable. Operations were grouped according to 
technical difficulty utilising a recent classification developed by an 1 1 -member national 
panel of paediatric cardiologists and cardiac surgeons (Jenkins, Gauvreau and others, 
2002).
4.2.3 Clinical care and outcome measures
On return to CICU, patients were mechanically ventilated using volume cycled 
intermittent positive pressure ventilation (Servo ventilator 900C, Siemens Medical 
Systems, Solna, Sweden). All patients received continuous infusions of vecuronium (1- 
3 mcg/kg/hr), morphine (20-40 mcg/kg/hr) and midazolam (1-3 mcg/kg/hr) until stable. 
The central body temperature was maintained at around 37°C using cooling mattress or 
warming blanket, and overhead radiant heater. Dopamine, dobutamine, glyceryl 
trinitrate, and diuretics (usually frusemide) were used as clinically indicated. Volume 
infusions (usually packed red blood cells or 5% albumin) were given to maintain 
adequate filling pressures. The patient was extubated upon clinical judgement, and the 
duration of mechanical ventilation was recorded.
Clinical care was unaffected by participation in this study, and results of investigations 
were not available to the treating physician. All children received 24 hours of peri­
operative antibiotic cover - amikacin and flucloxacillin. If there were clinical concerns 
about sepsis, additional antibiotics were started at the treating clinician’s discretion 
(amikacin and teicoplanin).
Outcome measures recorded are listed in table 4.1.
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Outcome measures
cardiac index
mixed venous saturation
hepatic or renal dysfunction
sepsis
SIRS
length of stay (LOS) in CICU 
death
Table 4.1 Outcome measures recorded prospectively.
4.2.3.1 Patient Monitoring
All patients had continuous invasive monitoring of systemic and pulmonary arterial and 
central venous pressures.
4.2.3.2 Measurement of Cardiac Index (Cl) and Mixed Venous 
Saturation
Arterial and mixed venous blood samples were taken from the peripheral arterial and 
pulmonary arterial catheters. Sampling was delayed if a change in ventilatory or 
haemodynamic support had been made in the preceding 15 minutes. Blood samples 
were analysed for oxygen and carbon dioxide using I-STAT Portable Clinical Analyser 
(Hewlett-Packard, GmbH Bolingen, Germany Chiron Diagnostics, Halstead, UK). 
Cardiac output (CO) was then calculated using the direct Fick method, according to the 
equation:
CO = V 0 2 / (Ca02 -Cv02)
where Ca0 2 and Cv0 2 are arterial and mixed venous oxygen contents respectively. 
Oxygen consumption (V02) was measured with an online respiratory mass 
spectrometry using mixed expirate inert gas (argon) dilution method (Davies and 
Denison, 1979;Li, Schulze-Neick and others, 2000). Cardiac Index (Cl) was calculated 
according to body surface area (BSA):
Cl = CO / BSA
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Low cardiac index was defined as a cardiac index < 2 1/min/m2 at any stage over the 1st 
24 hours (Wemovsky, Wypij and others, 1995).
4.2.3.3 Hepatic or Renal Dysfunction
Daily blood was routinely taken on all patients to monitor haematological and 
biochemical parameters post-operatively. Organ dysfunction was considered to have 
occurred if one or more of the following criteria were met.
Hepatic dysfunction -  total bilirubin > 4 mg/dL
-  alanine transaminase > 2  times the upper limit of normal.
Renal dysfunction -  creatinine > 2 times upper limit of normal age-adjusted limits
-  need for renal replacement therapy
4.2.3.4 Length of Stay
Consistent with the division of length of stay in Chapter 3, long stay was defined as 
requirement for > 5 days intensive care support
4.2.4 Blood sampling, measurement of MHC Class II expression 
and cytokines
Whole blood (2ml) was obtained from the arterial line and placed in a sterile container 
containing 10 units/ml of heparin. Sampling times were as follows: pre op, following 
induction and insertion of arterial line; X  clamp, on release of the aortic cross clamp; 
CPB, after the end of CPB; MUF, following modified ultrafiltration; CICU, upon arrival 
onto the CICU; 2, 4, 8, 14, 18, 24, and 48 hours after admission onto the intensive care 
unit.
Fifty microlitres of whole blood was removed and incubated with monoclonal 
antibodies as per the method described previously in chapter 2.3.4 and 3.2.5, to 
determine monocyte MHC Class II expression. Remaining whole blood was 
immediately centrifuged at 1500G for 6  minutes, plasma supernatant separated and 
frozen at -70°C for cytokine analysis.
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Stored plasma supernatants were analysed for cytokines using enzyme-linked 
immunosorbent assays for EL-6 , EL-8 , TNF-a, IL-10 and IL-lra as described in Chapter 
2.3.5. Each patient’s samples were analysed together on a single plate to ensure 
accuracy of intra-patient comparisons. Optimisation of the assays involved comparison 
of two commercial cytokine detection systems.
4.2.5 Cytokine load over the first 24 hours
Cytokine levels in the blood vary from minute to minute, have a short half-life, high 
clearance, and are recognised to have local as well as systemic effects. These 
characteristics, in combination with the recognised paracrine nature of cytokines, make 
interpretation of a single plasma measurement at any point in time difficult. In order to 
ascertain if there was a relationship between cytokine response and the patient’s clinical 
condition, the cytokine load for each patient was calculated. Cytokine load was 
calculated as the area under the curve from pre-op measurement through to 24 hours 
post admission onto the intensive care unit. This measurement was an approximation, 
calculated by drawing straight lines between each sequential cytokine measurement. 
Cytokine load equalled the sum of the area under the curve for each sampling point 
calculated using the following formula:
A U C  = Ci x  (Tj-Tj) + (T2-T])(C2-C])/2  
A U C  = area under curve;
T2-Tj = time difference between cytokine measurements (min);
C  = cytokine concentration at a particular time point (pg/ml).
4 .3  S t a t i s t i c s
Ix)g transformations were conducted to normalise the distributions of plasma cytokine 
levels. Data is expressed as mean + SEM unless otherwise stated. Comparisons 
between data at different time points or between data sets at a single time point were 
carried out using the Mann-Whitney U test, or Kruskal-Wallis if  there were more than 3
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data sets. Correlation between two data sets was assessed using Spearman’s correlation 
coefficient. The change of the data over the study period was analysed with a one-way 
analysis of variance for repeated measures (ANOVA).
4.4 R e s u l t s
4.4.1 Optimisation of the method for cytokine detection
4.4.1.1 Selection of Capture and Detection antibody.
There is very little literature available on levels of circulating cytokines in well young 
children. It was expected that young children would have very low levels of cytokines 
pre-operatively, but that levels may increase several fold following CPB. Published 
cytokine post-operative cytokine levels in children were: up to 400pg/ml for IL-6 , IL- 8  
(1200pg/ml), TNF-a (60pg/ml), EL-10 (200pg/ml) (Ashraf, Tian and others, 1997;Brix- 
Christensen, 2001;Butler, Pathi and others, 1996;Seghaye, Grabitz and others, 1996).
In order to ascertain the optimal method for cytokine detection in this patient group, 
plasma previously collected and stored at -70°C from the patient cohort in Chapter 3 
was utilised. Two commercially available cytokine ELISA antibody pairs, both 
claiming sensitivity in the < 10 pg/ml range, were compared (Fig 4.1). A random 
selection of 40 pre-operative samples was used. Twenty samples were tested for four 
different paired anti-cytokine antibodies. Unfortunately there was insufficient sample to 
test the same sample across all cytokines for both manufacturers.
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Figure 4.1 Plasma samples from 40 pre-operative cardiac patients were tested 
against two commercially available cytokine antibody pairs. Allowing for patient 
variability in resting cytokine levels, the Biosource paired antibodies for the cytokines 
of interest appeared to be more sensitive at low concentrations than the R&D paired 
antibodies.
4.4.1.2 Optimisation of manufacturer’s recommendations.
A dilutional gradient of capture antibody against detection antibody was performed for 
each cytokine of interest. The standard curves with a high signal to noise ratio were 
obtained with a capture antibody at a concentration of 1 pg/ml for all cytokines except 
TNF-a (5pg/ml), and a detection antibody concentration of 0.4pg/ml except for IL- 8  
(O.lpg/ml) (results not shown).
In order discriminate differences between samples at the low end of the cytokine range, 
several steps in the recommended protocol were modified. Best results were obtained 
by leaving the plasma samples and standards overnight at 4°C before applying the 
detection antibody rather than the co-application as recommended by the manufacturers. 
In addition, freshly made up tetramethylbenzidine (TMB) in a phosphate citrate buffer 
was found to be more reliable than the substrate solution obtained from the 
manufacturer.
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Figure 4.2 Modifications of manufacturers recommendations improved detection 
of cytokines at lower concentrations. Detection of lower levels of cytokines was 
improved by leaving the sample and standards in contact with capture antibody at 4°C 
for at least 1 2  hours before washing and adding detection antibody.
4.4.1.3 Samples: dilute or neat?
In view of the age of the children and the number of blood samples required, every 
effort was made to minimize blood volume required at each sample point. The 
Biosource paired antibodies recommended lOOpl of sample for each ELISA well. 
Utilising the plasma stored from Chapter 3, serial dilutions of samples taken over the 
peri-operative period were tested. It was apparent that neat samples were required in 
order to detect subtle changes in IL-6 , IL- 8  and IL-10. IL-lra in contrast, could be 
adequately assayed at a 1 in 10 dilution. Attempts at reducing the volume of sample 
placed in each well to 50pl gave unreliable results with increased coefficient of 
variation between replicas (results not shown).
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4.4.2 Patient Characteristics and Operative Details
Forty-six infants and children aged between 9 days and 24 months were entered into the 
study. Thirty-nine patients completed the study protocol, five of whom were neonates. 
The seven patients who did not complete the study protocol were withdrawn at the 
request of the operating surgeon during the surgical procedure. There was no difference 
between the patients studied and those who failed to complete the study in terms of 
patient characteristics (Table 4.2). Longer bypass time, cross-clamp time, and greater 
proportion requiring circulatory arrest, suggested that the group that did not complete 
had a more complicated intra-operative course. Two patients refused to participate.
Study Group Drop-out Group
Number 39 7
Age 6.5mths
(9days-24mths)
5mths
(12days-19mths)
Sex (m:f) 22:17 3:4
Weight 6.35kg 
(2.5-12.9kg)
5.1kg 
(3.3-10kg)
Operation: VSD 41% 43%
AVSD 17% 14%
Switch 1 1 % 14%
TOF 1 1 % 14%
other 2 0 % 14%
CPB duration 107min
(49-187min)
172min
(87-432)
Aortic X-clamp duration 56min 
(19-125 min)
69min
(41-93)
Circulatory arrest time n= 8
24min (2-32min)
n=3
21 min (15-24min)
Table 4.2: Patient characteristics and operative details.
39 patients completed the study protocol, 7 patients failed to complete the protocol and 
are not included in the analysis. The patients which failed to complete the study were 
similar to the study group in demographics but had longer operations with a greater 
requirement for circulatory arrest, suggesting a more technically difficult operative 
repair. X-clamp =aortic cross clamp.
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4.4.3 Outcome
Consistent with the study described in Chapter 3, length of stay was bimodally 
distributed, with 28 of the 39 patients (71%) staying less than 5 days, and 11 of the 39 
(28%) requiring more than 5 days intensive care (median stay 17 days; 6 - 8 6  days). 
Two patients died during the study, one in the short stay group and one in the long stay 
group. The first patient died on the day of surgery from an intracerebral bleed that 
occurred intraoperatively. The second patient died 32 days post surgery from septic 
complications. Both data sets are included in the analysis. Three patients fulfilled the 
criteria for sepsis, and an additional 1 patient for SIRS. One other patient had his 
wound re-explored for local infection but did not fulfil the criteria for either sepsis or 
SIRS.
Two patients required renal support during the post operative period, one of whom was 
septic. There were no patients with significant hepatic dysfunction. Whilst the 
percentage of patients with proven sepsis in this group was lower than in Chapter 3 
(3/39, 7.6% vs 11/82, 11%), 23 of the 39 patients had a complicated post-operative 
course (59% vs 46% of patients in Chapter 3). These complications included 3 patients 
needing to return to theatre, whilst a further 3 patients had their chest reopened or 
delayed sternal closure. Five patients had poor cardiac function, one of whom required 
extracorporeal membrane oxygenation (ECMO) support.
There was an overall impression that in addition to being younger (median age 6.5 vs 10 
months), this study group had a more complicated early post-operative period than 
patients studied in Chapter 3. However Figure 4.3 shows that there was no significant 
difference in the physiological state of the study groups on arrival into CICU using the 
risk of mortality (PIM) score (p=0.78).
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Figure 4.3 The risk of mortality score is plotted for each study patient in the 
Chapter 3 and 4 cohorts.
4.4.4 Cytokine profile in paediatric patients undergoing CPB
A primary aim of this study was to describe in detail the cytokine profiles of both pro- 
and anti-inflammatory cytokines pre-operatively and over the first 48 hours post surgery 
(Fig 4.4). Levels of all cytokines studied approached the lower limit of detection pre- 
operatively with the exception of IL-lra. Plasma cytokine levels rose following the 
initiation of cardiac surgery and CPB. Levels of IL-10 peaked at the end of surgery 
following modified ultrafiltration, whilst IL-6, -8, and TNF-a peaked soon after on 
arrival to CICU (paired t-test p< 0.001 for all except TNF-a). IL-lra progressively rose 
until 4 hours post-operatively. Circulating levels of IL-6, -8, -10, and IL-lra remained 
significantly elevated from the pre-operative levels at 8 and 24 hours post op (p<0.001).
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Figure 4.4 Systemic pro-inflammatory and anti-inflammatory cytokine responses 
to cardiopulmonary bypass in paediatric patients. Plasma samples were collected at 
induction of anaesthesia (pre op), at the end of surgery following modified ultrafiltration 
(MUF), on arrival onto CICU (CICU), and at set intervals over the first 48 hours. 
Plasma was spun immediately and supernatant collected for analysis of cytokine levels 
by ELISA. Results are presented as mean of the logged cytokine level ± SEM. All 
cytokines, except TNF-a, were significantly elevated on arrival to CICU and remained 
significantly elevated at 24 hours.
The greatest increase was seen in IL-6 (mean increase 820x baseline; 95%ci 0-1733), 
the least increase in TNF-a (48x baseline; 95%ci 0-122).
4.4.5 The systemic cytokine response to surgical insult
As discussed in the introduction (Section 1.2.2), it is assumed that increases in 
circulating cytokines following cardiac surgery are the result of pro-inflammatory 
triggers that occur intra-operatively. To investigate this assumption further, both peak
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cytokine levels and cytokine load in this patient population, were examined against 
measures of surgical insult, including cardiopulmonary bypass time, aortic cross-clamp 
time, circulatory arrest time, and lowest temperature at which the operation was 
performed. IL-6 and IL-8 levels 90 minutes after releasing cross-clamp have been 
shown in adult studies to significantly correlate with ischemic time (Wan, Marchant and 
others, 1996). In this patient group, there was only a weak positive correlation between 
peak IL-6 and IL-8 levels in the postoperative period and CPB time (Spearman 
correlation coefficient r=0.537 and r=0.596 respectively, /?<0.01), and IL-6, IL-8 and 
IL-10 levels and ischemic time (r=0.460, /?<0.01; r=0.445, p<0.01; r=0.343 p<0.05 
respectively) (Fig 4.5). No correlation was found between cytokine load over the first 
24 hours and any of the measures of surgical insult.
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Figure 4.5 Correlation between duration of CPB and peak concentration of IL - 6  
and IL - 8  post-operatively. Only a weak positive correlation was found between the 
duration of CPB and peak systemic levels of IL-6 and IL-8 (r=0.537 and 0.596 
respectively).
Active cooling during the cardiac repair was designed in an effort to reduce cellular 
metabolic rate and preserve end organ function. In this study, there was a suggestion 
that the greatest peaks in all cytokines were seen in the more actively cooled patients.
Dividing the study group into those actively cooled to 18°C or less (operations 
involving circulatory arrest) and those cooled to between 19-27°C and those maintained 
at >28°C, showed there was a trend for higher peak cytokine levels in the more actively 
cooled patients (Kruskal-Wallis p=0.06 for all cytokines except IL-lra) (Fig 4.6). 
Significantly higher peak concentrations of IL-6 were present in the circulatory arrest 
group (Mann-Whitney U p<0.03) compared to those operated at >28°C. Whilst peak 
concentrations appeared affected by temperature, overall cytokine load in the first 24 
hours was not (results not shown). This suggests that the same cytokine response may 
be occurring but that low temperatures result in a more rapid and higher initial response.
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Figure 4.6 A trend toward higher peak cytokine levels were seen in those patients 
operated on at a lower temperature.
Minimum operative temperature was grouped as extreme hypothermia (< 18°C), 
moderate hypothermia (19-27°C), and mild hypothermia (> 28°C). There was a trend 
toward peak cytokine levels increasing as operating temperatures decreased (p=0.06) 
(exception IL-lra). This reached significance for IL-6 when levels at < 18oC were 
compared to levels produced at > 28oC (p<0.03).
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Recently it has been suggested that blood cardioplegia reduces the inflammatory 
response to cardiopulmonary bypass (Billia, Carter and others, 2002;Liebold, 
Langhammer and others, 1999;Wan, Yim and others, 1999). In this study 46% (18/39) 
of patients received blood cardioplegia. Those patients with blood cardioplegia did not 
differ in age, gender, CPB time, X-clamp time, or lowest operative temperature, from 
patients managed with crystalloid cardioplegia. Nor was there any significant 
difference in cytokine response (peak or load) between patients managed with blood vs. 
crystalloid cardioplegia.
4.4.6 The timing of the decline in cardiac function varied in 
relation to release of the aortic cross clamp
The decline in cardiac function over the first post-operative night was measured using 
Cardiac Index (Cl) in 36 of the 39 patients. Twenty-one (58%) of these patients had a 
Cl measurement of < 2 l/min/m2 at some time in the 1st 24 post operative hours (Fig 
4.7a). The timing of the lowest recorded cardiac index was very variable. Eight 
patients (22%) had their lowest reading at 2 hours post arrival onto CICU, while 6  
patients (17%) had their lowest reading at a time point corresponding to Wemovsky’s 
findings ( 8  hours). Overall, 75% of patients studied had their lowest cardiac index 
within the first 8  hours of arriving onto CICU. Accepting that this was a heterogeneous 
group of patients, there was no pattern to suggest a decline in cardiac function at a set 
time following reperfusion.
There was no correlation between the lowest cardiac index measured during the first 24 
post-operative hours and CPB time, aortic cross-clamp time, or lowest operating 
temperature (4.7b). Nor was there a difference in range of cardiac indices between 
patients operated with and without circulatory arrest.
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Figure 4.7 Scatter plots of timing of lowest cardiac index and relationship to 
duration of CPB.
Thirty-six of the study patients had cardiac index measurements recorded over the first 
24 hours post-operatively. 75% of patients had their lowest measurement within the 
first 8 hours, however there was no clear nadir in cardiac function at the 8 hour time 
point (A). The lowest cardiac index in the first post-operative night appeared to be 
unrelated to the duration of CPB (B).
4.4.7 Poor cardiac function during the first post-operative night is 
associated with higher circulating levels of TNF-a
Those patients who had poor cardiac function (defined as cardiac index < 2 1/min/m2) 
over the first 24 hours post-operatively had higher levels of circulating TNF-a when 
compared to those patients whose Cl remained > 2 1/min/m2 (ANOVA p<0.05) (Fig 
4.8).
Whilst the literature in adults suggests that both IL-6 and IL-8 are myocardial 
depressants, the cytokine profiles for these cytokines were not significantly higher in 
patients whose cardiac index fell to < 2 1/min/m2 over the first post-operative night 
(Finkel, Oddis and others, 1992;Hennein, Ebba and others, 1994;Kawamura, Inada and 
others, 1999;Kawamura, Wakusawa and others, 1993) (Fig 4.8 & 4.9).
No relationship was found between the timing of peak pro-inflammatory cytokine 
concentration and timing of lowest recorded cardiac index.
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Figure 4.8 Cytokine profiles divided according to post-operative cardiac function.
Patients whose Cl fell to < 2 1/min/m2 had significantly higher levels of circulating 
TNF-a over the first post-operative night (ANOVA /?<0.05). There was no significant 
difference in the IL-6 or the EL-8 cytokine profiles in patients divided by cardiac 
function.
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Figure 4.9 Patients were divided according to their lowest measured cardiac 
index in the first post-operative 24 hours and cytokine load during this period 
examined. Those patients with poor cardiac function in the early postoperative period, 
tended to have a greater systemic load of TNF-a and IL-10 in the first 24 hours (p=0.07 
and 0.08 respectively). Solid shape; Cl > 2 1/min/m2, open shape; Cl < 2 1/min/m2.
4.4.8 The systemic cytokine response and outcome
Whilst cytokine levels were only weakly correlated with measures of surgical insult 
(Section 4.4.5), cytokine levels in the post-operative period were significantly higher in 
patients who subsequently required prolonged support (ANOVA /?<0.05)(Fig 4.10).
The frequency of other outcome measures, including organ dysfunction, sepsis/SIRS, 
and death was too low to allow for meaningful analysis.
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Figure 4.10 Significantly higher cytokine levels over the first 24 hours post- 
operatively were seen in those patients that subsequently required prolonged 
support. One notable difference was that circulating levels of the pro-inflammatory 
cytokines persisted at levels similar to those generated at the end of surgery over the 
early post-operative period in long stay patients, whilst levels in short stay patients 
declined. This pattern also occurred for IL-lra.
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4.4.9 Monocyte MHC Class II expression and response to surgical 
insult
Monocyte MHC Class II surface expression was measured over the first 48 hours post 
operatively. The median MHC Class II expression pre-operatively was 94% (S.D + 17). 
Cardiac surgery resulted in significantly reduction in surface expression of MHC Class 
II in all patients compared to preoperative levels (p<0.001). The reduction in 
expression postoperatively was greater in this study compared to the results presented in 
Chapter 3. There was no correlation between the reduction in MHC Class II expression 
and age, sex, measures of surgical insult (surgical group, lowest temperature, 
cardiopulmonary bypass time, cross-clamp time, circulatory arrest time) or 
physiological state on arrival onto CICU (PIM score, Risk of Mortality score). Figure 
4.11 shows that there was no relationship between the level of reduction of MHC Class 
II expression post-operatively and the degree of cooling the patient underwent during 
surgery.
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Figure 4.11 Lowest monocyte MHC Class II expression and operative 
temperature. The lowest temperature at which the patient was operated did not appear 
to affect the degree of reduction in monocyte HLA-DR expression seen post-op.
4.4.10 Monocyte MHC Class II expression and cytokine response to 
surgery
A weak negative correlation was found between systemic anti-inflammatory cytokine 
levels and monocyte surface MHC Class II expression (Spearman correlation coefficient 
r=-0.222 and r=-0.277, /?<0.001 for IL-10 and IL-lra respectively) (Fig 4.12). There 
was no relationship between systemic levels of TNF-a (peak or load) and MHC Class II 
expression on circulating monocytes.
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Figure 4.12 Correlation between high levels of systemic anti-inflammatory 
cytokines and low MHC Class II expression on circulating monocytes. There was a 
weak negative correlation between IL-10 or IL-lra and levels of monocyte MHC Class 
II expression (r=-0.222 and r=-0.277, /?<0.001). This correlation was not present when 
lowest MHC Class II expression was examined against peak IL-10 or peak IL-lra.
Whilst impossible to test with such a small study population, the fall in MHC Class II 
on monocytes during theatre appeared to coincide with the rise in circulating IL-10 
levels, with a slight recovery post-operatively that mirrored the increase in TNF-a 
levels (Fig 4.13).
ioq
o '
</>(/)
JSO
01
2
a>
*oo
cO
2
Q.
EA&S>
llr>5 £■C
Sample Time
I0 3
60-
40-
c  20-
Sample Time
MHC Class II (median) 
I  IL-10 
S  TNF
E
8
Figure 4.13 IL-10, TNF-a and monocyte surface MHC Class II expression. The
overall change in monocyte MHC Class II expression (%) for the patient group is 
plotted against the systemic levels of EL-10 and TNF-a (mean & SEM). The rise in 
systemic IL-10 levels during theatre corresponded in time to a fall in MHC Class II 
expression, whilst the direction of the TNF-a curve appears to follow the MHC Class II 
curve.
Whilst there was no difference in overall pro-inflammatory cytokine exposure (cytokine 
load), those patient’s whose MHC Class II expression fell to < 60% in the 1st 72 hours 
had significantly later peaks in pro-inflammatory cytokines (IL-6, IL-8, and TNF-a), 
compared to those patients who maintained their monocyte MHC Class II expression > 
60% (Mann-Whitneyp<0.05) (Fig 4.14).
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Figure 4.14 Patient’s systemic pro-inflammatory cytokine response divided 
according to the lowest MHC Class II expression over the same time period.
Patient’s whose monocyte Class II expression fell to < 60% in the first 72 hours had 
significantly later pro-inflammatory cytokine peaks (Mann-Whitney p  < 0.05). There 
was no difference in the timing of the anti-inflammatory response. Overall pro- 
inflammatory cytokine exposure (cytokine load) did not differ significantly between the 
two groups.
4.4.11 Monocyte MHC Class II expression and outcome
There did not appear to be any direct relationship between low monocyte MHC Class II 
expression and cardiac function postoperatively (Fig 4.15). There was no difference in 
surface expression of MHC Class II at 24 or 48 hours between those children with low
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cardiac index (< 2 1/min/m2) and children with cardiac index > 2 1/min/m2, suggesting 
that low cardiac function does not appear to predispose the patient to reduced MHC 
Class II expression on the surface of circulation monocytes.
Three children developed sepsis and one child developed SIRS in the post operative 
period. Two children died during the study (1 septic, 1 from non-septic causes). Ail 
these children had a reduction in MHC Class II expression to < 60% post op.
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Figure 4.15 Lowest monocyte MHC Class II expression was examined against 
normal (> 21/min/m2) or poor cardiac function (< 2 1/min/m2). Patients with poor 
cardiac function in the post operative period did not have significantly lower monocyte 
MHC Class II surface expression.
Patients requiring greater than 5 days in Intensive Care had a trend toward greater 
reduction in monocyte MHC Class II expression at 24 and 48 hours compared to those 
who were discharged within 5 days (Fig 4.16). This difference did not reach 
significance in the small number studied. All but 1 of the long stay patients had a fall in 
MHC Class II expression to < 60% in the first 48 hours postoperatively.
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Figure 4.16 The reduction in surface expression of MHC Class II on monocytes 
was greatest in those patients who required prolonged Intensive Care support.
Monocyte surface expression of MHC Class II fell in all patients following 
cardiopulmonary bypass. At 24 and 48 hours this fall was greater in those patients that 
subsequently required > 5 days intensive care support, (mean ± SEM)
4.4.12 Cytokine Balance
Increasingly, interest has centred on an attempt to quantify the balance of the 
inflammatory response to a critical illness or insult. To date there is no accepted 
method to quantitate cytokine balance. Consistent with published data on cytokine 
interactions/feedback, there were a number of positive correlations between pro- and 
anti-inflammatory cytokines in this study. Consistent with the effect TNF-a is known 
to have on IL-10, there was a positive correlation between IL-10 load and the TNF-a 
load over the first 24 hours (r=0.622, /?<0.001) (Fig 4.17). A positive correlation was 
also seen between both the peak and load IL-10 levels and peak and load IL-8 levels 
(r=0.567,/?<0.001 and r=0.643,/?<0.001 respectively).
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Figure 4.17 There was a positive correlation between the IL-10 and the TNF-a 
load over the first 24 post-operative hours (r=0.622,/?<0.001).
Previously published attempts to quantitate cytokine balance include IL-10 to TNF-a 
ratio and IL-10 to IL-6 ratio (Hovels-Gurich, Schumacher and others, 2002). If 
cytokine imbalance is a major factor in the development of low MHC Class II 
expression, poor cardiac index, and need for prolonged support, these previously 
published cytokine ratios were not reflective of this imbalance in this patient population 
(Fig 4.18).
4.4.13 Age and gender
In contrast to other paediatric studies(Alcaraz, Sancho and others, 2002;Trotter, Muck 
and others, 2001), this study showed no difference in cytokine levels or post operative 
morbidity between neonates & non-newboms, or males & females.
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Figure 4.18 Lowest monocyte MHC Class II expression, lowest cardiac index, and group according to length of stay were examined against 
IL-10:TNF-a ratio and IL-10:IL-6 ratio. No significant differences were seen between previously published measures of cytokine balance and the 
three parameters shown.
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4.5 D is c u s s io n
This study describes in detail the early cytokine response to cardiac surgery involving 
CPB. It shows that both pro- and anti-inflammatory cytokines rise simultaneously from 
as early as release of aortic cross-clamp and that peak cytokine concentrations occur 
within the first 2 hours (4hrs for IL-lra) of the child arriving onto the intensive care 
unit. Both pro- and anti-inflammatory cytokines remain significantly elevated at 24 
hours post-op.
4.5.1 Effects of Temperature
The results presented here suggest that active cooling to < 18°C increases the 
inflammatory response to cardiac surgery. Since late 1960 / early 1970, congenital 
heart defects in newborns and infants have been corrected by using deep hypothermic 
circulatory arrest. This was thought to both protect the heart and minimise 
inflammation. However, with the development of concerns about neurological 
morbidity associated with prolonged periods of circulatory arrest, moderate 
hypothermia and low flow cardiopulmonary bypass has gained favour. Whilst many 
congenital heart defects can be operated on with a continuous perfusion technique, 
circulatory arrest provides excellent surgical exposure in a small heart by eliminating 
the need for multiple canulas within the field. Thus in some anomalies it is still the 
preferable technique. In previous paediatric studies, deep hypothermia (^18°C) and 
circulatory arrest has been associated with lower levels of pro-inflammatory cytokines 
(Tassani, Barankay and others, 2002). However animal models have suggested that the 
effect of temperature on inflammatory response is not linear. A study in pigs suggested 
that moderate hypothermia (28°C) had lower levels of pro-inflammatory cytokines and 
higher levels of anti-inflammatory cytokines compared to either normothermia (37°C) 
or deep hypothermia (<, 20°C) (Qing, Vazquez-Jimenez and others, 2001 ;Wan, DeSmet 
and others, 1996). This and other studies have also suggested that moderate 
hypothermia is associated with a lower histological organ damage score (Vazquez- 
Jimenez, Qing and others, 2001).
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The results presented here showed a trend toward increasing cytokine levels at lower 
operative temperatures. Whilst more complex surgery is often performed at 18°C under 
circulatory arrest, this trend is unlikely to be due to complexity of surgery alone as there 
was poor correlation between duration of circulatory arrest and cytokine response and 
only a weak correlation with duration of aortic cross-clamp. The high cytokine 
response seen in patients operated on at < 18°C may be a direct effect of temperature. 
Temperatures < 20°C have been shown to disrupt general cellular function and cause 
cell membrane damage through disruption of membrane lipids (Cohen, Ophir and 
others, 1990;Funk, Wunderlich, and Kreutz, 1982;Gousset, Wolkers and others, 
2002;Ramlov, 2000;Tablin, Wolkers and others, 2001). Whilst moderate hypothermia 
may decrease inflammation, extreme hypothermia may result in general cell membrane 
disruption and exacerbate the inflammatory response seen following bypass.
4.5.2 Cardiac Function
There was only a weak correlation between peak levels of pro-inflammatory cytokines 
(IL- 6  and IL-8 ) and duration of cardiopulmonary bypass and ischaemia-reperfusion. 
However, as discussed earlier in section 4.1, these may not be good surrogates for 
surgical insult. In this study it was possible to measure cardiac function using cardiac 
index. This is both time consuming and invasive and is rarely performed in children. 
From the 39 patients studied, there was no clear pattern of a decline in cardiac function 
during the 12 hours following surgery. This contrasts with the data of Wemovsky who 
studied 171 neonates and infants all following an arterial switch procedure. They found 
a clear nadir in cardiac function 9 and 11 hours post reperfusion (Wemovsky, Wypij 
and others, 1995). While the study groups differ in heterogeneity of the underlying 
cardiac lesion, it was surprising that the study presented here failed to show even a trend 
towards this post-operative nadir.
Despite the assumption that TNF-a plays an important role in *post-pump syndrome * 
only very low levels of TNF-a were found in this population. However, the only 
significant finding with regards to cytokines and cardiac function was an increase in 
TNF-a levels post-operatively in those children whose cardiac index fell to < 2 
1/min/m2. Systemic levels of the other known myocardial depressants (IL- 6  and IL-8 ) 
were not particularly elevated in those children with poor post-operative cardiac
( '  \ !i; )!.\< I ; i !'■■■:. - \ i  - i ; ;i i \ i ! , \ m m  \ I< >;n ivi . s rc>\ s i .  i (> ( ' P B
function. This difference in TNF-a is particularly interesting when considering that 
plasma cytokine levels may not reflect cytokine levels produced locally within tissues. 
This is important as levels of both TNF-a and IL- 6  in patients undergoing CPB have 
been shown to be significantly higher in coronary sinus blood than in arterial blood, 
indicating that the myocardium is a major source of these pro-inflammatory cytokines 
(Wan, DeSmet and others, 1996). The small difference in TNF-a seen systemically in 
those patients with poor cardiac function may therefore represent a much greater 
difference in TNF-a produced by the myocardium. To investigate this further, it would 
require a study such as that by performed by Wan et al (1996) involving sampling of 
blood from the coronary sinuses. This is unlikely to get ethical approval in a paediatric 
patient base (Wan, DeSmet and others, 1996).
The only other finding of note was that IL-10 levels at the end of bypass appeared to be 
greater in those patients who subsequently had good cardiac function. Interestingly, 
until this time point, circulating levels of TNF-a between the two groups were similar. 
After the IL-10 rise however, TNF-a levels fell in those patients who maintained good 
cardiac function. The numbers studied were insufficient for this difference to be 
significant, but it raises an interesting hypothesis. Could the degree of anti­
inflammatory response elicited by surgery (level at end of CPB) determine the degree of 
inflammation present over the first post-operative night? This hypothesis will be tested 
in a subsequent study.
4.5.3 MHC Class II expression
Monocyte MHC Class II expression following bypass was significantly reduced. In 
keeping with chapter 3, the degree of reduction o f MHC Class II expression was 
unrelated to surgical insult, or measures of post-operative cardiac function, but greatest 
in those children who subsequently required prolonged intensive care support. MHC 
Class II expression fell to < 60 % in all children who developed sepsis/SIRS or died 
during this study.
In this patient group, a direct relationship between circulating cytokine levels and 
reduction in MHC Class II expression on monocytes did not exist. Nor was an altered
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cytokine balance (as measured by IL-10:TNF-a and IL-10:IL-6 ratios) present in those 
patients who had the greatest fall in MHC Class II. So the aetiology of the reduction in 
MHC Class II expression in the post-operative period remains unclear.
The number of children whose MHC Class n  expression fell post-operatively to < 60% 
was greater in this study population compared to the population studied in Chapter 3 
(29/39, 74% compared to 21/82, 26%). The reason for this is unclear. This study 
involved smaller patient numbers and was restricted to younger children (9 days -  24 
months, median age 6.5 months vs 2 days -  16 years, median age 10 months). Age 
however, is unlikely to be the explanation as the reduction in MHC Class II expression 
in the previous study was not skewed towards children < 2 years (24% of children < 2 
years had reduction in MHC Class II expression to < 60% vs 27% of those children > 2 
years). By selecting out just the children < 2 years in both chapter 3 and 4, it can be 
clearly shown, that the reduction in MHC Class II expression was significantly greater 
in the children described in chapter 4 (Table below).
Mean Class II expression % (± S.D)
Timing of Samples Chapter 3 Study Chapter 4 Study
Pre op 93% ±16% 87% ± 18%
Day 1 78% ±21% 42% ±18
Day 2 78% ±23% 49% ±22%
Day 3 80% ± 2 1 %
As previously noted in section 4.4.2, the small patient group presented in this chapter 
appeared to have more immediate postoperative complications unrelated to sepsis. This 
may be in keeping with the observation of lower MHC Class II expression. The 
question then arises, ‘Why did younger age, lower MHC Class II expression and 
increased frequency of early post-operative complications not translate into a greater 
proportion of patients requiring prolonged intensive care support?’
Technical problems with MHC Class II staining are a possibility. Throughout both 
Chapter 3 and 4, the flow cytometer was calibrated regularly, and all samples were
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handled according to the optimal staining and analysing method previously determined 
(section 3.4.2 & 3.4.3). All samples were handled by a single operator. During the 
course of this study and the study presented in chapter 3, the monoclonal antibodies 
used for staining were changed several times. With each change, samples at the time 
were co-stained using both the old and new antibody to ensure comparable results. 
Several samples were also randomly checked with the specific HLA-DR specific 
monoclonal antibody. In addition the consistently high pre-operative MHC Class II 
expression (%) in patients that subsequently had a marked reduction in expression post- 
operatively, argues against the aetiology being technical.
This study design necessitated a study clinician to be present at the bedside for the first 
24 hours. Whilst investigation results were not available to the clinical team, the 
presence of the study clinician may have had minor affects on patient management. 
Fluid boluses may have been given earlier and more frequently than normal, nursing 
staff may have been more attentive to procedures. Such influence may have resulted in 
earlier stabilisation, earlier detection and treatment of any complications, and potential 
for earlier extubation and discharge from the intensive care unit. Equally the presence 
of the study clinician could have placed the patient at increased risk of nosocomial 
infection because of additional invasive equipment and additional sampling from central 
lines. These results however suggest a low rather than high incidence of sepsis (3/39, 
8 % compared with 11/85,13%, chapter 3).
It has been shown that some medication can itself influence MHC Class II expression. 
One such drug is fentanyl. Anaesthetic doses of fentanyl have been shown to 
downregulate surface expression of HLA-DR molecules on circulating monocytes in 
vivo (Carrera, Catala and others, 1993;McBride, Armstrong and others, 1995;Prieto, 
Subira and others, 1989). Fentanyl was used to a similar extent in both patient groups. 
However one change that has occurred is a shift from dobutamine to dopamine as a first 
line inotrope in the immediate post-operative period. This has resulted in part from the 
personal preference of the different operating surgeons, and in part because of the 
increased use of milronone as a vasodilator. There is some evidence to suggest that 
dopamine acts via increased prolactin to decrease surface expression of MHC Class II 
on monocytes (personal communication Dr J.Carcillo, USA, 2003). The tantalising
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prospect that all patients are experiencing a greater reduction in their monocyte MHC 
Class II expression because of what would be clinically considered a trivial drug 
difference begs further investigation, however not during this thesis.
The finding of low MHC Class II expression (<60%) without the association of 
requirement for prolonged support, or increased incidence of sepsis highlights that 
reduced MHC Class II expression alone is not sufficient to condemn a patient to a 
complicated recovery. However, the presence of reduced monocyte MHC Class II 
expression may highlight a group of patients that are immunoparalysed and unable to 
respond to a second post-operative insult if discharge from the intensive care unit is not 
imminent.
4.5.4 Summary
Whilst this is a relatively small study and limited to children two years and under, it 
suggests that there are significant differences in the cytokine response of children 
compared to adults following cardiopulmonary bypass. Pro- and anti-inflammatory 
cytokines rose simultaneously in the early post-operative period and were only weakly 
related to surgical insult. In addition, systemic levels of TNF-a appear to be greater in 
those children who have a decline in cardiac function during the first post-operative 
night, raising the possibility that the biological effects of TNF-a are being 
underestimated by the low or absent measurements of this cytokine systemically.
Finally, the postoperative reduction in monocyte Class II expression appears unrelated 
to the cytokine response to surgery, or to measures of cardiac function, but was greatest 
in those children who subsequently required prolonged support.
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5.1 I n t r o d u c t io n
The results presented in chapter 4 demonstrated that cardiac surgery in children 
involving cardiopulmonary bypass (CPB) is associated with an inflammatory response 
(Laffey, Boylan, and Cheng, 2002;Wan, LeClerc, and Vincent, 1997;Wan and Yim, 
1999). Whilst much research in the area of bypass has centred on the role pro- 
inflammatory cytokines play in the post-operative complications of hypotension, 
capillary leak and multiorgan failure (Casey, Hauser and others, 1992;Hovels-Gurich, 
Schumacher and others, 2002;Marano, Garulacan and others, 2000), it is now rare for a 
patient to die in the early post-operative period from uncontrolled inflammation. The 
problem facing clinicians is one of delayed morbidity, where patients are ventilator 
dependant, appear to be immunocompromised, and frequently develop nosocomial 
infection, followed by multiple organ dysfunction (McBride, Armstrong and others, 
1995).
Immune paresis describes a state in critically ill adults following trauma surgery or 
sepsis, where there is marked suppression in cell-mediated immunity and an associated 
increased susceptibility to infection. It is thought to be produced endogenously when 
circumstances elicit a predominantly anti-inflammatory response, or exogenously, when 
too much immunosuppression is administered. This state is frequently associated with 
the development of sepsis, unresolving multiple organ dysfunction and late death. 
Experimental and clinical studies indicate that immune paresis involves altered 
monocyte and T-cell function.
Monocytes from immunoparalysed patients show a reduced capacity to secrete TNF-a 
in response to LPS challenge(Adib-Conquy, Adrie and others, 2000;Haupt, Riese and 
others, 1998;Heagy, Nieman and others, 2003;Keel, Schregenberger and others, 
1996;Marie, Muret and others, 1998;Yadavalli, Auletta and others, 2001). This has 
been termed monocyte deactivation, and has been reported to persist for three to five 
days (Haupt, Riese and others, 1998). In addition, this population of monocytes also 
frequently express reduced levels of MHC Class II expression. Transient immune 
paresis may be protective after an inflammatory insult. However prolonged or extreme 
deactivation of monocyte function may be harmful as it reduces the host’s ability to kill 
and clear infection.
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The findings in Chapter 3 that reduction in monocyte MHC Class II expression 
preceded the development of sepsis/SIRS by a minimum of 4 days raises the question of 
whether there monocyte deactivation was present in the early post-operative period.
The study discussed in this chapter was designed to investigate the following:
(i) Does cardiac surgery involving CPB in children alter the production of 
pro- and anti-inflammatory cytokines in response to lipopolysaccharide 
(LPS) ex vivo?
(ii) Are high levels of systemic IL-10 following surgery associated with an 
attenuated response to LPS?
(iii) Are such cases at increased risk of post-operative sepsis?
5.2 M e t h o d s
5.2.1 Patient selection
This study was carried out over a 15 month period and involved a subgroup of 36 
children from the patient group described in chapter 4.
5.2.2 Ex vivo whole blood cytokine stimulation
For the purpose of this study, whole blood cultures were used rather than peripheral 
blood mononuclear cells (PMBC’S) in an effort to mimic the cellular and humoral 
interactions that occur in vivo. One ml of the blood sample was centrifuged 
immediately at 1500G for 6  minutes, plasma separated and frozen at -70°C, for analysis 
o f baseline plasma cytokine levels (Chapter 4). The remaining whole blood was diluted 
1:2 in RPMI 1640 and cultured for 24 hours in the presence or absence of lOng/mL of 
purified meningococcal LPS (kind gift from Dr Svein Andersen, EJIVR, Compton UK) 
at 37°C in atmosphere of 5% CO2 in air. Following culture, the supernatant was 
separated by centrifugation and stored at -70°C.
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Stored plasma and supernatants were analysed for cytokines using the previously 
optimised ELISA’s. The following cytokines were assessed IL-6 , IL-8 , TNF-a, IL-10, 
and IL-lra. Each patient’s samples were analysed together on a single plate. To correct 
for cytokines already present in the blood before ex vivo stimulation with LPS, the 
amount of each cytokine produced following stimulation was calculated as the 
difference between cytokine concentrations found after incubation with and without 
LPS.
5.3 S t a t i s t i c s :
Logarithmic transformations were conducted to normalise the distributions of plasma 
cytokine levels. Levels are presented on a logged scale and values are expressed as 
mean ± SEM unless otherwise stated. Comparisons at different time points were 
performed using the non-parametric Wilcoxon signed-rank test for 2 related samples. A 
comparison of cytokines between groups over time was made using ANOVA one-way 
analysis of variance.
5.4 R e s u l t s :
5.4.1 Dose and time response curves
Prior to commencing this study, dose and time response curves were performed to 
ascertain the ideal concentration of LPS to be used, and the duration of stimulation (Fig 
5.1). The literature varies in the type of endotoxin, dose and duration of stimulation 
(Dehoux, Hemot and others, 2000;Grundmann, Rensing and others, 2000;Marie, Muret 
and others, 1998;Munoz, Carlet and others, 1991;Ogata, Okamoto and others, 
2000;Randow, Syrbe and others, 1995). The laboratory in which this work was 
undertaken have an interest in Neisseria meningitides, and all results presented are using 
LPS derived from N.meningitidis.
On the basis of results obtained in these preliminaiy experiments, a concentration of 10 
ng/ml of LPS with an incubation period of 24 hours was selected. A stimulation period 
of 4 hours would have detected maximal TNF-a production but failed to detect the IL-
10 response. Maximal IL-6 and IL-8 responses occurred between 6 - 1 2  hours (results 
not shown).
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Figure 5.1 IL-10 and TNF-a response to whole blood cultured with varying 
concentrations of N.meningitidis LPS over 30 hours. Experiments were performed 
with whole blood from 2 adult controls. There were low levels of IL-10 but minimal 
TNF-a produced in whole blood cultured without LPS. The addition of 1 ng/ml 
resulted in a small amount of TNF-a production at 4-8 hours, but minimal increase in 
IL-10 production. There was a dramatic increase in both IL-10 and TNF-a production 
by whole blood in response to 10 ng/ml LPS. This response was not significantly 
different to the response seen with 100 ng/ml of LPS. IL-10 production was minimal at 
4 hours increasing in a linear fashion to 30 hours. TNF-a production was maximal at 4 
hours but appeared to persist at maximal levels for 24 hours. Three out of four of the 
control samples had decreasing levels of TNF-a when culture times were pushed 
beyond 24 hours.
Im m u n e  P a r e s i s  f o l l o w i n g  CPB
5.4.2 Patient Characteristics and Operative Details
Three patients included in the Chapter 4 study were not included in this study because 
of an inability to process cultured blood the following day. There was no significant 
difference in the demographics (Mann-Whitney p>0.6). Details of the study patients 
and 3 patients omitted are given in Table 5.1.
Study Patients
Sex
(m:f)
Age
(months)
Weight
(kg)
CPB
Time
(mins)
X-clamp 
time (mins)
Circ arrest 
Time 
(mins)
Length of 
stay (hrs)
21:15 6.5
(9 days -  24 
mths)
6.36 
(3.1 -  12.9)
110 
(49- 187)
60
(19-109)
22
(2-24)
n=7
89
(24 - 2064)
Omitted Patients
Sex Age Weight
(kg)
CPB
Time
(mins)
X-clamp 
time (mins)
Circ arrest 
Time 
(mins)
Length of 
stay (hrs)
female 24 days 2.2 99 35 32 100
male 7 months 7.6 52 28 0 21
female 11 months 8.7 60 29 0 65
Table 5.1 Details of 36 study patients and the 3 omitted patients
Results for study patients are presented as mean and ranges.
5.4.3 Outcome
Patients had a median length of stay of 3.7 days (range 1-86), with one third of the 
patient group requiring greater than 5 days intensive care support. All the patients that 
developed sepsis/SIRS, or died were included in this study.
5.4.4 E x  v iv o  whole blood cytokine production was reduced in all 
patients
Pre-operatively whole blood from all patients responded well to LPS stimulation. 
Whole blood cytokine production to LPS fell significantly for IL-6, IL-8, IL-10 and 
TNF-a during the period on bypass (Fig 5.2). Maximal hypo-responsiveness to LPS 
was seen for all these cytokines, on arrival at the intensive care unit (p<0.001). There 
was an approximate 100 fold reduction in the ability of whole blood to respond to LPS 
stimulation at this point. Over the following 48 hours, whole blood IL-10 and TNF-a 
response to LPS remained significantly below pre-operative levels (p < 0.005).
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Figure 5.2 Ex vivo responsiveness of whole blood to LPS.
Samples of whole blood were drawn from children before during and following cardiac 
surgery and incubated with and without lOng/ml of LPS for 24 hours. Plasma 
supernatants were collected and cytokine concentrations determined by ELISA for 
interleukin (IL)-6, IL-8, IL-10, and tumour necrosis factor (TNF-a). Cytokine 
responses to LPS were calculated as [LPS stimulated]-[medium control] at each time 
point for 36 patients and expressed as mean ± SEM for the logged values. Clinically 
relevant time points were chosen (CICU, 24 and 48 hours) and responsiveness was 
compared to the pre-operative values using Wilcoxon Signed-Rank test. All patients 
had a significant reduction in cytokine responsiveness to LPS at the end of surgery 
p<0.001. This persisted for TNF-a and IL-10 levels at 24 and 48 hours p<0.005. 
(Mean background levels of cytokines in whole blood cultured with medium were 130 ± 
30, 590 ±110, 37 ± 7, and 44 ± 7 for IL-6, IL-8, IL-10, and TNF respectively.)
5.4.5 Reduction in cytokine response is not due to a reduction in 
circulating monocyte numbers in whole blood
One possible explanation for the reduction in whole blood responsiveness to LPS is a 
fall in the number of circulating monocytes following CPB. However when monocyte 
counts of whole blood were examined there was no significant reduction in circulating 
numbers peri-operatively, and an increase in circulating numbers post-operatively when 
LPS hypo-responsiveness is observed (Fig 5.3).
Monocyte count (mean
Pre op: 0.72 ±0.44
CICU: 0.71 ±0.57
12 hrs: 1.01 ±0.38
18 hrs: 0.97 ±0.39
24 hrs: 1.09 ±0.31
48 hrs: 0.97 ±0.44
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Figure 5.3 Total white cell count, neutrophil and monocyte counts for patient 
group. Monocyte counts did not significantly change during surgery. Total white cell 
count, neutrophil and monocyte counts rose in whole blood over the first 24 hours post- 
operatively before drifting back toward preoperative levels. Monocyte counts were 
significantly higher than pre-operative levels between 1 2 - 4 8  hours post-op (paired t- 
test p<0.05).
5.4.6 Whole blood hypo-responsiveness precedes the systemic rise 
in cytokines
There was a steady decline in whole blood TNF-a and IL-10 production in response to 
LPS through the intra-operative sampling points. This contrasts with the delay seen in 
systemic cytokines shown in Figure 4.4 of Chapter 4. Whilst whole blood from patients 
had reduced ability to respond to LPS as early as release of the aortic cross clamp, 
systemic concentrations of cytokines EL-6 , EL-10, and TNF-a were not elevated at this 
stage. However peak hypo-responsiveness and peak systemic cytokine levels both 
occurred around the arrival onto CICU.
5.4.7 Patients with high systemic IL-10 response to surgery 
appeared to be more hypo-responsive to LPS in the post­
operative period.
EL-10 cytokine load was calculated as described in Chapter 4 (area under the curve 
drawn by the systemic IL-10 response for the first 24 hours). Patients with plasma 
levels > 1 SEM were defined as having a high cytokine load. Five of the 36 patients 
(14%) were defined as having a high EL-10 load. These patients had a trend towards a 
greater drop in IL- 6  and IL-10 response to LPS stimulation in the post-operative period. 
Unfortunately 1 of the five patients did not have stimulated samples collected from t= 8  
hrs for technical reasons. Due to the small study size, the apparent greater reduction in 
responsiveness seen in Figure 5.4 did not reach significance (p=0.07). Such a trend 
however was not seen for IL- 8  and TNF-a.
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Figure 5.4 Those patients with high circulating IL-10 responses to surgery 
(cytokine load), appeared to have a greater reduction in cytokine response (IL - 6  
and IL-10) to whole blood stimulation with LPS. The patient group was divided 
according to the IL-10 cytokine load produced in response to surgery (Chapter 4). 
Those patients with a high IL-10 load (n=5) appeared less responsive to LPS stimulation 
(as determined by IL-6 & IL-10 levels) during the first 24 hours post-operatively. One 
patient in the high IL-10 load group was not sampled at 8 and 24 hours. Horizontal bars 
represent mean cytokine response for group.
One striking aspect to Figure 5.4 was that patients with a high IL-10 response to surgery 
(IL-10 load) had a greater pre-operative IL-10 response to LPS stimulation. This 
difference was not seen when pre-operative levels of the other cytokines were divided 
according to IL-10 load, and raises the question of the role inter-individual variation in 
cytokine production.
5.4.8 Patients who developed post-operative complications had 
reduced cytokine responses to stimulation in the early post­
operative period
Those patients who subsequently required prolonged ventilation and intensive care 
support had significantly lower cytokine responses to stimulation with LPS in the early 
post-operative period (ANOVA/?<0.05 for all cytokines) (Fig 5.5).
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Figure 5.5 Long stay patients were more hypo-responsive to LPS stimulation in 
the post-operative period than short stay patients.
The patient group was divided according to whether their stay in CICU was short (< 
5days) or long (> 5days). Those patients who subsequently required prolonged support 
were less responsive to LPS stimulation in the early post-operative period.
There was also a trend toward a lower cytokine response to stimulation in the 4 patients 
who developed sepsis or SIRS. This reached significance for IL-10 and TNF-a 
responses when sepsis/SIRS and deaths (n=5) were considered together (ANOVA p  = 
0.026 and p = 0.017 respectively) (Fig 5.6).
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Figure 5.6 Patients who developed sepsis/SIRS or died following surgery had a 
more profound inability to respond to LPS.
36 patients were examined for LPS hypo-responsiveness following cardiac surgery 
involving CPB. Three patients developed sepsis, 1 patient fulfilled the criteria for 
SIRS, and 2 patients died (1 was also septic). Examination of these 5 patients’ cytokine 
responses to LPS revealed lower cytokine responses for IL-6, IL-8, IL-10, and TNF-a. 
This reached significance for IL-10 and TNF-a when the 3 outcomes were combined 
(ANOVA p  =0.026 and 0.017 respectively).
5.4.9 Timing of the whole blood hypo-responsiveness coincides with 
the reduction in monocyte MHC Class II expression
The reduced ability of whole blood to respond to LPS stimulation peri-operatively 
parallels in time the reduction in surface expression of MHC Class II on monocytes 
described in chapter 4. Figure 5.7 shows graphs for each cytokine (mean +SEM), where 
the patient’s responsiveness to stimulation at each sampling time has been expressed as 
a percentage of the pre-operative whole blood response. Monocyte MHC Class II 
expression (%) is superimposed. Neither the MHC Class II expression nor the whole 
blood responsiveness to LPS had returned to pre-operative levels at the end of this study 
(Fig 5.7).
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Figure 5.7 MHC Class II expression (%) on circulating monocytes superimposed 
on whole blood cytokine responsiveness. MHC Class II expression (— median).
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5.4.10 Whole blood hypo-responsiveness to LPS stimulation 
following CPB does not occur for all cytokines
Whilst whole blood cultures stimulated with LPS from patients following cardiac 
surgery had a significant reduction in the ability to produce IL-6, -8,-10 and TNF-a this 
was not true for all cytokines. Figure 5.8 shows that the same patient cultures continued 
to produce high levels of IL-lra through surgery and over the first 48 hours following 
surgery. As these were whole blood cultures, the possible role of neutrophils in 
maintaining the production of IL-lra has not been excluded.
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Figure 5.8 Whole blood IL -lra  response to LPS stimulation. There was no change 
in whole blood IL-lra production in response to LPS through the peri-operative period.
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5.5 D isc u ssio n
The results presented in this chapter show that children undergoing cardiac surgery 
involving cardiopulmonary bypass enter a period of LPS hypo-responsiveness in the 
peri-operative period. This hypo-responsiveness was profound and prolonged, and 
coincided with the reduction in surface MHC Class II expression documented in chapter 
4. The specific combination of reduced MHC Class II and an inability of whole blood 
to produce TNF-a on LPS stimulation has been suggested as an objective clinical 
measure of ‘immune paresis* (Docke, Randow and others, 1997;Volk, Reinke and 
others, 1996;Volk, Reinke, and Docke, 1999). The hypo-responsiveness to LPS reported 
here is most likely reflecting an inability of monocyte to respond, as these are the major 
cytokine secreting cell in whole blood. This inability of monocytes to respond to LPS 
stimulation with the production of pro-inflammatory cytokines has been termed 
monocyte deactivation.
The timing of cytokine production may be critical to the subsequent induction of LPS 
hypo-responsiveness. In chapter 4, high levels of all cytokines were detected 
systemically within the first two hours of surgery. This corresponds to the maximal 
period of cytokine hypo-responsiveness. The reasons for this are unclear. If it is 
assumed that monocytes are the main producers of these cytokines in whole blood, then 
one possibility is that circulating monocytes become *exhausted' and cannot mount a 
response to a secondary challenge. However the persistence of the IL-lra response to 
stimulation, which occurred at levels comparable to those measured pre-operatively, 
argues against such a hypothesis although selective ‘exhaustion* is still a possibility. In 
addition, IL-1 and IL-lra can be produced by neutrophils to a greater extent than the 
other cytokines examined. The persistence of an IL-lra response may merely reflect 
ongoing secretion of EL-Ira by neutrophils in response to the LPS stimulation. 
Additional experiments involving stimulation of both whole blood and isolated 
monocytes are required to investigate this observation further.
This observation that deactivation is selective has also been reported by Randow et al 
(1995) (Randow, Syrbe and others, 1995). In this study Randow cultured PBMC’s from 
healthy donors with first a low and then a high dose of Escherichia coli endotoxin over 
two 24 hour periods. Whilst IL-10 and TNF-a production were greatly decreased
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following the second period of culture, IL-lra production was not. He went on to 
confirm these findings in stimulation experiments involving PBMC’s isolated from 
septic adult patients. Selective tolerance of monocytes has not been reported in trauma 
or surgical patients to date.
The mechanism underlying the selective deactivation of monocytes is not completely 
understood. Most of the work has been done in in vitro cell cultures using LPS - 
induced tolerance, and not trauma. Initially, using an endotoxin tolerance model 
developed with mouse peritoneal macrophages it was felt that tolerance may have been 
due to a reduction in surface Toll-like receptor-4 (TLR4) expression in response to 
exposure to LPS (Nomura, Akashi and others, 2000;Takeda and Akira, 2001), but this 
has not been a consistent finding (Medvedev, Kopydlowski, and Vogel, 
2000;Medvedev, Lentschat and others, 2002). Whilst LPS is recognised to bind to 
CD 14, it signals through the TLR4 molecule via the myeloid differentiation factor 8 8  
(MyD8 8 ) / IL-lR-associated kinase 1 (IRAK-1) pathway to activate NF-kB resulting in 
TNF-a production (Adib-Conquy and Cavaillon, 2002;Jacinto, Hartung and others, 
2002). More recently a decrease in TLR4-MyD88 complex formation with subsequent 
impairment of IRAK-1 activity has been shown to occur in LPS-tolerant monocytes 
(Jacinto, Hartung and others, 2002;Medvedev, Lentschat and others, 2002). Whilst it is 
most likely that tolerance involves alteration of distinct TLR signalling components, 
neither of these findings addresses the fact that LPS-tolerant monocytes can still 
respond to further LPS stimulation by expressing other genes and proteins.
In vitro studies would suggest that the aetiology of immune paresis is in part due to high 
circulating levels of IL-10 (Randow, Syrbe and others, 1995). Certainly IL-10 was 
shown in Chapter 4 to be elevated in this patient group by the end of surgery. In 
addition those patients with the greatest IL-10 response to surgery (IL-10 load), had a 
more marked hypo-responsiveness to endotoxin.
The onset of hypo-responsiveness appeared to precede the systemic rise in circulating 
cytokines, in particular IL-10. Many patients had a 50% reduction in cytokine response 
to endotoxin by the time the aortic cross-clamp was release, suggesting that factors 
other than IL-10 may play a role. This concept is supported by work carried out in 
isolated CPB circuits where hypo-responsiveness is seen in the absence of circulating
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EL-10 (Dehoux, Hemot and others, 2000;McBride, Armstrong and others, 1995). 
Dehoux et al (2000) (Dehoux, Hemot and others, 2000) showed that within 30 minutes 
of passing control whole blood through a sham bypass circuit there was reduced IL-6 , 
IL-10, and TNF-a response to LPS stimulation. This hypo-responsiveness persisted 
whilst the blood circulated in contact with the circuit (up to 180 min), and occurred 
despite the absence of detectable levels of IL-10 or endotoxin.
Circulating levels of IL-10 may contribute to the ongoing immune paresis, with high 
systemic levels of IL-10 appearing to further suppress whole blood IL- 6  and IL-10 
response to endotoxin in this study. Whilst it has been possible to show an association 
between poor outcome and reduced MHC Class II expression and reduced capacity of 
whole blood to respond to endotoxin, it has not been possible to show a direct 
correlation between high IL-10 plasma load, long stay and the development of sepsis or 
SIRS.
The development of immune paresis is felt to be a risk factor for the subsequent 
development of nosocomial infection and post-operative complications, and represents 
dysregulation of the immune balance toward an anti-inflammatory state (CARS). In 
this small study group it was possible to show that patients who required prolonged 
intensive care support, or who developed sepsis/SIRS had a greater degree of whole 
blood hypo-responsiveness in the immediate post-operative period.
From in-vitro and in-vivo studies it appears that both MHC Class II expression and 
reduced TNF-a production can be reversed by immunomodulation with interferon- 
gamma (IFN-y) or granulocyte-macrophage colony-stimulating factor (GM-CSF), and 
that restoration of MHC Class II expression is associated with improved outcome 
(Docke, Randow and others, 1997;Flohe, Borgermann and others, 1999;Kox, Bone and 
others, 1997).
Interleukin-10 can be shown to cause suppression of pro-inflammatory cytokine 
secretion by monocytes, and reduced surface expression of Class II molecules with 
corresponding impaired antigen presentation (Randow, Syrbe and others, 1995). 
However there are potentially two problems with the hypothesis that IL-10 is the 
primary mediator behind both LPS hypo-responsiveness and reduced monocyte MHC
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Class II surface expression. IL-10 secretion inhibits its own production in addition to 
that pro-inflammatory cytokines, so any monocyte deactivation may be short lived or 
cyclical in nature. Secondly, this study showed that LPS hypo-responsiveness precedes 
the systemic rise in IL-10 following CPB in children. It is important to recognise that 
plasma levels of IL-10 may not reflect levels in the immediate vicinity of tissue/cells.
A possible alternative explanation may be that there are 2 phases to the hypo- 
responsiveness. The first is induced by anaesthesia, interaction of patient’s blood with 
the bypass circuit, or as a direct result of the trauma of surgery. Then, circulating 
inflammatory mediators maintain the later hypo-responsiveness and reduction in Class 
II surface expression, in particular, high levels of IL-10.
It is now known that LPS binding to TLR4 induces a wide array of gene expressions, 
including the TNF-a and COX-2 gene, initiating the septic response. However these 
pro-inflammatory genes are rapidly and continuously down-regulated soon after 
initiation. Whilst the anti-inflammatory genes are also activated early in sepsis, they do 
not appear to be switched off. This differential expression of pro- and anti­
inflammatory genes can potentially lead to a state of immunosuppression.
Alternatively, a factor we have not examined in this study may be responsible for both 
the hypo-responsiveness and the high IL-10 load. Such a factor could include humoral 
mediators rapidly released with the onset of CPB, mechanically induced damage, or 
change in cellular function following contact of blood with bypass circuit.
Other mediators which may be considered in LPS hypo-responsiveness following CPB 
include transforming growth factor-p (TGF), endotoxin, opioids, prostaglandins, and 
glucocorticoids. TGF-p is an immunoinhibiting cytokine and has been shown to induce 
LPS hypo-responsiveness in PBMC’s in vitro. Addition of neutralising anti-TGF-p 
monoclonal antibodies prevents this induction (Randow, Syrbe and others, 1995). TGF- 
p was not measured in this study or that reported in Chapter 4. Like IL-10, TGF-p 
levels have been shown to be raised at the end of CPB in adult patients, but quickly 
return to pre-operative levels by 6  hours post-op (Sablotzki, Welters and others, 1997). 
Based on this kinetics, TGF would not explain the persistent hypo-responsiveness seen 
in these results and does not augment plasma EL-10 levels.
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Endotoxin levels have been associated with adverse outcomes following cardiac 
surgery. Endotoxin and anti-endotoxin core antibodies have been documented in the 
plasma of adults undergoing cardiac surgery, peaking 30 minutes postoperatively and 
preceding plasma peaks of IL- 6  and IL- 8  (Neuhof, Wendling and others, 
2001;Rothenburger, Soeparwata and others, 2001). The primary source of endotoxin 
has traditionally been perceived to be gut translocation, but it has also been found in 
pooled pericardial blood (Spanier, Tector and others, 2000). Whilst endotoxin would 
explain both LPS hypo-responsiveness and high plasma IL-10 levels in vivo, endotoxin 
is absent in in-vitro studies involving isolated bypass circuits where LPS hypo- 
responsiveness has occurred (Dehoux, Hemot and others, 2000;McBride, Armstrong 
and others, 1995).
Randomised adult CPB studies using high vs. low dose opioid anaesthesia showed no 
difference in pro- and anti-inflammatory cytokine response (Brix-Christensen, 
Tonnesen and others, 1998). The kinetics of LPS hypo-responsiveness presented above 
and in other studies has shown an onset of hypo-responsiveness following CPB, not 
anaesthetic induction. In addition, the presence of fentanyl to whole blood cultures 
from healthy volunteers does not alter ex-vivo LPS-induced cytokine production 
(Larsen, Hoff and others, 1998;Paquin, 1996), and LPS hypo-responsiveness has 
occurred when blood was passed through an isolated bypass circuit in the absence of 
opioids (Dehoux, Hemot and others, 2000).
Following cardiac surgery, there is an increase in both prostaglandin E2 and 
glucocorticoids. These endogenous mediators are known to inhibit LPS-induced 
production of cytokines (Scales, Chensue and others, 1989;van der, Jansen and others, 
1994). However it is unlikely that endogenous cortisol is responsible for the LPS hypo- 
responsiveness seen in this patient group as adult studies suggest that anaesthesia used 
for CPB blocks the neuroendocrine stress response, and the rise in systemic cortisol 
occurs on arrival onto the intensive care unit (Roth-Isigkeit, Brechmann and others, 
1998;Roth-Isigkeit, Dibbelt, and Schmucker, 2000). This time course would be out of 
keeping with the intra-operative hypo-responsiveness reported here.
Steroids have been used in numerous adult clinical studies involving cardiac surgery. 
Whilst results are not always consistent, it appears that steroids reduce systemic pro- 
inflammatory cytokine levels and augment the IL-10 response (Chaney, 2002;Fillinger, 
Rassias and others, 2002;Harig, Feyrer and others, 1999;Tabardel, Duchateau and 
others, 1996). However no patient in this study received exogenous glucocorticoids 
during theatre.
In summary, all children entered a period of monocyte hypo-responsiveness following 
CPB marked by a reduction in surface expression of MHC Class II and reduced ability 
to mount a cytokine response to LPS stimulation. Whilst those patients who required 
prolonged support, developed sepsis/SIRS or died had a more profound hypo- 
responsiveness, and a greater hypo-responsiveness was seen in those patients with a 
high IL-10 load, IL-10 alone does not appear to be the sole mediator. Long stay and 
septic patients did not have significantly higher levels of IL-10, and hypo- 
responsiveness preceded the systemic rise in IL-10.
It is clear that environmental factors can and probably do influence the outcome and 
cytokine dynamics of children undergoing cardiac bypass. However it is also possible 
that genetic factors may be important and this is addressed in the next chapter.
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6.1 In t r o d u c t io n :
“Gene isolation provides the best hope for understanding human 
disease at its most fundamental level. Knowledge about genetic 
control o f  cellular functions will underpin future strategies to prevent 
or treat disease phenotypes. ”
Francis Collins Shattuck lecture: medical and societal consequences 
o f the Human Genome Project (1999).
The outcome for any individual after major surgery is determined by the nature and
magnitude of both the peri-operative challenge and patient response. Each of these
components is itself multifaceted. It has become increasingly clear that the genetic 
constitution of the patient plays a powerful role in the transduction of the environmental 
stimulus and the nature of subject response.
Several studies have highlighted the inter-individual variation in cytokine responses to 
endotoxin (Lowe, Galley and others, 2003 ;Molvig, Baek and others, 1988;Westendorp, 
Langermans and others, 1995 ;Westendorp, Langermans and others, 1997 ). Recent 
studies in both adults and children have suggested that cytokine responses are under 
significant genetic control (Andreotti, Porto and others, 2002 ;Brull, Montgomery and 
others, 2001 ). In the results presented thus far, two sections have raised the question 
‘Is an individual genetically predisposed to respond to an inflammatory insult in a 
particular way?’ The first was in chapter 3 (section 3.4.13) where the MHC Class II 
intensity on monocytes (mfi) preoperatively was significantly lower in those children 
who subsequently required prolonged support, developed sepsis and/or SIRS. The 
second was in Chapter 5 (section 5.4.7), where it was found that children who were high 
IL-10 producers in response to surgery, had a significantly greater degree of hypo- 
responsiveness to secondary challenge with endotoxin. Not surprisingly, this subgroup 
of children had a much greater IL-10 response to endotoxin stimulation pre-operatively, 
before becoming profoundly hypo-responsive post-operatively (Fig 5.4).
The concept that a child could be genetically predisposed to do poorly following the 
inflammatory insult of CPB is very attractive clinically. At present every effort is made 
to accurate stratify each patient according to operative risk. However the host response 
is still the greatest unknown.
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The aim of this chapter was to investigate the relative role of key functional cytokine 
polymorphisms on the cytokine response and outcome of children undergoing 
cardiopulmonary bypass. The hypothesis was that children with a promoter 
polymorphism that resulted in increased systemic levels of IL- 6  or TNF-a would be 
more likely to have a complicated postoperative period. Cytokines chosen were IL- 6  
and TNF-a because of repeated implication in the pathogenesis of myocardial 
dysfunction and ischaemia-reperfusion injury following cardiac surgery, and IL-10 
because of its recently highlighted role in attaining immune balance. Whilst a number 
of polymorphisms have been reported in each of these cytokine promoters, IL- 6  -174 
(G/C), TNF-a -308 (A/G), and IL-10 (-1082, -819, -592) have been consistently shown 
to have a functional effect on protein levels.
6.2. M e t h o d s
6.2.1 Patient Selection
Any patient undergoing cardiac surgery involving cardiopulmonary bypass over an 18 
month period was eligible for entry into this study.
6.2.2 Blood sampling for genotyping and measurement of cytokines
Each patient had 1-2 ml of whole blood collected into EDTA pre-operatively as 
described in Section 2.3.6 of the Chapter 2. In an initial subgroup of 42 patients, plasma 
cytokine levels were measured pre and post-operatively, and over the following 48 
hours.
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6.2.3 Heteroduplex Genotyping
Initially a heteroduplex method for genotyping was examined for detection of the IL-10 
promoter polymorphism. This method involved generation of a universal heteroduplex 
generator (UHG). The UHG was a section of the genomic DNA of interest which 
contained a small polypurine insert adjacent to the site of the polymorphism. Both the 
UHG and the genomic DNA were amplified using primers designed to span the area 
containing the polymorphism. Equal amounts of both UHG and PCR product were then 
combined and denatured. When the denatured products were allowed to slowly 
renature, they formed DNA duplexes. Those duplexes with the same sequence in both 
strands, (homoduplexes) electrophoresed more quickly than those duplexes with a base 
pair mismatch (heteroduplex) (Bhattacharyya and Lilley, 1989).
6.2.3.1 DNA extraction and standardisation
DNA was extracted and standardised as described in Section 2.3.6.1.
6.2.3.2 PCR Primers
Table 6.1 details the primer pairs that were used for PCR amplification of genomic 
DNA and the heteroduplex generators:
Polymorphism Oligonucleotide Sequence 5’-3* 
(Forward / Reverse)
IL-10 -1082 G/A 5’-AAT CCA AGA CAA CAC TAC TAA GGC-3’ 
5’-CTG GAT AGG AGG TCC CTT AC-3*
IL-10 -819 C/T 5’-TAC AGT AGG GTG AGG AAA CC-3’ 
5’-GGT AGT GCT CAC CAT GAC CC-3’
IL-10 -592 C/A 5’-GAA ATC GGG GTA AAG GAG CC-3’ 
5’-AGT TCC CAA GCA GCC CTT CC-3’
Table 6.1 Prim er pairs for amplification of DNA around the IL-10 promoter area 
of interest (Morse, Olomolaiye and others, 1999).
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6.2.3.3 Universal Heteroduplex Generators (UHG)
UHG’s were synthesised as single long oligonucleotides (kindly provided by Dr N 
Wood, University of Bristol, Bristol, UK) (Table 6.2).
IL-10 -1082 UHG 5’-AAT CCA AGA CAA CAC TAC TAA GGC TTC 
TTT GGG AAA AAA AGG GGA AGT AGG GAT 
AGG TAA GAG GAA AGT AAG GGA CCT CCT 
ATC CAG-3’
IL-10 -819 UHG 5’-TAC AGT AGG GTG AGG AAA CCA AAT TCT 
CAG TTG GCA CTG GTG TAC CCT TGT ACA GGT 
GAT GTA ACA AAA AAT CTC TGT GCC TCA GTT 
TGC TCA CTA TAA AAT AGA GAC GGT AGG GGT 
CAT GGT GAG CAC TAC C-3’
IL-10 -592 UHG 5’-GAA ATC GGG GTA AAG GAG CCT GGA ACA 
CAT CCT GTG ACC CCG CCT GTC AAA ACT GTA 
GGA AGC CAG TCT CTG GAA AGT AAA ATG 
GAA GGG CTG CTT GGG AAC T-3’
Table 6.2 Nucleotide sequences for the UHG molecules
6.2.3.4 Optimisation of PCR and Heteroduplexing
The PCR for all 3 promoter polymorphisms were optimised for MgCb concentration 
and temperature (1.5mM and 57°C respectively) using control DNA. Extremely dilute 
amounts of UHG were used in order to avoid smearing from excess product.
Equal volumes of genomic DNA and UHG product were mixed, denatured at 95°C for 5 
min and allowed to cool slowly from 95°C to 37°C over 30 minutes. Diffusion through 
15 and 20% vertical non-denaturing polyacrylamide gels was examined using varying 
currents. Low currents for long periods were required to achieve even diffusion of 
samples. Optimal electrophoresis conditions were found to be 6  hours at 160V in 20%
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polyacrylamide gel. Gels were stained for 5 min in lx TBE containing 0.5pg/ml 
ethidium bromide, and examined using a UV transilluminator.
6.2.4 Microtitre Array Diagonal Gel Electrophoresis (MADGE)
A detailed description of the method used in this chapter is presented in section 2.3.6 of 
Chapter 2. Detection of promoter polymorphism for IL- 6  -174 (G/C) had been 
previously established using Microtitre Array Diagonal Gel Electrophoresis (MADGE) 
by the Cardiovascular Genetic laboratory at The Rayne Institute, University College 
London (Brull, Montgomery and others, 2001 ;Fishman, Faulds and others, 1998 ). 
After optimisation of the IL- 6  method for this patient group, the technique was extended 
and optimised for the detection of the IL-10 -1082 (G/A), -819 (C/T), -592 (C/A) and 
TNF-a -308 (G/A) promoter polymorphisms. Appropriate digestion enzymes for these 
promoter polymorphisms were obtained from the literature and conditions optimised to 
give clear digest bands (Turner, Williams and others, 1997).
6 .3  S t a t i s t i c a l  A n a l y s i s
Allele frequencies were estimated by gene counting. The goodness of fit between 
observed and expected allele frequency was statistically tested using a %2 test. Plasma 
cytokine levels are presented on a log scale and comparisons between data sets was 
made using Kruskal-Wallis. Variations in plasma cytokine levels between genotype 
groups were examined by ANOVA. Multiple comparisons were adjusted for using 
Bonferroni corrections and a p-value of <0.05 was considered statistically significant. 
A 2-tailed t-test for equality of means was utilised when comparing duration of 
ventilation and length of stay between genotypes.
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6.4 R e s u l t s
6.4.1 Heteroduplex genotyping for IL-10 promoter polymorphisms
The heteroduplex method enabled differentiation of the three IL-10 polymorphisms (Fig 
6.1). However considerable time was required for optimisation and it was therefore felt 
that time would be prohibitive for optimisation of this method for the other cytokine 
polymorphisms. An alternative system was therefore explored.
IL-10 - 8 1 9 IL-10 - 5 9 2IL-10 -1082
Figure 6.1 Image of a 20% polyacrylamide gel of the IL-10 promoter 
polymorphisms. This gel contained 7 samples examined for the 3 IL-10 promotor 
polymorphisms. A key to the bands is drawn under each sample on the gel. On this 24 
well gel there were 2 blanks and one drop out (6th well from the left). The 1st sample 
(from the left), would be read as a GCC/ATA haplotype, the 5th sample as GCC/ACC, 
and the last control an AT A homozygote
6.4.2 Development of MADGE and optimisation of the IL-10 -1082, 
-819, -592, and the TNF-a -308 promoter polymorphisms
Primer pairs to amplify the appropriate region of the promoters of interest were obtained 
from the literature (Morse, Olomolaiye and others, 1999 ). Optimisation of PCR 
conditions was performed in a 96 well plate combining a temperature gradient on the 
Thermocycler with a MgCb gradient in the PCR mix. Optimisation was performed on 
patient samples with duplicates of each condition. Figure 6.2 is a photograph of a gel 
optimising the TNF-a -308 promoter polymorphism. Extra bands are seen in the lower 
left comer, where low temperatures and high magnesium conditions (for these primers) 
were present. This contrast with the top right region of the gel, where high temperatures 
and low magnesium concentrations give clear single bands of product. Well C12 -  G12 
were blank in this gel. In this case optimal conditions for this PCR were chosen to be 
57°C with 1.5 mM concentration of MgCL2 . After optimisation the product was 
checked on an agarose gel against an appropriate ladder to ensure it was of the correct 
size.
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Figure 6.2 Optimization MgCh and annealing temperature for TNF-a -308 
(G/A) promoter polymorphism PCR. Each PCR was optimized for magnesium 
concentration and annealing temperature to minimize non-specific binding and primer 
dimmer. Conditions involving the highest temperature and lowest magnesium 
concentration producing a clear band of product of the appropriate size were chosen.
A literature search was performed to identify restriction enzymes that cut at or near the 
site of the promoter polymorphism of interest. Ideally the enzyme chosen would cut the 
common sequence. This, in combination with the presence of a positive control on each 
plate, ensures that the operator can be certain the digest has worked even in rare 
polymorphisms. Figure 6.3 demonstrates the restriction enzyme EcoNl used for the IL- 
10 -1082 promoter polymorphism.
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GG -  3 fragments 
2 5 3 / 9 7 / 2 7  bp
G A -  4 fragments 
2 8 0 / 2 5 3 / 9 7 / 2 7
AA -  2 fragments 
280 / 97 bp
Figure 6.3 Microtitre Array Diagonal Gel Electrophoresis (MADGE) for IL-10 (- 
1082 G/A) promoter polymorphism. Following digestion with EcoNl overnight at 
37°C, 5pl of the PCR product was added to 2pl of formamide dye and loaded onto a 
7.5% polyacrylamide gel. The gel was electrophoresed at 100V to separate digest 
products and visualised using UVP Gel Documentation System. The digestion enzyme 
EcoNl cuts the PCR product 3 times if guanine is present at the -308 position, but only 
twice if there has been a base change to adenine.
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6.4.3 Patient Characteristics and Operative Details
Over the 18 months of study recruitment, 450 children underwent elective cardiac repair 
involving cardiopulmonary bypass. Two hundred and thirty of these were randomly 
approached (depending on availability of the author to recruit). All but three agreed to 
participate. Complete phenotypic and genotypic data was available on 219 patients. 
Demographics and operative details for the whole study cohort are show in Table 6.3. 
In addition the same details are presented for each of the promoter polymorphisms 
examined. There was no statistically significant difference in demographics and 
operative details within any of the cytokine promoter genotypes, nor between a 
particular genotype and the overall study group.
IL - 6  (-174) IL-10 (-1082, -819, -592) TNF-a (-308)
All
(n=219)
GG
(n=87)
GO
(n=104)
c c
(n=28)
GCC/GCC
(n=45)
GCC/-
(n=104)
-/-
(n=70)
GG
(n=142)
GA
(n=71)
AA
(n=6)
Age (mths)
7.4
(2.6-31)
6.5 
(0.9 - 20)
8.1 
(2.7 -  44)
8.7
(3.6-23)
8.8 
(3 32)
8.2
(2.7-31)
5.2
(2.1-34)
7.4
(2 -3 3 )
7.2
(3.2-18)
33.8 
(2.1 -111)
Male 120 (55%) 49 (56%) 57 (55%) 14 (50%) 17 (38%) 57 (55%) 46 (66%) 88 (62%) 28 (40%) 4 (67%)
Weight (kg) 7 ± (4-10) 5 (4-9) 7(4-17) 8 (5-10) 5 (4-9) 7(4-10) 8(5-14) 6(4-12) 7(5-9) 10 (5-40)
Operative Group (Jenkins Criteria)
1 17 (8%) 8(10%) 8 (8%) 1 (4%) 5 (9%) 9 (9%) 3 (4%) 11 (8%) 6 (8%) 0 (0%)
2 85 (39%) 32 (37%) 38 (37%) 15(53%) 16(36%) 42 (40%) 27 (38%) 58(41%) 24 (34%) 3 (50%)
3 77 (34%) 32 (36%) 36 (34%) 9 (32%) 16(36%) 32 (31%) 29 (42%) 50 (35%) 24 (34%) 3 (50%)
4 33 (15%) 12(14%) 19(18%) 2(7%) 8(19%) 15(14%) 10(14%) 20(14%) 13 (19%) 0 (0%)
5 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
6 7 (4%) 3(3%) 3(3%) 1 (4%) 0 (0%) 6 (6%) 1 (2%) 3 (2%) 4 (5%) 0 (0%)
CPB time (min) 107 (67 - 135)
112 
(67 - 149)
101
(64-134)
103
(80-124)
110
(85-131)
108 
(63 -  132)
102
(70-144)
108 
(68 -  140)
103 
(6 7 - 132)
104 
50 - 140
Aortic cross clamp time (min)
44
(16-73)
52 
(20 -  79)
39
(14-70)
51
(15-74)
50 
(35 -  78)
39
(19-71)
39
(0 -77 )
45
(15-77)
47
(20-72)
0
(0 -  56)
Circulatory arrest time (min)
0
(0 -4 )
0
(0 -5 )
0
(0 1)
0
(0 -2 )
0
(0)
0
(0 -4 )
0
(0 -8 )
0
(0 -5 )
0
(0)
0
(0)
Lowest operative temp < 18°C 37(15%) 19 (20%) 15 (13%) 3 (10%) 10(20%) 17(15%) 10(13%) 27(18%) 10(14%) 0 (0%)
Table 6.3 Clinical and surgical characteristics for the whole study group and divided for individual genotype. For categorical data, data 
is presented as number of patients (% of group). For continuous variables, data is presented as median ± IQR. There was no statistically 
significant difference in demographics and operative details within any of the cytokine promoter genotypes, nor between a particular genotype 
and the overall study group.
( ! ( )KI \ i .  Put >MO I I K W >I.Y\!Okl‘ IIISMs:
i ' i  ! M i ! ) \  Ixi  I. \ ! \ !M.VI ( >K V Rl M’OX'SI' &  O u o >m i :
6.4.4 Outcome for the whole study group
The median duration of ventilation was 2.75 days (range 0 hrs -  8 6  days), and the 
median length of stay in the intensive care unit was 3.9 days (16 hours -  8 6  days). In 
the majority of patients (62%, 136/219) the LOS was < 5 days, with the remainder 
(38%, 83/219) requiring a median of 12.6 days (6 - 8 6  days).
During the Intensive Care stay, nine patients (4.1%) fulfilled the criteria for sepsis and a 
further three patients for SIRS (frequency of sepsis/SIRS = 5.5%). All septic/SIRS 
patients were long stay patients. There was an overall mortality rate of 3.7% (8/219). 
These figures are consistent with the overall incidence of complications within the 
cardiac intensive care unit at Great Ormond Street Hospital. Seven patients died during 
the hospital admission and one after transfer back to the local hospital. Of the patients 
that died post-operatively, only one patient died in the first 5 post-operative days from a 
non-infective cause. Two of the patients who died also fulfilled the criteria for sepsis.
6.4.5 Distribution of Genotyping
Genotyping for all promoter polymorphisms revealed a distribution that did not differ 
significantly from that predicted by the Hardy-Weinberg equilibrium law utilising 
predicted frequencies from other UK studies (Table 6.4). The population studied here 
was however, very mixed in ethnicity. A large number of the patients who have cardiac
surgery in this centre are referred from overseas, particularly the Arab states. There
does not appear to be any previously published studies describing the allele or gene 
frequencies of these promoter polymorphisms in an Arab population.
Patient characteristics and measures of surgical stress were comparable between the 
various haplotypes (Kruskal-Wallis /?>0.05). This was true even for TNF-a -308A 
homozygotes who, whilst few in number, were noticeably older, had different surgical 
repairs undertaken, and required neither aortic cross-clamping nor circulatory arrest 
during their surgery.
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Haplotype Predicted frequency (%)
Observed 
frequency (%) 
in overall 
patient group 
(n=219)
Observed 
frequency in 
subgroup of 
study 
(n=42)
IL-6-174 GG 36 39.7 43 (n=l 8 )
GC 45.5 47.5 36 (n=15)
CC 18.5 1 2 . 8 21 (n=9)
IL-10 GCC/GCC 21.3 20.5 24 (n=10)
GCC/- 41.2 47.6 43 (n=18)
- / - 37.5 31.9 3 3 (n=14)
TNF-a GG 57-84 64.7 62 (n=26)
GA 16-40 32.6 3 8 (n=16)
AA 0-4 2 . 8 (n=0 )
Table 6.4 The frequency of investigated genotypes in the study population did not 
differ significantly from the reported incidence in control populations.
TNF-a values are given as a range due to the combination of several study 
results(Allen, 1999 ;Brull, Leeson and others, 2002 ;Brull, Montgomery and others, 
2001 ;Fishman, Faulds and others, 1998 ;Morse, Olomolaiye and others, 1999 ;Tumer, 
Williams and others, 1997).
6.4.6 IL-6 genotype and inflammatory response to CPB
42 patients (subgroup within the study) had plasma cytokine levels measured. All 
patients had low levels of circulating IL- 6  at surgical induction. Patients who were 
homozygous for IL- 6  -174 CC had significantly lower IL- 6  response during cardiac 
surgery (Kruskal-Wallis p<0.05), and significantly lower systemic levels over the first 
24 postoperative hours (Fig 6.4). This difference in circulating levels of IL- 6  between 
the three genotypes persisted at 48 hours.
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Figure 6.4 Patients who were homozygous for the IL - 6  (-174) C/C haplotype had 
significantly lower systemic IL - 6  levels following cardiac surgery involving 
cardiopulmonary bypass. All patients had blood collected for genotyping pre- 
operatively. Plasma was collected from induction of anaesthesia (pre op), at the end of 
surgery (MUF), through to 48 hours post-op, and levels of IL-6 were measured using 
ELISA. Patients were divided into 3 groups based on genotyping of the IL-6 -174 
promoter polymorphism. Those patients that were homozygous for the IL-6 promoter 
polymorphism -174CC had significantly less circulating IL-6 at the end of surgery ( 
Kruskal-Wallis p<0.05) and over the first 48 post-operative hours (ANOVA with 
Bonferroni correction /?<0.001).
There was no significant difference in the timing of peak IL-6 levels amongst the 3 
genotypes, but there was a stepwise decrease in peak concentration of IL-6 from 
patients homozygous for the GG allele to those patients homozygous for the CC allele 
(Fig 6.5)
p = 0.001
GG GC
IL-6 (-174) promoter
Figure 6.5 The presence of IL - 6  -174CC promoter polymorphism significantly 
reduced the systemic peak of IL - 6  seen following paediatric cardiac surgery.
There was a stepwise decrease in the peak concentration of IL-6 measured systemically 
in those patients who carried a C allele at position -174 of the IL-6 promoter.
6.4.7 IL-6 genotype and outcome
Outcome measures were examined for the whole study group (n=219). Twenty-eight 
patients (13%) were homozygous for IL-6 -174C haplotype. These patients had a 
significantly shorter duration of ventilation in the post-operative period (Kruskal-Wallis 
p<0.05). There was also a trend for the patients who were homozygous for the CC 
promoter polymorphism to have a shorter length of stay compared to the rest of the 
patients; however this did not reach significance (Fig 6.6). There was no sepsis / SIRS 
or deaths among the IL-6 -174 C homozygotes.
3001
(/)
§  20(7s  J2  ?  c
>
O  10(7
I
p < 0.05
I
GG GC
IL-6 (-174 G/C)
CC
400T
30(7
20(7
Co
3  100f 
Q
X
I
GG GC
IL-6 (-174 G/C)
CC
Figure 6 . 6  IL - 6  genotype and outcome measures. Patients who were homozygous 
for the IL-6 -174CC haplotype had a significantly shorter duration of ventilation and 
trend toward shorter length of stay compared to the other haplotypes.
6.4.8 TNF-a genotype and inflammatory response to CPB
In the subgroup of patients in which plasma cytokines were measured, there were no 
homozygotes for the TNF-a -308A promoter polymorphism. There were 16 patients 
(34%) who were heterozygotes for the polymorphism. These patients had significantly 
lower levels of TNF-a systemically over the first 24 hours post-operatively (ANOVA p 
= 0.002) (Fig 6.7).
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Figure 6.7 The presence of the TNF-a -308A allele was associated with 
significantly lower plasma levels of TNF-a post-operatively.
TNF-a levels following cardiopulmonary bypass were divided according to the 
presence or absence of the TNF-a -308 promoter polymorphism. The presence of the 
G/A substitution at -308 was associated with significantly lower levels of TNF-a over 
the first 24 hours post-operatively (ANOVA p=0.002).
6.4.9 TNF-a genotype and outcome
Six patients of the total study group (2.8%) were homozygous for the rare TNF-a -308A 
promoter polymorphism. Whilst few in number, these patients had significantly shorter 
ventilation requirements, and stayed less time in CICU compared to the overall study 
population (Fig 6.8). None of the patients homozygous for the -308A TNF-a promoter 
polymorphism developed sepsis/SIRS or died during the study. However whilst not 
significant, these patients tended to be older and had less technically difficult repairs 
with no periods of aortic cross clamping or hypothermia (Table 6.3).
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Figure 6 . 8  Those patients who were homozygous for the TNF-a -308A allele had 
significantly shorter duration of ventilation and length of stay in intensive care
(Kuskal-Wallis p<0.01).
6.4.10 IL-10 genotype, outcome and inflammatory response
following CPB
Of the 42 patients in whom plasma IL-10 levels were measured 10 (24%) were 
homozygous for the GCC promoter polymorphism. These 10 patients had significantly 
greater systemic levels of IL-10 over the initial 24 post-operative hours (as determined 
by cytokine load) (Fig 6.9). There was a trend towards those patients who carried the 
GCC IL-10 promoter polymorphism to have reduced ventilation requirements and 
shorter duration of stay in the intensive care unit, but this did not reach significance (Fig 
6 .10).
p  < 0.05
▲▲i i i i
GCC/GCC GCC/-
IL-10 promoter haplotype
Figure 6.9 Circulating levels of IL-10 over the first 24 hours (IL-10 load) 
according to IL-10 promoter haplotype. Those patients who were homozygous for 
the GCC promoter polymorphism had significantly higher circulating levels of IL-10 in 
the immediate post-operative period (p<0.05 Kruskal-Wallis).
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Figure 6.10 There was a trend toward reduced duration of ventilation and shorter 
intensive care stay in those patients who had the IL-10 GCC haplotype.
6.4.11 Effect of IL-10 genotype on systemic levels of pro- 
inflammatory cytokines
There was no direct discemable effect of IL-10 genotype on circulating levels of TNF-a 
or IL-6 in the immediate post-operative period.
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6 .5  D i s c u s s i o n
Recovery from cardiac surgery is determined by many factors including the pre­
operative physiological state of the patient, the success of the technical repair (always 
excellent if you ask the surgeons!), and the inflammatory response of the host to the 
insult.
This chapter describes a study designed to gain insight into the potential genetic 
regulation of the inflammatory response. Previous studies have shown that the IL-6, IL- 
10, and TNF-a genes all possess promoter polymorphisms which affect gene 
transcription and the production of the associated protein. High cytokine levels have 
been associated with the presence of the IL-6 and TNF-a alleles, and the IL-10 
haplotype displayed in Table 6.3
(Allen, 1999 ;Burzotta, Iacoviello and others, 2001 ;Fishman, Faulds and others, 1998 
;Heesen, Kunz and others, 2003 ;Kroeger, Carville, and Abraham, 1997 ;Lowe, Galley 
and others, 2003 ;Stuber, Petersen and others, 1996 ;Tomasdottir, Hjartarson and others, 
2003 ;Tumer, Williams and others, 1997 ;Wilson, Gordon and others, 1994 ;Wilson, 
Symons and others, 1997 ).
Cytokine Position Allele
IL-6 -174 G
-1082 G
IL-10 -819 C
-592 C
TNF-a -308 A
Table 6.5 Cytokine promoter polymorphisms associated with higher protein 
levels.
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6.5.1 Association between cytokine polymorphisms and outcome
Results from 219 infants and children undergoing cardiac surgery involving CPB are 
presented here. The gene frequencies of the cytokine polymorphisms being investigated 
were in keeping with the frequencies previously published in other UK cohorts (Brull, 
Leeson and others, 2002 ;Brull, Montgomery and others, 2001 ;Fishman, Faulds and 
others, 1998 ;Morse, Olomolaiye and others, 1999 ;Tumer, Williams and others, 1997). 
The presence of polymorphisms in the promoters of IL- 6  and TNF-a had a significant 
association with duration of ventilation and/or length of stay in intensive care. There 
was also a trend for IL-10 promoter polymorphisms to be associated with outcome. 
Results presented here do not include HLA genotyping. This is the first description of 
these polymorphisms in paediatric surgical patients and to date there has been only one 
study in paediatric septic patients (Nadel, Newport and others, 1996).
In adults these 3 cytokine polymorphisms have been more extensively examined, 
however with frequently conflicting results. As in the results presented here, outcomes 
measures included duration of ventilation, length of stay, organ dysfunction and 
mortality. The most consistent finding has been with the TNF-a -308A allele. In adult 
studies this allele has been associated with adverse outcome in septic shock, cerebral 
malaria, and hepatitis B infection (Hohler, Kruger and others, 1998 ;McGuire, Hill and 
others, 1994 ;Mira, Cariou and others, 1999 ;Tang, Huang and others, 2000 ). Whilst 
the presence of the -308A allele has been shown to be over-represented in two studies of 
critically ill patients (Mira, Cariou and others, 1999 ;Reid, Perrey and others, 2002), it’s 
association with susceptibility to, or outcome from sepsis (excluding septic shock) has 
not been supported by association studies (Emonts, Hazelzet and others, 2003 ;Reid, 
Perrey and others, 2002 ;Stuber, Udalova and others, 1995 ;Tang, Huang and others, 
2000). In contrast, a single study of this promoter polymorphism in outcome following 
cardiac surgery, showed an association between the -308A allele and shorter times to 
extubation with lower risk of prolonged mechanical ventilation (Yende, Quasney and 
others, 2003).
No clear pattern has emerged in IL- 6  and IL-10 promoter polymorphism outcome 
association studies to date.
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6.5.2 Outcome and protein levels
As described in section 1.5.3, there are strong associations reported between some
cytokine genotypes and associated protein levels in in vitro experiments. This makes it
tempting to ascribe the outcome differences between genotypes to protein levels. 
However, when attempts have been made to assess genotype and protein levels with 
outcome, a clear association is frequently not observed (Gaudino, Andreotti and others, 
2003 ;Lowe, Galley and others, 2003 ;Schluter, Raufhake and others, 2002).
In this study, findings supported an association between IL- 6  -174G allele and the IL-10 
GCC haplotype with higher circulating protein levels of these cytokines. This 
association would be predicted from studies performed in vitro. However in contrast to 
previously published in vitro and in vivo data, patients carrying the TNF-a -308A allele 
had lower circulating levels of TNF-a compared to the -308GG homozygotes 
(Abraham, French, and Dawkins, 1993 ;Bouma, Crusius and others, 1996 ;Heesen, 
Kunz and others, 2003 ;Jacob, Fronek and others, 1990 ;Louis, Franchimont and others, 
1998 ;Stuber, Petersen and others, 1996 ;Wilson, Symons and others, 1997 ). 
Unfortunately there were no plasma levels of TNF-a available from -308AA 
homozygotes on which to confirm this finding.
6.5.3 Importance of circulating cytokine levels
Plasma cytokine levels measured in this and other studies are the cumulative response to 
the stress of surgery and bypass and come from many cellular sources. Circulating 
cytokine levels give no information about monocyte potential to respond to stimulation 
which would be a better correlate of the in vitro experiments suggesting an association 
between genotype and phenotype.
Associating genotype with plasma or serum levels of cytokines may be misleading as it 
fails to take into account local cytokine production and the complex regulatory 
mechanisms that control cytokine secretion. In addition intermittent sampling carries 
with it the risk of missing peak concentrations.
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In the study reported here, patients who were homozygous for the rarer IL- 6  -174 
promoter polymorphism (CC), had significantly lower systemic levels of IL- 6  post- 
operatively. The highest circulating levels of IL- 6  were seen in those patients 
homozygous for the -174G allele. This association directly contrasts with the adult 
findings published by Brull (2001) and Jones (2001). The reason for this discrepancy is 
not clear. It may be a product of the sample timing. Results presented in this chapter 
looked at cytokine levels over 48 hours, examining both peak and load, whereas Brull 
and Jones analysed genotype against the cytokine level taken at a single time point, 
admitting in the earlier study that the relationship did not hold true if other time points 
were examined. Another possible reason for this difference may be the age of the study 
populations. IL-6 ’s release occurs wherever there is an acute phase response. In older 
patient groups many other pathogenic processes may therefore contribute to circulating 
IL- 6  levels under the stress of CPB -  smoking, atherosclerosis, other end organ disease 
etc. Thus in adult studies, the IL- 6  response is less likely to be solely due to the 
interaction between genetic potential and surgical stress, and more likely to be 
‘muddied’ by confounders. In the results presented above, IL- 6  levels probably reflect 
the stress of surgery with a only a small contribution from the underlying cardiac 
condition. This may explain why in the subset of patients in which genotype and 
phenotype were analysed such a clear relationship was seen.
6.5.4 Summary
The results presented in this chapter highlight the role that genetic predisposition may 
play in the host response to surgery and CPB. The presence of IL- 6  -174C and TNF-a - 
308A promoter polymorphisms were associated with significantly shorter durations of 
ventilation and duration of intensive care support following surgery. It is important to 
point out that this is an association, rather than causation. Furthermore while it would 
be convenient to explain this association on the basis of cytokine levels, this is probably 
an over simplified view of the role of the promoter.
Despite the reservations expressed above, this and other studies have shown an 
association between outcome and genotype indicating a role for these genes in 
determining the host response to surgery. Future studies should concentrate on the
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mechanisms of how these genes are operating in this clinical setting. In addition the 
value of this type of analysis should be viewed critically, particularly with regards to 
patient pre-operative risk stratification.
CHAPTER 7
Regulation of MHC Class II expression in Cardiopulmonary
Bypass
1 In t r o d u c t io n ..............................................................................................................................199
2 M e t h o d s ........................................................................................................................................ 200
7.2.1 Measurement of plasma cytokines......................................................................200
7.2.2 Semi-quantitative Assessment of mRNA levels................................................. 202
7.2.2.1 Extraction of mRNA and generation of cDNA..................................... 202
7.22.2 RT-PCR of MHC Class H related genes...............................................204
3 R e s u l t s ...........................................................................................................................................206
7.3.1 Optimisation of monocyte purification using small volumes of whole blood 206
7.3.1.1 Isolation of monocytes......................................................................... 206
7.3.1.1.1 Purity...................................................................................... 206
7.3.1.1.2 Monocyte activation.................................................................206
7.3.1.2 Optimisation of confocal staining.........................................................210
7.3.1.3 Summary............................................................................................. 212
7.3.2 Detection of MHC Class II localisation in patients............................................ 215
7.3.2.1 Patient characteristics, operative details and outcome.......................... 215
7.3.2.2 Relationship between surface and intracellular MHC Class II 
expression by flow cytometry...............................................................219
7.3.2.3 Monocyte HLA-DR distribution using confocal microscopy................222
7.3.2.3.1 Surface HLA-DR expression.................................................. 222
7.3.2.3.2 Intracellular HLA-DR expression.......................................... 225
7.3.2.4 Quantitation of HLA-DR and CUTA mRNA....................................... 228
7.3.2.5 MHC Class II expression, mRNA levels and circulating cytokines 230
7.4 D is c u s s io n .........................................................................................................................233
i i l  < .i ; \  I !i > \  () ! '  M l  !( . ’ C l  A S S  II F X P R I  S S U  ) \  IN ( ’ P i *
7.1 I n t r o d u c t i o n
Consistently throughout this work, cardiopulmonary bypass has been associated with 
reduced MHC Class II expression on circulating monocytes. This reduction in 
expression occurred rapidly over the first 24 hours, was maximal within the first 72 
post-operative hours, and was related in time to an observed hypo-responsiveness of 
whole blood to LPS. Reduced MHC Class II expression could be shown to correlate 
with an increased susceptibility to secondary infections.
The molecular mechanism for this reduction however is unclear. It is known that MHC 
Class II expression is tightly regulated, and transcription is under the control of the 
Class II transactivator (CIITA). In normal circulating monocytes, excessive amounts of 
MHC Class II are present intracellularly in the Class II compartment (MHC) awaiting 
peptide loading (Reith and Mach, 2001;Ting and Trowsdale, 2002). Recycling of the 
surface MHC Class II molecules occurs by re-endocytosis into the MHC followed by re­
expression with a new antigenic peptide (Cresswell, 1994;Pathak and Blum, 2000;Pinet 
and Long, 1998;Roche, Teletski and others, 1993). The reduction in monocytic MHC 
Class II expression in an adult cohort of septic patients has been shown to be a 
posttranslational effect, with no significant change in the rate of transcription of HLA- 
DR or CIITA (Fumeaux and Pugin, 2002). To date, this is the only clinical study 
examining the molecular mechanisms for reduced MHC Class II expression. IL-10 and 
TGF-P have been proposed as the mediators of this process as in vitro studies show that 
these cytokines downregulate MHC Class II by inhibiting exocytosis and recycling (de 
Waal, Haanen and others, 1991;Koppelman, Neefjes and others, 1997). However, in the 
clinical study mentioned above, the authors were unable to show a significant 
correlation between plasma levels of IL-10 and monocyte levels of HLA-DR expression 
or levels of MHC Class D-related gene expression.
Whilst no direct correlation has been shown, elevated plasma levels of IL-10 appear to 
be persistent finding in patients with monocyte deactivation and septic shock. 
Cardiopulmonary bypass causes an early systemic release of IL-10 in paediatric patients 
over a time course similar to monocyte MHC Class II expression reduction (Fig 5.7). In 
addition to inhibiting exocytosis and recycling, IL-10 has also been shown to
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downregulate the transcription of CIITA and thus MHC Class II in vitro (Harton and 
Ting, 2000), raising a second possible site of action.
The aims of this chapter were:
(1) To define which step(s) of the MHC Class II pathway was(were) 
affected by cardiac surgery involving cardiopulmonary bypass
(2) To relate circulating IL-10 levels to changes in gene transcription as 
measured by mRNA levels
7.2 M e t h o d s
Throughout this thesis an ongoing challenge has been the limited blood volume 
available. As the age of surgical repair decreases, so to does the patient’s weight and 
the total volume of blood that is acceptable to request for study purposes. In order to 
gain meaningful information about where CPB was having its affect on MHC Class II 
surface expression, each patient required a series of sampling points pre- and post- 
operation. In addition blood obtained at each time point needed to be analysed for all 
steps of the MHC Class II pathway being investigated.
Most of the methods utilised in this chapter have been described in detail in Chapter 2. 
Additional methods are described below.
7.2.1 Measurement of plasma cytokines.
The ELISA technique used to measure plasma cytokines in chapters 4 and 5 was not 
appropriate to use in this patient group because of the sample volumes available. A 
commercially available multiplexed bead assay technique (Cytometric Bead Array) was 
used that is highly sensitive on small sample volumes. This assay uses a sandwich 
technique to capture and detect soluble cytokines. Capture antibody for each cytokine is 
attached to beads of a distinct size so that simultaneous assaying of cytokines in a single 
sample is possible. Bound cytokine is detected using a fluorescently labelled antibody
and quantitated by comparing the median fluorescent intensity of the detection antibody 
for a specific cluster of beads to a known standard.
Specifically, a 25pl solution of mixed human inflammation capture beads for IL-6, IL-8, 
IL-10, and TNF-a (lOpl/cytokine/sample) was incubated with 50pl of patient plasma or 
standard for 1.5 hours. Samples were then washed and incubated for a further 1.5 hours 
with a detection antibody labelled with a PE fluorochrome. All incubations occurred in 
the dark. The samples were washed again and analysed on flow cytometry using BD 
FACSComp Software (BD Biosciences, UK) (Fig 7.1).
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Figure 7.1 Appearance of plasma cytokine data using the multiplexed bead assay.
Each assay contains clusters of capture beads with varying fluorescence (FL3-H) for the 
cytokines of interest. It was possible to measure 6 cytokines within this bead set (FL3- 
H 102 to 104). With increased levels of cytokine binding there is increased fluorescence 
from the detection antibody (FL2-H), moving the cloud generated to across to the right. 
The cytokines of interest were IL-8 (top cloud), IL-6 (3r from the top), IL-10 (4th from 
the top), TNF-a (2nd bottom).
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7.2.2 Semi-Quantitative Assessment of mRNA Levels
Real time reverse transcription-polymerase chain reaction was chosen as the most 
sensitive technique for mRNA detection and quantitation in view of the small sample 
volumes. This method was used to quantitate changes in post-operative gene expression 
for MHC Class II related genes compared to pre-operative expression.
7.2.2.1 Extraction of mRNA and generation of cDNA
A known number of monocytes isolated from 2mls of whole blood by Ficoll hypaque 
gradient and CD 14 positive selection (Section 2.4.1) were resuspended in 200pl of cell 
lysis/binding buffer (to release message RNA) and frozen at -70°C to minimise 
degradation of mRNA, until all samples for that patient were obtained. This ensured 
that for each patient, serial samples were handled together and processed for 
quantification of mRNA under identical conditions.
Cell lysate was combined with 250pg of Oligo (dT) 2 5  covalently coupled to magnetic 
Dynabeads. The solution was incubated at room temperature with gentle tilting and 
rotation for 5 minutes during which the monocyte mRNA hybridised to the Oligo (dT) 2 5  
sequence. The vial was placed back on the magnet, supernatant was removed, and the 
magnetic bead-mRNA complex was washed twice in Washing Buffer A before solution 
was changed to Washing Buffer B (Overview shown in Fig 7.2).
Complementary DNA was generated from mRNA by reverse transcription. The 
Dynabeads-mRNA-Buffer complex was placed on the magnet and supernatant removed. 
The Dynabeads-mRNA complex was resuspended in 11 pi of RNase free water before 
adding 4pi of 5x first strand buffer, 2pl of 0.1 M DTT, and 2pl of 5mM dNTP’s. Each 
sample was placed at 42°C for 2 minutes, before lp l of Superscript was added. Reverse 
transcription occurred at 42°C over 50 minutes, before the sample was placed at 70°C to 
heat-inactivate the transcriptase.
All patient samples were left undiluted in a total volume of 20pl. A normal control 
cDNA was prepared from 0.2 x 106  monocytes by an identical method. Control cDNA 
was diluted to 1:3 with RNase free water and frozen in small aliquots at -20°C (final 
concentration mRNA from 0.33 x 104  cells/pl).
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Figure 7.2 Schematic diagram of monocyte mRNA isolation from PBMC’s.
Monocytes were positively selected from PBMC’s before being lysed to release mRNA. 
Capture of mRNA was maximised by the use of an oligo-dT sequence coupled to 
magnetic beads. Isolated mRNA was converted to cDNA by reverse transcription, and 
stored for RT-PCR.
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1222 RT-PCR of MHC Class II related genes
Complimentary DNA for MHC Class II related genes were quantified using real time- 
polymerase chain reaction. The real time-PCR amplification of samples was performed 
using the TaqMan sequence detection system (ABI Prism 7000 SDS Software, Applied 
Biosystems, UK). Fluorescent probes and primers for MHC Class II and CIITA were 
obtained from the literature (Fumeaux and Pugin, 2002) and checked against the known 
gene sequence using Primer express (Applied Biosystem, UK). HLA-DRA was chosen 
as a constant sequence of genome that would allow quantitation of MHC Class II 
mRNA regardless of haplotype. Both probes were labelled with FAM and quenched 
with TAMRA. The details of the primers, probes and PCR mix are given in Tables 7.1 
and 7.2.
Oligonucleotide Sequence
CIITA Primer
(Forward / Reverse)
5’-CCT GCT GTT CGG GAC CTA AA-3’ 
5’-GGA TCC GCA CCA GTT TGG-3’
CIITA Probe 5’-AGG GCC CAG CGC AAA CTC CAG T-3’
HLA-DRA Primer
(Forward / Reverse)
5’-GCC AAC CTG GAA ATC ATG ACA-3’ 
5’-AGG GCT GTT CGT GAG CAC A-3’
HLA-DR Probe 5’-CAA CTA TAC TCC GAT CAC CAA TGT ACC TCC AG A G-3’
Table 7.1 Oligonucleotide sequences of the primers and probes used for RT-PCR
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Real time PCR was performed in triplicate and all samples from a single patient were 
prepared and run together. Complementary DNA from a positive control was run with 
each RT-PCR.
PCR Mix Volume Final
Concentration
Universal Master Mix 12.5pl -
Forward Primer [5pM] 4.5pl 900nM
Reverse Primer [5pM] 4.5 pi 900nM
Probe [5pM] lid 200nM
cDNA Template 2pl -
Water 0.5pl -
Reaction volume 25pl
Table 7.2 PCR Mix for RT-PCR.
Volumes and where appropriate, final concentrations for reagents used per PCR 
reaction.
RT-PCR quantitates the amount of reaction product for each sample in every PCR 
cycle, by assessing the increase in fluorescence (OD). To quantify the results, a 
comparative threshold (Ct) method was utilised. The threshold is set at a point at which 
all the reaction rates have ceased to be exponential and entered a linear phase of 
amplification. The Ct is the fractional cycle number at which the amplified cDNA 
reaches this fixed threshold.
The number of monocytes in each sample from which the mRNA was collected, was 
divided by the mean Ct for the 3 replicas and multiplied by 10 to give a value of 
expression.
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7.3 R e s u l t s
7.3.1 Optimisation of techniques to be used
A number of techniques to be used in this chapter needed to be optimised first in adult 
controls to ensure sensitivity when small blood volumes were utilised.
7.3.1.1 Isolation of monocytes
7.3.1.1.1 Purity
Monocytes were purified from whole blood using density gradients and positive 
selection as described in Chapter 2, section 2.4.1. Decreasing initial volumes of whole 
blood resulted in a loss in monocyte purity when a second density gradient was used 
(Fig 7.3). Attempts at isolating monocytes from 5ml or less resulted in only 70-80% of 
isolated cells being CD 14 positive. In contrast positive selection using CD14+ beads 
and MACS column persistently returned a >95% purity even when as little as 2-3ml of 
whole blood was used.
7.3.1.1.2 Monocyte activation
For small whole blood sample volumes CD14+ positive selection yielded the greatest 
purity. The degree of cellular activation as a result o f isolation was examined at both 
the density gradient and positive selection steps. There was minimal change in MHC 
class II surface expression following separation of PBMC’s. However positive 
selection using MACs columns resulted in increased mfi (Fig 7.4). For this reason in 
subsequent work, expression of monocyte surface and intracellular MHC Class II was 
assessed after separation of PBMC’s.
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Figure 7.3 Percentage of monocytes, T cells and B cells are compared in whole blood, following PBMC isolation, SIP gradient and 
CD14 positive selection. Three millilitres of whole blood was collected and 50pl stained with monoclonal antibodies to CD14 (marker of 
monocytes), CD3 (marker of T-cells), and CD 19 (marker of B-cells). Percentage positive cells within the gated area on the forward scatter 
-  side scatter plot is given above the marker. The whole blood sample was then placed on a Ficoll-gradient and PBMC’s isolated. 
PBMC’s were divided and further purified using either a SEP gradient or CD 14 positive bead selection. At each stage, cells were stained 
with the CD 14, CD3, and CD 19 monoclonal antibodies, and percentage purification calculated.
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Figure 7.4 MHC Class II expression on the surface of patient monocytes (% and 
mfi) was increased by the purification processes. At the time points where MHC 
Class II expression was lowest on the surface of monocytes stained in whole blood, 
there was a marked increase in expression of this protein on monocytes separated by 
positive selection.
7.3.1.2 Optimisation of Confocal staining
Preliminary experiments to determine the most suitable fluorescent antibody for 
confocal imaging were performed on control blood. Comparisons in intensity of 
staining were made between the pan-MHC Class II antibody and a specific HLA-DR 
antibody, and between directly conjugated and double staining techniques. The most 
intense staining was obtained using a directly conjugated FITC labelled HLA-DR 
monoclonal antibody (Fig 7.5). There was no visible fluorescence in cells incubated 
with an isotype control monoclonal antibody (Fig 7.6).
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Figure 7.5 Comparison of FITC labelled monoclonal antibodies to MHC Class II 
and HLA-DR Monocytes from normal adult controls with a high level of MHC Class 
II surface expression (>85%) were examined by confocal microscopy. Monocytes were 
identified by staining with a monoclonal antibody to CD14 (texas red). Hie directly 
conjugated monoclonal antibody specific to HLA-DR provided the best staining of both 
surface and intracellular MHC Class II at low laser voltages.
Figure 7.6 PBMC’s surface stained with a second layer fhiorochrome to CDI4 
(Texas red) and FITC labelled IgGl isotype control (green). There is clear ring 
staining of the cell surface of monocytes with the texas red fhiorochrome. In contrast 
there is no co-staining of the cell surface with the FITC fluorochrome.
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A series of in vitro experiments were undertaken in adult control blood to ensure that a 
reduction in surface expression of MHC Class II on flow cytometry would be detectable 
by confocal microscopy. Culture of monocytes in the presence of IL-10 has been 
shown to reduce the surface expression of MHC Class II on monocytes (de Waal, 
Abrams and others, 1991;Koppelman, Neefjes and others, 1997). In addition, culture of 
monocytes in the presence o f LPS, TNF-a and IFN-y has been shown to increase MHC 
Class II surface expression (Celia, Engering and others, 1997). Based on dose and time 
response curves (results not shown), PBMC’s were cultured in the presence of EL-10 
(lOng/ml), IFN-y (lOOU/ml), and LPS (lng/ml) at 37°C with 5% CO2 for 24, 4, and 4 
hours respectively (Fig 7.7). Following culture, cells were recovered and stained for 
both confocal and flow cytometry assessment of CD 14, MHC Class D/HLA-DR surface 
expression.
Baseline MHC Class II expression (mfi) was 35-65 on flow cytometry. Co-culture with 
IFN-y and LPS resulted a mild increase in MHC Class II expression (mfi: 47-112) 
which was not obvious on confocal microscopy. PBMC’s cultured in the presence of 
IL-10 had a fall in surface expression of MHC Class II (mfi) which was detectable by 
both flow cytometry and confocal microscopy (Fig 7.8 and 7.9). This reduction in 
MHC Class II expression was partially restored by an additional 4 hours of culture with 
IFN-y. This was seen using both flow cytometry and confocal microscopy
7.3.1.3 Summary
From these results, it was possible to develop protocols that would enable analysis of 
both surface and intracellular MHC Class II expression by both flow cytometry and 
confocal microscopy. Subsequent confocal microscopy and flow cytometry was 
performed on PBMC’s separated by Ficoll hypaque gradients.
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Figure 7.7 Optimisation experiments using PBMC’s isolated from healthy adult 
controls. Peripheral blood mononuclear cells were isolated from 50ml of whole blood 
using a Ficoll hypaque gradient. Surface expression of MHC Class II and HLA-DR was 
examined using flow cytometry, and 105 cells were stained for confocal microscopy. 
The remaining cells were cultured for a variable amount of time with/without cytokines. 
Cells were washed twice and the cells from each culture plate were stained for CD 14, 
MHC Class II and HLA-DR for both flow cytometry and confocal microscopy. A 
subgroup of cells cultured in the presence of IL-10 for 24 hours underwent secondary 
culture in the presence of IFN-y before being stained.
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Figure 7.8 Effect of IL-10 on PBMC surface expression of MHC Class II. PBMC’s 
were cultured with and without lOng/ml of IL-10 for 24 hours. Cells were then 
assessed by flow cytometry for MHC Class II expression. A subgroup of cells was 
cultured for an additional 4 hours in the presence of lOOU/ml of IFN-y and surface 
expression of MHC Class II reassessed. Monocytes cultured in the presence of IL-10 
showed a marked reduction in MHC Class II surface expression that was partially 
restored by an additional period of culture in the presence of IFN-y.
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Figure 7.9 Effect of IL-10 on surface staining of HLA-DR. PBMC’s were cultured 
in RPMI 1640 with and without IL-10 (lOOng/ml) for 24 hours. Cells were washed and 
stained with fluorescently labelled monoclonal antibodies to CD 14 (Texas red) and 
HLA-DR (FITC). The finding on flow cytometry of reduced surface expression of 
HLA-DR was easily confirmed with confocal microscopy.
Ri < ,i i. m ion or Ml ic  Class II lxlrlssion in CPB
7.3.2 Detection of MHC Class II localisation in Patients
Ten infants and children undergoing cardiac surgery involving CPB were randomly 
recruited over a 6  week period. Any child undergoing cardiac surgery involving CPB 
was eligible for this study. On each sample a series of experiments were performed in 
an effort to localise the primary cellular site at which the alteration in MHC Class II 
expression was originating.
An outline of the investigations performed at each time point is shown in Figure 7.10. 
Samples were collected pre-operatively, on completion of CPB (post op), and each 
morning for the first 3 post-operative days. Fifty microlitres of whole blood was stained 
for CD 14 and MHC Class II expression. Plasma from one millilitre of blood was 
separated and stored at -70°C for cytokine analysis. PBMC’s were extracted from the 
remainder l- 2 ml of whole blood, and aliquots of 1 0 4  cells were stained for surface and 
intracellular assessment of MHC Class II expression by flow cytometry and HLA-DR 
expression by confocal microscopy.
Monocytes from the remaining PBMC’s were isolated using CD14+ beads as described 
in the Chapter 2, section 2.4.1.2.2. A cell count was performed using a haemocytometer 
before the monocytes were lysed in 200pl of lysis/binding buffer and frozen at -70°C for 
RT-PCR of HLA-DRA and CIITA cDNA. The techniques of mRNA extraction, 
conversion to cDNA, and RT-PCR have been described in the methods above.
The patient characteristics followed by the results from each part of the study are 
presented below, with a final section summing up the results as a whole.
7.3.2.1 Patient characteristics, operative details and outcome
The demographic and operative details are presented in Table 7.3 and 7.4. Outcome 
measures included the patient’s duration of ventilation and length of stay in the 
Intensive Care Unit. None of the 10 patients fulfilled the criteria for sepsis or SIRS. 
All patients survived to discharge.
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Figure 7.10 Study design. At each time point a number of investigations were 
performed in an effort to determine at what point MHC Class II expression is 
interrupted post-operatively. Surface expression of MHC Class II was examined on 
whole blood, before PBMC’s were separated over a ficoll density gradient. PBMC’s 
were examined for surface and intracellular MHC Class II staining by confocal and flow 
cytometry. After further purification monocytes were lysed for quantitation of message 
RNA levels.
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Patient Age
(days)
Sex Weight
(kg)
Cardiac Lesion
1 222 F 5.60 Congenitally corrected transposition of great 
arteries,
VSD, sub-pulmonary stenosis, severe tricuspid 
incompetence
2 20 F 2.72 Transposition of great arteries
3 1254 M 13.10 Double outlet right ventricle,
VSD, Pulmonary outflow trace obstruction
4 122 M 4.72 VSD
5 449 M 9.60 Pulmonary atresia 
VSD, Major aorto-pulmonary collateral arteries
6 94 F 4.00 Coarctation of the aorta / Transverse arch 
hypoplasia 
VSD x2, Small left heart
7 99 F 3.80 Atrioventricular septal defect 
Patent ductus arteriosus
8 806 F 9.40 Tetralogy of Fallots (severe) 
Patent ductus arteriosus
9 226 M 7.88 Tetralogy of Fallots 
Tracheal stenosis
1 0 28 M 3.77 Transposition of great arteries
Table 7.3 The demographic details and cardiac diagnosis for the 10 patients 
enrolled. Ventriculoseptal defect (VSD)
Table 7.4 (over page) Operative details and outcome measures for the 10 study 
patients. Details of the cardiac repair performed, lowest temperature achieved during 
theatre, cardiopulmonary bypass (CBP), aortic cross clamp (X-clamp), and circulatory 
arrest time is given for each patient. Outcome measures including duration of 
ventilation and length of stay in the cardiac intensive care unit are also included. 
Ventricular septal defect (VSD), Atrial septal defect (ASD), Patent ductus arteriosus 
(PDA), Total cavopulmonary circulation (TCPC), Patent foramen ovale (PFO), 
Atrioventricular septal defect (AVSD), Tetrallogy of Fallot’s (TOF)
Table 7.4 Operative Details and outcome measures for the 10 study patients.
Patient Cardiac Operation Lowest
operating
temperature
CPB
time
(min)
X-clamp
time
(min)
Circulatory 
arrest time 
(min)
Duration of 
ventilation 
(hrs)
Duration in
CICU
(hrs)
1
Unable to perform planned switch due to 
severe pulmonary stenosis, Tricuspid valve 
replacement, Pulmonary valvotomy, VSD 
closure
22°C 159 1 1 2 0 64 93
2
Arterial switch 
ASD closure, PDA ligation 18°C 121 81 7 39 91
3 TCPC / Fontan 32°C 50 0 0 5 47
4 VSD closure 
PFO closure 28°C 103 50 0 21 42
5 VSD patch, unifocalisation of right 
collateral vessels, right ventricle to 
pulmonary artery conduit, ASD closure
23°C 202 48 0 31 44
6
Closure of multiple VSD’s 
Pulmonary artery banding 16°C 92 54 36 97 186
7 A VSD repair Suture of mitral cleft, PDA ligation 28°C 98 69 0 119 165
8
TOF repair 
Bovine pericardial patch, Enlargement of 
main pulmonary artery, creation of small 
ASD, PDA ligation
28°C 68 39 0 13 66
9 TOF repair Slide tracheoplasty, PDA ligation 30°C 126 34 0 148 168
1 0
Arterial switch 
ASD closure 22°C 128 77 7 299 474
7.3.2.2 Relationship between surface and intracellular MHC Class II
expression by flow cytometry
Whole blood and PBMC’s were stained for surface and intracellular expression of MHC 
Class n. Consistent with the findings presented in previous chapters, surface expression 
of MHC Class II on monocytes (% & mfi) fell in all patients following cardiopulmonary 
bypass. MHC Class H surface expression (% & mfi) from monocytes in whole blood 
and PBMC’s was significantly reduced at the end of CPB from pre-operative levels 
(Wilcoxon signed rank test p< 0.05), and remained significantly lower over the first 
three post- operative days (%: p<0.05, mfi: /?<0.01 on Day 1-2 for whole blood, and % 
& mfi: p< 0.05 for PBMC) (Fig 7.11 & 7.12).
The percentage of monocytes staining intracellularly for MHC Class II remained high 
(>85%) both pre and post-operatively. However, the median fluorescent intensity (mfi) 
of monocyte staining fell significantly following bypass (Day 1 p<0.005 Wilcoxon 
signed rank test) (Fig 7.12).
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Figure 7.11 Changes in monocyte MHC Class II expression (%) with cardiac surgery involving CPB.
Ten patients had blood samples drawn pre and post-operatively for 3 days following their operation. Whole blood was dually stained with CD 14 and 
MHC Class II fluorescently labelled monoclonal antibodies to CD14 and MHC Class II. PBMC’s were separated from the blood and both surface 
and intracellular staining for MHC Class II was examined on CD14+ cells. There was a significant fall in surface expression of MHC Class II on 
CD 14+ cells in whole blood which was mirrored in the paired PBMC sample. Intracellular staining for MHC Class II remained >85% post- 
operatively.
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Figure 7.12 Changes in the median fluorescent intensity (mfi) of monocyte MHC Class II staining following CPB.
The intensity of intracellular staining for MHC Class II in circulating monocytes was a log fold higher than the corresponding surface staining. 
Cardiac surgery involving CPB resulted in a significant fall in the intensity of both a surface and intracellular MHC Class II staining (mfi) which was 
greatest on Day 1 and Day 2 (p<0.005).
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7.3.2.3 Monocyte HLA-DR distribution using confocal microscopy
Confocal microscopy was used to investigate the cellular localisation of the MHC 
Class II protein, and confirm the results obtained from flow cytometry. No attempts 
to quantitate fluorescence were made using the confocal. However the images 
analysed and the example shown below were representative of the cells seen on each 
slide. Figure 7.13 shows a series of fluorescent images from a monocyte stained for 
intracellular HLA-DR. Each image is 0.5 pm apart. The top image is a computer 
generated composite of the series of images. All images subsequently shown in this 
chapter are single optical slices captured from the central part of the cell, 
corresponding approximately to the 2nd-3rd of the optical slices presented at the 
bottom of figure 7.13.
In addition to HLA-DR, all cells were stained with To-pro-3 iodine nuclear stain 
(Chapter 2 section 2.8.3), and monocytes were selected for imaging based on their 
cell morphology. When images were taken at 800x magnification, the To-pro-3 
iodine nuclear staining was rapidly bleached, and recorded images presented here 
frequently appear absent for this fluorochrome.
7.3.2.3.1 Surface HLA-DR expression
In all 10 patients studied, monocytes had a noticeable reduction in surface HLA-DR 
fluorescence by confocal microscopy in the post-operative samples when compared 
to pre-operative expression. It would be expected that confocal findings would 
parallel the median fluorescent intensity (mfi) changes in monocyte MHC Class II 
surface expression measured by flow cytometry. The change in surface fluorescence 
by confocal microscopy was more dramatic than that suggested by the corresponding 
change in mfi on flow cytometry (Fig 7.14). For all 10 patients, confocal microscopy 
showed a reduction in surface HLA-DR expression immediately following bypass, 
which persisted over the first 24-48 hours. Five patients appeared by microscopy to 
have some recovery in surface fluorescence during the study period (patient 1,3,5, 6 , 
& 10).
Figure 7.13 Images from confocal microscope of a monocyte with FITC staining for intracellular HLA-DR.
The bottom series of images show the intracellular distribution of HLA-DR in a single monocyte. Images are stored from a series of Z-sections 
(0.5|im apart), and can then be superimposed to form a single picture of cellular staining (top image).
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Figure 7.14 Surface fluorescence HLA-DR on monocytes, examined by confocal microscopy (Patient 5)
There was a reduction in HLA-DR surface fluorescence from pre-operative levels immediately post-op. HLA-DR fluorescence appeared to increase 
on circulating monocytes on Day 3. When compared to flow cytometry, confocal findings appeared to reflect changes seen in MHC Class II surface 
expression (% & mfi).
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7.3.2.3.2 Intracellular HLA-DR expression
There was marked variation in the degree of intracellular HLA-DR staining seen on 
confocal microscopy amongst the pre-operative samples. Most patients had strong 
intracellular staining that decreased in the immediate post-operative period. A 
representative patient of this is illustrated in Figure 7.15. Intracellular staining of this 
patient’s monocytes, showed reduction in HLA-DR fluorescence on the post­
operative and Day 1 samples, but return of bright fluorescence on Day 2 and 3. One 
of the ten patients deviated from this pattern with low levels of HLA-DR pre- 
operatively, and increased fluorescence by Day 3 (Fig 7.16). These patterns were 
reflected by the median fluorescent intensity (mfi) of intracellular staining (inset top 
right comer of Figs 7.14-7.16).
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Figure 7.15 Intracellular staining of circulating 
monocytes for HLA-DR. Confocal microscopy was used 
to examine monocyte intracellular staining for HLA-DR 
and compared to results obtained by flow cytometry. 
Single mid optical sections of the cell are shown. 
Monocytes can be seen to be brightly fluorescent pre- 
operatively. Cells staining positive for just the nuclear 
stain were identified as lymphocytes by morphology. 
Staining appeared markedly reduced on the first post­
operative day, but improved on Day 2 and 3. Confocal 
fluorescence appeared to reflect similar changes to those 
seen in the median fluorescent intensity (mfi) of MHC 
Class II staining assessed by flow cytometry
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Patient 6: MHC Class II by flowcytometry
100 T
80
60
40
20
0
--------------------- --
— -  PBMC S u rface  MHC C la ss  II (%) 
PBMC S u rface  MHC C la ss  II (mfl)
—  PBMC intracellular MHC C la ss  II (%) 
•*■<»• PBMC intracellular MHC C la ss  II (mfl)
-—r—■........... ,■■■■■■■ l ---7—■
Pre op Ftost op Day 1 Day 2 Day 3
Figure 7.16 HLA-DR intracellular staining on confocal 
microscopy mirrors the median fluorescent staining of 
monocytes by flow cytometry. Patient 5 had low preoperative 
intracellular MHC Class II levels (mfi) on flow cytometry. 
Flow cytometry suggested that intracellular content of MHC 
Class II increased by the 3rd postoperative day. Examination of 
monocytes from the same blood samples by confocal 
microscopy confirmed these results.
7.3.2.4 Quantitation of HLA-DRA and CIITA mRNA
To test whether the decrease in monocyte MHC Class II expression observed in 
patients following cardiac surgery was due to a transcriptional effect, messenger 
RNA levels of HLA-DR and CIITA, the molecule critical for MHC Class II 
expression, were quantified by real time-PCR.
For each patient, messenger RNA was obtained from a >95% purified population of 
monocytes at each sampling point. In all ten patients, levels of mRNA for HLA- 
DRA and CITTA were low prior to surgery (Fig 7.17). Gene transcription did not 
appear to increase at the end of the surgery. However by Day 2, seven of the 10 
patients had increased levels of both CITTA and HLA-DRA mRNA. One additional 
patient had increased mRNA levels on day 3.
Consistent with previously published reports, levels of HLA-DRA expression 
paralleled that of CIITA expression (Fig 7.18)(Sims and Halloran, 1999;Ting and 
Trowsdale, 2002). The timing of the samples was too infrequent (24 hourly) to detect 
the reported delay (Sims and Halloran, 1999;Ting and Trowsdale, 2002) between 
CRT A and HLA-DRA gene expression.
All the patients studied in this group had a fall in monocyte MHC Class II expression 
(both % and mfi) that preceded the increased transcription in CIITA and HLA-DRA. 
Patients 3, 4, 5, 6 and 10 had an increase in intracellular MHC Class II expression 
within 24 hours of the increase in MHC Class II related mRNA. One additional 
patient (pt 9) had an increase 48 hours after a rise in mRNA levels.
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Figure 7.17 MHC Class II expression (mfi) and mRNA levels for 10 patients. Each patients MHC Class II surface expression on monocytes 
from whole blood and PBM C’s is plotted along with intracellular MHC Class II (left axis). The quantitative values o f  messenger RNA for HLA- 
DRA and CIITA are plotted in red. In all but two patients (pt 1 & 8) there was an increase in mRNA levels following surgery. This increase in 
mRNA preceded an increase in the intracellular staining for MHC Class n. There was no Day 3 m RNA sample for Patient 5. For simplicity, axes 
are only labelled on patient 1-3 and 10. These axis apply to all graphs presented in this figure.
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Figure 7.18 Levels of HLA-DRA mRNA pre and post-operatively tightly 
correlated with levels of CIITA mRNA. (Spearman correlation co-efficient r=0.95, 
/KO.OOOl).
7.3.2.5 MHC Class II expression, mRNA levels and circulating
cytokines
Systemic cytokine levels were measured in this study group because of the intimate 
relationship reported between TNF-a, IL-10 and MHC Class II expression (Fig 7.19). 
The overall cytokine profile did not differ from the results presented in Chapter 4 
where a larger cohort of cardiac patients was examined. All 10 patients had a 
significant rise from pre-operative levels of IL-6 and IL-8 at the end of surgery 
(p<0.001 Mann-Whitney). Information gained from Chapter 4 would suggest that 
peak levels of both cytokines may have been missed as no samples were collected 
between the end of cardiopulmonary bypass and 0900 the next morning. Systemic 
levels of IL-6 and IL-8 remained significantly elevated on Day 3 (p<0.01). Levels of 
IL-6 and IL-8 peaked between 70 and 325 pg/ml and 36 and 225pg/ml respectively 
which were lower than peak levels recorded by ELISA in the Chapter 4 cohort.
In both this study and that presented in Chapter 4, peak levels of IL-10 were seen at 
the end of surgery following modified ultrafiltration. All 10 patients studied here had 
a significant rise in IL-10 from pre-operative levels during theatre (p<0.001). IL-10 
levels at the end of surgery ranged from 20 to 335 pg/ml, with a median of 112.8 
pg/ml. This was higher than the median IL-10 level seen in Chapter 4 at the same 
time point (end of modified ultrafiltration: median 67 pg/ml).
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Figure 7.19 Appearance of plasma cytokine data for one patient. At the end of
theatre, IL-8, -6 and -10 are all increased from pre-operative levels. IL-8 and -6 
remain elevated on the 3rd post-operative day. FL2-H mfi is read against a standard 
curve to calculate cytokine concentration.
The peak levels of IL-10 at the end of surgery did not correlate with duration of 
bypass, aortic cross-clamp, or circulatory arrest time, however they did negatively 
correlated with the lowest intra-operative temperature (Fig 7.20). The height of the 
peak of circulating IL-10 did not correlate with the degree of reduction in surface 
MHC Class II expression seen in the post-operative period, nor did it appear to have a 
direct relationship to levels of HLA-DRA or CIITA mRNA levels.
TNF-a levels were largely undetectable in this patient population using this method, 
so no assessment of the role of TNF-a as an inducer of transcription of MHC Class II 
related genes could be made.
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Figure 7.20 Levels of IL-10 at the end of surgery negatively correlated with the 
operating temperature chosen for the surgical repair, (r = -0.78, p = < 0.005). 
There was no correlation between IL-10 levels at the end of theatre and CPB time, 
circulatory arrest time, or length of stay.
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7.4 D i s c u s s i o n
A reduction in surface MHC Class II expression on monocytes from children following 
cardiac surgery was shown in Chapter 3 to be a significant independent risk factor for 
the development of post-operative complications. There are now several studies 
confirming that an inflammatory insult results in a reduction of surface MHC Class II 
on monocytes, and that the degree and persistence of reduction is a predictive parameter 
for the incidence of sepsis and/or clinical outcome (Cheadle, Hershman and others, 
1991;Giannoudis, Smith and others, 1999;Hershman, Cheadle and others, 1990;Klava, 
Windsor and others, 1997;Tschaikowsky, Hedwig-Geissing and others, 2002;van den 
Berk, Oldenburger and others, 1997;Wakefield, Carey and others, 1993). The 
molecular mechanisms underlying this fall in surface expression of MHC Class II is at 
present poorly understood. In vitro studies suggest that IL-10 and TGF-0 play a role by 
blocking exocytosis and recycling of intracellular molecules (Astiz, Saha and others, 
1996;Docke, Randow and others, 1997;Randow, Syrbe and others, 1995). There has 
been a single clinical study in septic adults that suggested reduction in surface MHC 
Class II expression was a post-translational effect and that this was partially mediated 
by circulating levels of IL-10 (Astiz, Saha and others, 1996). The findings of the work 
presented above raise an alternative hypothesis.
Results from the 10 patients in this study suggest that monocyte HLA-DR and CIITA 
mRNA production is normally at a low level, and that this is sufficient to maintain high 
levels of surface MHC Class II expression and excessive amounts of intracellular HLA- 
DR. Following the inflammatory insult of cardiac surgery and CPB, surface expression 
of MHC Class II (both % and mfi) fell. Associated with this was a reduction in 
intracellular MHC Class II median fluorescent staining in 9 out of 10 patients, and an 
increase in mRNA levels for HLA-DR and CITTA. The relative increase in gene 
transcription was not clearly related to the degree of fall in surface or intracellular 
expression of MHC Class II (Fig 7.17), nor was it related to measurable systemic levels 
of TNF-a or IL-10.
These finding would argue against the hypothesis that the fall in surface MHC Class II 
expression following CPB is due to re-endocytosis and cellular sequestration of the
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greatest risk of post-operative complications following cardiac surgery. This was 
particularly true for sepsis.
8.2.2 Children have reduced capacity to respond to a second 
inflammatory insult in the immediate period following cardiac 
surgery
It has also become apparent from this work, that all children enter a state of immune 
paresis in the immediate post-operative period as demonstrated by reduced whole blood 
cytokine response to LPS stimulation. This state persists for at least 48 hours. This 
means that during the early post-operative period, children may not be able to mount an 
appropriate inflammatory response to a further insult and particularly to infection. 
During the early post-operative period patients are at particular risk of a number of such 
insults which include infection from an indwelling catheter, translocation of bacteria 
from the GI tract, poor tissue perfusion, haemorrhage and barotrauma from excessive 
ventilation. These may also be sufficient to propagate an excess anti-inflammatory state 
further increasing the risk of nosocomial sepsis, multi-organ failure and death. This 
‘multi-hit* model where CPB primes the patient but a secondary insult in the post­
operative period is required to drive the loss of homeostasis would fit nicely with the 
clinical picture.
As monocytes are the major circulating cell producing cytokines, it has been postulated 
here, but not proven, that the LPS hypo-responsiveness is due to monocyte deactivation. 
Whilst the degree of LPS hypo-responsiveness could not be directly related to the 
degree of reduction in MHC Class II expression, these two events were related in time, 
and may have a similar underlying aetiology. In vitro studies (Brandtzaeg, Osnes and 
others, 1996;Dehoux,Hemot and others, 2000;Grundmann,Rensing and others, 
2000;Randow,Syrbe and others, 1995) would suggest that IL-10 is a potential candidate. 
In support of this, the studies undertaken here show that circulating levels of IL-10 
significantly increased following CPB. An another candidate is TGF beta (Randow, 
Syrbe and others, 1995).
Interleukin-10 has been shown to reduce MHC Class II surface expression on the 
monocytes of septic patients at a post-transcriptional level, by impeding recycling of 
surface MHC Class II and exocytosis of newly formed MHC Class II, with no change to
the mRNA levels (Fumeaux and Pugin, 2002). The results presented in Chapter 7 
questions whether this is the mechanism behind the reduction in MHC Class II in 
cardiac surgical patients. The fall in surface expression of MHC Class II on monocytes 
was paralleled by a fall in intracellular MHC Class II (mfi) staining. This was 
confirmed with confocal microscopy. Twenty-four to forty-eight hours following the 
reduction in surface and intracellular MHC Class II staining, an increase in transcription 
of genes required for production of MHC Class II was observed. These observations 
suggest an alternate hypothesis for the reduction in MHC Class II seen following CPB. 
Secretion or cleaving of surface bound MHC Class II molecules maybe occurring 
during surgery. Depletion of intracellular stores occurs, presumably in order to 
replenish surface expression, but appears to be ineffective during the first 72 hours 
following surgery. At this stage increased transcription occurs but only leads to greater 
MHC class II expression in patients who are recovering.
8.2.3 Genetic predisposition plays a role in determining outcome
Whilst the inflammatory insult delivered can be stratified and has the potential for 
modification, the host response to this insult is at present an unknown. Certainly 
younger age, and co-morbid conditions are associated with a worse outcome (Brown, 
Ridout and others, 2003), however genetic factors which modify the host’s 
inflammatory response are also likely to play an important role in determining outcome. 
From the work undertaken in this thesis it appears that the presence of polymorphisms 
in the IL-6 and TNF-a promoters have a significant association with duration of 
ventilation and/or length of stay. Whether this is through a direct effect on cytokine 
levels produced in response to an insult, or the result of a more complicated process 
remains to be determined. It is interesting that these results differ from those found in 
some adult studies and further work will be required to clarify the reasons why.
8.3 L im it a t io n s  o f  t h is  w o r k
8.3.1 Confounding variables
There are many limitations of the work presented here. Some of these are inevitable in 
clinical studies, and particularly those performed in children. While studies of the type
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undertaken here introduce many potential confounders, interestingly, environmental 
factors are less likely to confound paediatric studies. This should enable potential 
genetic contributions to be accurately assessed. That said, the heterogeneity of the 
congenital cardiac defect population is still restrictive and only large multicentre studies 
will eliminate this as a confounder.
8.3.2 Considering monocytes in isolation
Much of the data presented in this thesis emanates from studies performed in whole 
blood. An assumption has been made that the changes observed are reflecting changes 
in monocytes. However monocytes are only one group of cells operating in an 
extremely complex inflammatory environment. As such there is an inherent risk of over 
interpretation of the data.
Circulating monocytes and plasma levels of cytokines were examined in detail during 
this project. Whilst peripheral blood is relatively easy to obtain, it is distal to the site of 
primary insult. Results presented here may not reflect local tissue levels of 
inflammatory mediators or local cytokine balance. The cardiac myocyte may be 
exposed to far greater cytokine peaks than are evident from analysis of plasma. 
However the likelihood of designing a study acceptable to an ethics committee that 
examines cardiac tissue or coronary sinus blood is remote in children.
Monocytes have a short life span in the circulation (ti/2 = 17 hours). Therefore one 
possible explanation for the findings is that changes in MHC Class II represent changes 
solely in the circulating population of monocytes. There are features of this work which 
argue against this being so. For example if the inflammatory stimulus of surgery 
resulted in all monocytes with high MHC Class II surface expression leaving the 
circulation, one would expect a significant fall in the number of circulating monocytes. 
This did not occur (Fig 5.3). In addition the findings of increased transcription of MHC 
Class II related genes in monocytes with reduced surface and intracellular expression of 
MHC Class II48-72 hours post-operatively, supports the view that the changes in MHC 
class II was common to more than just the circulating population of monocytes.
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greatest risk of post-operative complications following cardiac surgery. This was 
particularly true for sepsis.
8.2.2 Children have reduced capacity to respond to a second 
inflammatory insult in the immediate period following cardiac 
surgery
It has also become apparent from this work, that all children enter a state of immune 
paresis in the immediate post-operative period as demonstrated by reduced whole blood 
cytokine response to LPS stimulation. This state persists for at least 48 hours. This 
means that during the early post-operative period, children may not be able to mount an 
appropriate inflammatory response to a further insult and particularly to infection. 
During the early post-operative period patients are at particular risk of a number of such 
insults which include infection from an indwelling catheter, translocation of bacteria 
from the GI tract, poor tissue perfusion, haemorrhage and barotrauma from excessive 
ventilation. These may also be sufficient to propagate an excess anti-inflammatory state 
further increasing the risk of nosocomial sepsis, multi-organ failure and death. This 
‘multi-hit* model where CPB primes the patient but a secondary insult in the post­
operative period is required to drive the loss of homeostasis would fit nicely with the 
clinical picture.
As monocytes are the major circulating cell producing cytokines, it has been postulated 
here, but not proven, that the LPS hypo-responsiveness is due to monocyte deactivation. 
Whilst the degree of LPS hypo-responsiveness could not be directly related to the 
degree of reduction in MHC Class II expression, these two events were related in time, 
and may have a similar underlying aetiology. In vitro studies (refs) would suggest that 
IL-10 is a potential candidate. In support of this, the studies undertaken here show that 
circulating levels of IL-10 significantly increased following CPB. An another candidate 
is TGF beta (ref)
Interleukin-10 has been shown to reduce MHC Class II surface expression on the 
monocytes of septic patients at a post-transcriptional level, by impeding recycling of 
surface MHC Class II and exocytosis of newly formed MHC Class n, with no change to 
the mRNA levels (de Waal, Haanen and others, 1991 ). The results presented in 
Chapter 7 questions whether this is the mechanism behind the reduction in MHC Class
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II in cardiac surgical patients. The fall in surface expression of MHC Class II on 
monocytes was paralleled by a fall in intracellular MHC Class II (mfi) staining. This 
was confirmed with confocal microscopy. Twenty-four to forty-eight hours following 
the reduction in surface and intracellular MHC Class II staining, an increase in 
transcription of genes required for production of MHC Class II was observed. These 
observations suggest an alternate hypothesis for the reduction in MHC Class II seen 
following CPB. Secretion or cleaving of surface bound MHC Class II molecules maybe 
occurring during surgery. Depletion of intracellular stores occurs, presumably in order 
to replenish surface expression, but appears to be ineffective during the first 72 hours 
following surgery. At this stage increased transcription occurs but only leads to greater 
MHC class II expression in patients who are recovering.
8.2.3 Genetic predisposition plays a role in determining outcome
Whilst the inflammatory insult delivered can be stratified and has the potential for 
modification, the host response to this insult is at present an unknown. Certainly 
younger age, and co-morbid conditions are associated with a worse outcome (Brown, 
Ridout and others, 2003 ), however genetic factors which modify the host’s 
inflammatory response are also likely to play an important role in determining outcome. 
From the work undertaken in this thesis it appears that the presence of polymorphisms 
in the IL-6 and TNF-a promoters have a significant association with duration of 
ventilation and/or length of stay. Whether this is through a direct effect on cytokine 
levels produced in response to an insult, or the result of a more complicated process 
remains to be determined. It is interesting that these results differ from those found in 
some adult studies and further work will be required to clarify the reasons why.
8.3 L i m i t a t i o n s  o f  t h i s  w o r k
8.3.1 Confounding variables
There are many limitations of the work presented here. Some of these are inevitable in 
clinical studies, and particularly those performed in children. While studies of the type 
undertaken here introduce many potential confounders, interestingly, environmental
shedding or shearing of MHC Class II from the surface of the monocyte contrasts with 
findings in septic patients. The pilot work presented here could be supplemented at 
several levels. Absolute quantitation of the transcriptional products from the MHC 
related genes could be performed using RT-PCR. Changes in intracellular staining on 
flow cytometry and confocal microscopy could be further supported by quantitating the 
intracellular protein content of the monocyte with a technique such as western blotting. 
Plasma from patients pre and post-operatively could be examined using flow cytometry 
and ELISA for unbound MHC Class II. Isolated bypass circuits primed with whole 
blood could be used to examine changes in surface MHC Class II expression due to 
mechanical stress.
These experiments will not however identify the mediators responsible for changes in 
MHC Class II expression. To investigate this further, design may necessitate the use of 
validated animal models of bypass, and monocytic cell lines so that local levels of 
mediators can be determined and blocking antibodies trialled.
8.6.2 Validating the findings of a genetic predisposition to outcome
Additional work has already commenced to validate the genetic findings presented here. 
All patients admitted to CICU following surgery involving CPB are being genotyped 
for the cytokine polymorphisms investigated above, as well as MHC genotyping. In 
addition plasma has been collected daily for the first 3 days to assess plasma cytokine 
levels. Collaboration with an American paediatric cardiac centre will enable validation 
of results on another patient cohort. Larger study numbers will enable the genetic 
contribution to outcome to be further assessed by construction of logistic regression 
models such as those described in Chapter 3.
There are no published studies looking for genetic factors which may influence the 
degree of reduction in MHC Class II expression that occurs following an inflammatory 
insult. In Chapter 6 changes in surface MHC Class II were not examined. Regulation 
of MHC Class II expression is in part controlled by local cytokine levels. The presence 
of a promoter polymorphism that is associated with high levels of IL-10 could be 
hypothesised to result in an exaggerated fall in MHC Class II expression in the post­
operative period, with the reverse being true for the TNF-a promoter polymorphism.
G l ' . N I ' K A L  D x  I NSI O. N
The response of monocyte surface expression may also be influenced by the MHC 
haplotype, especially as it is in linkage disequilibrium with other inflammatory genes.
8.6.3 Targeted immunomodulation
The strong predictive value of post-operative MHC Class II surface expression in the 
immediate post-operative period and the subsequent development of sepsis/SIRS raise 
the possibility of therapeutic immunomodulation. At present there is no immune 
monitoring or treatment strategy for patients in cardiac intensive care. Monitoring 
MHC Class II surface expression and whole blood responsiveness to LPS stimulation 
over the first 72 post-operative hours enables identification of the subgroup of patients 
most likely to develop post-operative complications including sepsis/SIRS. Combining 
this laboratory result with a clinical assessment that the patient is unlikely to leave the 
unit in the following 24 hours, would result in selecting a target population for 
immunomodulation. The most promising candidate for immune modulation would be 
GM-CSF. GM-CSF has been shown to stimulate haematopoiesis resulting in an 
increased granulocyte count, increase MHC Class II expression and restore the antigen 
presenting potential on monocytes (Flohe, Borgermann and others, 1999;Mellstedt, 
Fagerberg and others, 1999;Perry, Mostafa and others, 2003). Evidence for the clinical 
use of GM-CSF suggests that it is well tolerated even in neonates (Bilgin, Yaramis and 
others, 2001;Presneill, Harris and others, 2002). The hypothesis would be that by 
selecting the group of patients with both immune paresis and a requirement for ongoing 
intensive care support, treatment with GM-CSF would result in an increase in both 
circulating monocyte count and MHC Class II expression, a reduction in the septic 
complications, and a reduction in mortality.
8.6.3 Mathematical modelling
The nature of the immune system is extremely complex with many interactions between 
systems. Clinical studies are ‘muddied’ by confounders and the inability to control for 
the other immunological mediators. In vitro work equally has limitations. Whilst cell 
work enables the researcher to isolate the cell of interest, that in itself may cause 
misleading results. One possibility to maximise scientific gains from both fields of 
research would be to embark on mathematically modelling the inflammatory response
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to bypass. This is complex but may provide insights into pathogenesis not possible 
through other means.
8.7 Current conceptual model
From the results obtained from this thesis combined with those reported in the existing 
literature it is possible to map out potential inflammatory sequences which could 
explain the observed clinical course in children undergoing cardiac surgery. This is 
described below and in figure 8.1.
Cardiac surgery and CPB elicits a profound systemic inflammatory response in 
children. This may to some extent be genetically determined. After surgery, the 
inflammatory system attempts to restore homeostasis, and in doing so passes from an 
excessive pro-inflammatory response in the first few hours to an excessive anti­
inflammatory response over the first few days. This can be monitored by the reduction 
in monocyte MHC Class II expression. Any second insult that occurs may propagate 
the see-sawing of the immune system and prevent the return of homeostasis. Under 
such circumstances a series of minor sequential insults may result in the persistent 
immune imbalance, overt sepsis, development of multi-organ dysfunction and late 
death.
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shedding or shearing of MHC Class n from the surface of the monocyte contrasts with 
findings in septic patients. The pilot work presented here could be supplemented at 
several levels. Absolute quantitation of the transcriptional products from the MHC 
related genes could be performed using RT-PCR. Changes in intracellular staining on 
flow cytometry and confocal microscopy could be further supported by quantitating the 
intracellular protein content of the monocyte with a technique such as western blotting. 
Plasma from patients pre and post-operatively could be examined using flow cytometry 
for unbound MHC Class n. Isolated bypass circuits primed with whole blood could be 
used to examine changes in surface MHC Class II expression due to mechanical stress.
These experiments will not however identify the mediators responsible for changes in 
MHC Class II expression. To investigate this further, design may necessitate the use of 
validated animal models of bypass, and monocytic cell lines so that local levels of 
mediators can be determined and blocking antibodies trialled.
8.6.2 Validating the findings of a genetic predisposition to outcome
Additional work has already commenced to validate the genetic findings presented here. 
All patients admitted to CICU following surgery involving CPB are being genotyped 
for the cytokine polymorphisms investigated above, as well as MHC genotyping. In 
addition plasma has been collected daily for the first 3 days to assess plasma cytokine 
levels. Collaboration with an American paediatric cardiac centre will enable validation 
of results on another patient cohort. Larger study numbers will enable the genetic 
contribution to outcome to be further assessed by construction of logistic regression 
models such as those described in Chapter 3.
There are no published studies looking for genetic factors which may influence the 
degree of reduction in MHC Class II expression that occurs following an inflammatory 
insult. In Chapter 6 changes in surface MHC Class II were not examined. Regulation 
of MHC Class II expression is in part controlled by local cytokine levels. The presence 
of a promoter polymorphism that is associated with high levels of IL-10 could be 
hypothesised to result in an exaggerated fall in MHC Class II expression in the post­
operative period, with the reverse being true for the TNF-a promoter polymorphism. 
The response of monocyte surface expression may also be influenced by the MHC 
haplotype, especially as it is in linkage disequilibrium with other inflammatory genes.
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8.6.3 Targeted immunomodulation
The strong predictive value of post-operative MHC Class II surface expression in the 
immediate post-operative period and the subsequent development of sepsis/SIRS raise 
the possibility of therapeutic immunomodulation. At present there is no immune 
monitoring or treatment strategy for patients in cardiac intensive care. Monitoring 
MHC Class II surface expression and whole blood responsiveness to LPS stimulation 
over the first 72 post-operative hours enables identification of the subgroup of patients 
most likely to develop post-operative complications including sepsis/SIRS. Combining 
this laboratory result with a clinical assessment that the patient is unlikely to leave the 
unit in the following 24 hours, would result in selecting a target population for 
immunomodulation. The most promising candidate for immune modulation would be 
GM-CSF. GM-CSF has been shown to stimulate haematopoiesis resulting in an 
increased granulocyte count, increase MHC Class II expression and restore the antigen 
presenting potential on monocytes (Flohe, Borgermann and others, 1999 ;Mellstedt, 
Fagerberg and others, 1999 ;Perry, Mostafa and others, 2003 ). Evidence for the 
clinical use of GM-CSF suggests that it is well tolerated even in neonates (Bilgin, 
Yaramis and others, 2001 ;Presneill, Harris and others, 2002 ). The hypothesis would 
be that by selecting the group of patients with both immune paresis and a requirement 
for ongoing intensive care support, treatment with GM-CSF would result in an increase 
in both circulating monocyte count and MHC Class II expression, a reduction in the 
septic complications, and a reduction in mortality.
8.6.3 Mathematical modelling
The nature of the immune system is extremely complex with many interactions between 
systems. Clinical studies are ‘muddied’ by confounders and the inability to control for 
the other immunological mediators. In vitro work equally has limitations. Whilst cell 
work enables the researcher to isolate the cell of interest, that in it may cause misleading 
results. One possibility to maximise scientific gains from both fields of research would 
be to embark on mathematically modelling the inflammatory response to bypass. This is 
complex but may provide insights into pathogenesis not possible through other means.
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8.7 Current  conceptual  model
From the results obtained from this thesis combined with those reported in the existing 
literature it is possible to map out potential inflammatory sequences which could 
explain the observed clinical course in children undergoing cardiac surgery. This is 
described below and in figure 8.1.
Cardiac surgery and CPB elicits a profound systemic inflammatory response in 
children. This may to some extent be genetically determined. After surgery, the 
inflammatory system attempts to restore homeostasis, and in doing so passes from an 
excessive pro-inflammatory response in the first few hours to an excessive anti­
inflammatory response over the first few days. This can be monitored by the reduction 
in monocyte MHC Class II expression. Any second insult that occurs may propagate 
the see-sawing of the immune system and prevent the return of homeostasis. Under 
such circumstances a series of minor sequential insults may result in the persistent 
immune imbalance, overt sepsis, development of multi-organ dysfunction and late 
death.
Genetic predisposition 
-low MHC Class II 
-cytokine polymorphism 
Neonate, ventilated, co-morbid conditions
Operation Minimise inflammatory insults 
(CPB time, ischemic time, 
temperature etc)
Brief & limited 
reduction in 
MHC Class II 
expression
CICU
Admission Failure to 
restore 
homeostasis
Rapid 
restoration of 
homeostasis
Sequential
insults
avoided
Persistently 
reduced MHC 
Class II 
expression
Recovery
IHC Class II 
recovery
Overt
sepsis DeathMOF
Figure 8.1 Outline of possible pathways a child may take following cardiac 
surgery. Pre-operatively the child may be at particular risk of post-operative 
complications because of age, requirement for assisted ventilation prior to surgery, or 
have associated co-morbid conditions. In addition, the child’s inflammatory response to 
surgery may be influenced genetically. There are features of the operation, such as 
prolonged bypass and ischemic time which are suggest risk of a complicated post­
operative period. When the patient is admitted into CICU, the inflammatory system 
will be attempting to regain homeostasis. Initially all children will have a fall in their 
MHC Class II surface expression on monocytes. If homeostasis is achieved, the MHC 
Class II expression will be normalising in the first few post surgical days. If 
homeostasis is not achieved, the MHC Class II expression may remain reduced, and the 
child may be at particular risk of secondary infection and organ dysfunction. If further 
inflammatory insults can be avoided, homeostasis may return and the patient may 
recover. If sequential inflammatory insults can not be avoided then immune imbalance 
may persist, and the patient is at high risk of significant post-operative morbidity and/or 
mortality.
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APPENDIX I
P henotypic data collected  on each patient
Demographics Operative details CICU Course
Date of birth Date and time of 
operation
Dat and time of 
admission
Gestation Weight PIM score
Race Operation performed Risk of Mortality score
Gender Operator Duration of intubation
Cardiac diagnosis Anaesthetic agents used Total time in CICU
Age at diagnosis Lowest temperature Outcome at 28 days
Previous interventions CPB time Inotropes
Co-morbid conditions X-clamp time Rhythm disturbances
Recent infection Circ arrest time Chest open
Invasive proceedure in 
last 2 weeks
Dexamethasone Bleeding
Saturations pre-op Cardioplegia solution Reexploration
Shunt pre op Pre op Hct Sepsis -  organism / site
Post op Hct SIRS
Line sepsis
DIC
Renal failure
Liver failure
Other complications
A p p e n d ic ie s
APPENDIX II
Paediatric Index of Mortality (PIM Score)
Variables Values (1 if Yes, 0 otherwise) Beta
Elective adm ission 3 0
Underlying condition 3 0
R esp o n se  of pupils to bright light 
(> 3 mm and both fixed) ------------  A 0
Mechanical ventilation
(at any time during first hour in
ICU) '
0
Systolic  Blood Pressure (mmHg) 120 0.021
B ase  e x c e s s  (mmHg) 
(arterial or capillary blood)
0 0.071
Fi02 (%) 1 Pa 0 2  (mmHg) r7 - 0.415
Predicted Death Rate :
(help)
j 0 Qear_ |
Logit = (-4.873) + (values * Beta) + (0.021 * (absolute(SBP-120))) + (0.071 * (absolute 
base ex cess)) + (0.415 * (F i02 /P a02))
Predicted death rate = e Logit/ (1+eLogit)
A p p e n d ic ie s
APPENDIX III
American College of Chest Physicians / Society of 
Critical Care Medicine Consensus Conference 1992
Abbreviated definitions of Sepsis and the systemic inflammatory 
response syndrome (SIRS) 
SIRS
The systemic inflammatory response to a variety of severe clinical insults. 
Includes 2 or more of the following:
Temperature 
Heart rate 
Respiratory rate 
White blood cell count
>38 C (100.4 F) or <36 C (96.8 F)
>90 beats/min
>20 breaths/min or Paco2 <32 torr (<4 kPa)
>12,000 cells/mm3, <4000 cells/mm3 or > 10% band 
cells
Sepsis
The systemic response to infection. The response is manifest by the same criteria 
as SIRS
Severe sepsis
Sepsis associated with organ dysfunction, hypoperfusion, or hypotension. 
Hypoperfusion and perfusion abnormalities may include but are not limited to 
lactic acidosis, oliguria, or an acute alteration in mental status.
Septic shock
Sepsis associated with hypotension, despite adequate fluid resuscitation, along 
with the perfusion abnormalities listed for severe sepsis. Patients who are on 
inotropic or vasopressor agents need not be hypotensive at the time perfusion 
abnormalities are measured.
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